<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication Issue 6, 2011" DOI="10.1002/14651858.CD003123.pub2" GROUP_ID="ARI" ID="084400112811193084" MERGED_FROM="" MODIFIED="2011-05-03 01:27:04 +0200" MODIFIED_BY="Liz Dooley" REVIEW_NO="A033" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2011-05-03 01:16:47 +0200" MODIFIED_BY="Liz Dooley">
<TITLE>Epinephrine for bronchiolitis</TITLE>
<CONTACT MODIFIED="2011-05-03 01:16:47 +0200" MODIFIED_BY="Liz Dooley"><PERSON ID="12166" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lisa</FIRST_NAME><LAST_NAME>Hartling</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>hartling@ualberta.ca</EMAIL_1><EMAIL_2>lisa.hartling@ualberta.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One, Room 9424</ADDRESS_1><ADDRESS_2>11402 University Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 6124</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-05-03 01:16:47 +0200" MODIFIED_BY="Liz Dooley"><PERSON ID="12166" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lisa</FIRST_NAME><LAST_NAME>Hartling</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>hartling@ualberta.ca</EMAIL_1><EMAIL_2>lisa.hartling@ualberta.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One, Room 9424</ADDRESS_1><ADDRESS_2>11402 University Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 6124</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON><PERSON ID="5181AE9182E26AA2017F61BBC7800C63" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Liza</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Bialy</LAST_NAME><SUFFIX>BSc</SUFFIX><POSITION>Project Coordinator</POSITION><EMAIL_1>lbialy@ualberta.ca</EMAIL_1><URL>http://www.ualberta.ca/ARCHE/</URL><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>9428 Aberhart Centre One</ADDRESS_1><ADDRESS_2>11402 University Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+780 492 6184</PHONE_1><PHONE_2>+780 407 6435</PHONE_2></ADDRESS></PERSON><PERSON ID="19902" ROLE="AUTHOR"><FIRST_NAME>Ben</FIRST_NAME><LAST_NAME>Vandermeer</LAST_NAME><SUFFIX>BSc, MSc</SUFFIX><POSITION>Statistician</POSITION><EMAIL_1>bv1@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Alberta Research Centre for Child Health Evidence &amp; University of Alberta Evidence-based Practice Centre</ORGANISATION><ADDRESS_1>Aberhart Centre One, Room 9418</ADDRESS_1><ADDRESS_2>11402 University Avenue</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 6355</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON><PERSON ID="11506" ROLE="AUTHOR"><FIRST_NAME>Lisa</FIRST_NAME><LAST_NAME>Tjosvold</LAST_NAME><POSITION>Child Health Research Librarian</POSITION><EMAIL_1>tjosvold@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Alberta Research Centre for Child Health Evidence</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Aberhart Centre One, Room 9420</ADDRESS_1><ADDRESS_2>11402 University Ave.</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2J3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 0550</PHONE_1><FAX_1>+1 780 407 6435</FAX_1></ADDRESS></PERSON><PERSON ID="12282" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>W</MIDDLE_INITIALS><LAST_NAME>Johnson</LAST_NAME><POSITION>Pediatric Emergency Physician and Medical Toxicologist</POSITION><EMAIL_1>david.johnson@albertahealthservices.ca</EMAIL_1><MOBILE_PHONE>+1 403 473 6442</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Calgary, Alberta Children's Hospital</ORGANISATION><ADDRESS_1>2888 Shaganappi Trail NW</ADDRESS_1><CITY>Calgary</CITY><ZIP>T3B 6A8</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 403 955 7507</PHONE_1><FAX_1>+1 403 955 7552</FAX_1></ADDRESS></PERSON><PERSON ID="3EAE70D982E26AA2001AB0E3CC7C1AFE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Amy</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Plint</LAST_NAME><POSITION>Clinician Scientist</POSITION><EMAIL_1>plint@cheo.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Departments of Pediatrics and Emergency Medicine</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><CITY>Ottawa</CITY><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 613 737 7600, ext 3237</PHONE_1><FAX_1>+1 613 738 4885</FAX_1></ADDRESS></PERSON><PERSON ID="5344" ROLE="AUTHOR"><FIRST_NAME>Terry</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Klassen</LAST_NAME><SUFFIX>MD, MSc, FRCPC</SUFFIX><POSITION>Director</POSITION><EMAIL_1>tklassen@mich.ca</EMAIL_1><URL>http://www.mich.ca</URL><MOBILE_PHONE>+1 780 970 3615</MOBILE_PHONE><ADDRESS><ORGANISATION>Manitoba Institute of Child Health</ORGANISATION><ADDRESS_1>513-715 McDermot Avenue</ADDRESS_1><CITY>Winnipeg</CITY><ZIP>MB R3E 3P4</ZIP><REGION>Manitoba</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 204 789 3754</PHONE_1></ADDRESS></PERSON><PERSON ID="12313" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hema</FIRST_NAME><LAST_NAME>Patel</LAST_NAME><POSITION>Program Head, Intensive Ambulatory Care Service / Clinical Investigation Unit</POSITION><EMAIL_1>hema.patel@muhc.mcgill.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>The Montreal Children's Hospital</ORGANISATION><ADDRESS_1>McGill University Health Centre</ADDRESS_1><ADDRESS_2>2300 Tupper Street, Room A216</ADDRESS_2><CITY>Montreal</CITY><ZIP>H3H 1P3</ZIP><REGION>Quebec</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 514 412 4420</PHONE_1><FAX_1>+1 514 412 4424</FAX_1></ADDRESS></PERSON><PERSON ID="9B59478682E26AA200C3FEB6F44498DB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ricardo</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Fernandes</LAST_NAME><POSITION>MD\PhD student (Pediatrics)</POSITION><EMAIL_1>fernandescunharicardo@gmail.com</EMAIL_1><EMAIL_2>rcfern@igc.gulbenkian.pt</EMAIL_2><ADDRESS><DEPARTMENT>Departamento da Criança e da Família (Child and Family Department) and Farmacologia Clínica e Terapêutica (Clinical Pharmacology and Therapeutics Unit)</DEPARTMENT><ORGANISATION>Hospital de Santa Maria, Centro Hospitalar Lisboa Norte EPE and Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa</ORGANISATION><ADDRESS_1>Avenida Professor Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-028</ZIP><REGION>Lisboa</REGION><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>+351 21 780 21 20/7</PHONE_1><FAX_1>+351 21 780 21 29</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-11-17 14:08:44 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="27" MONTH="9" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="9" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="9" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2011-04-25 21:42:00 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-04-25 21:42:00 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Searches were conducted in September 2010 (March 2010 for PubMed). Seven new studies were added to this update. For this update we revised the inclusion criteria to only include studies that defined bronchiolitis as the first episode of wheezing. As a result of this new criterion five studies included in the original review have been excluded from this update (<LINK REF="STD-Hariprakash-2003" TYPE="STUDY">Hariprakash 2003</LINK>; <LINK REF="STD-Kristjansson-1993" TYPE="STUDY">Kristjansson 1993</LINK>; <LINK REF="STD-Lowell-1987" TYPE="STUDY">Lowell 1987</LINK>; <LINK REF="STD-Ray-2002" TYPE="STUDY">Ray 2002</LINK>; <LINK REF="STD-Reijonen-1995" TYPE="STUDY">Reijonen 1995</LINK>). The conclusions have changed to recommend the superiority of epinephrine compared to placebo for short-term outcomes for outpatients, particularly in the first 24 hours of care.<BR/>Six new authors have participated in this update: Liza Bialy, Ben Vandermeer, Lisa Tjosvold, David W Johnson, Amy C Plint and Ricardo M Fernandes.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-17 14:13:32 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-04-25 20:21:01 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-22 09:19:30 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-07-18 16:31:29 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="3" MONTH="1" YEAR="2007"/>
<DESCRIPTION>
<P>Feedback and reply added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-04-25 20:21:01 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="11" YEAR="2003"/>
<DESCRIPTION>
<P>Searches conducted. Review first published Issue 1, 2004</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-04-12 13:12:14 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-06-02 05:08:27 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-06-02 05:08:27 +1000" MODIFIED_BY="[Empty name]">
<NAME>Alberta Research Centre for Health Evidence (ARCHE)</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-04-12 13:12:14 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-06-02 05:09:16 +1000" MODIFIED_BY="[Empty name]">
<NAME>Canadian Institutes of Health Research</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-04-12 13:12:14 +1000" MODIFIED_BY="[Empty name]">
<NAME>Programme for Advanced Medical Education (Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e Tecnologia)</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION>
<P>Ricardo M Fernandes (Fellowship)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-05-03 09:11:27 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-04-25 21:43:41 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-09-27 11:59:51 +1000" MODIFIED_BY="[Empty name]">Epinephrine for acute viral bronchiolitis in children less than two years of age</TITLE>
<SUMMARY_BODY MODIFIED="2011-04-25 21:43:41 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchiolitis is the most common acute infection of the airways and lungs during the first years of life. It is caused by viruses, the most common being respiratory syncytial virus. The illness starts similarly to a cold, with symptoms such as a runny nose, mild fever and cough. It later leads to fast, troubled and often noisy breathing (for example, wheezing). While the disease is often mild for most healthy babies and young children, it is a major cause of clinical illness and financial health burden worldwide. Hospitalizations have risen in high-income countries, there is substantial healthcare use, and bronchiolitis may be linked with preschool wheezing disorders and the child later developing asthma.</P>
<P>There is variation in how physicians manage bronchiolitis, reflecting the absence of clear scientific evidence for any treatment approach. Bronchodilators are drugs that are often used for asthma attacks to relax the muscles in the airways so that breathing is easier. Epinephrine is one type of bronchodilator. With several new trials having been published since the 2004 publication of this Cochrane Review it is important to incorporate the most recent evidence.</P>
<P>Our systematic review found 19 studies involving 2256 children that use epinephrine for the treatment of bronchiolitis in acute care settings. When comparing epinephrine with placebo, no differences were found for length of hospital stay but there is some indication that epinephrine is effective for reducing hospital admissions. Exploratory results from one large, high-quality trial suggest that combined treatment with systemic glucocorticoids (dexamethasone) and epinephrine may significantly reduce admissions. There is insufficient evidence to support the use of epinephrine for the treatment of bronchiolitis among children admitted to the hospital.</P>
<P>The evidence shows no important differences in adverse effects with epinephrine over the short-term with long-term safety not being assessed. Some limitations of this review include the quality of the included studies and inconsistent timing of measurement across studies which limited the number of children included in some meta-analyses. Further research is needed to confirm the efficacy, applicability and long-term safety of epinephrine as a treatment for bronchiolitis.</P>
<P>In summary, our systematic review provides evidence that epinephrine is more effective than placebo for bronchiolitis in outpatients. Recent research suggests combined epinephrine and steroids may be effective for outpatients. There is no evidence to support the use of epinephrine for inpatients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-05-03 09:07:14 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-05-03 09:06:02 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchodilators are commonly used for acute bronchiolitis, despite uncertain effectiveness.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-09-27 11:57:26 +1000" MODIFIED_BY="[Empty name]">
<P>To examine the efficacy and safety of epinephrine in children less than two with acute viral bronchiolitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-17 14:12:33 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2010, Issue 3) which contains the Acute Respiratory Infections Group's Specialized Register, MEDLINE (1950 to September Week 2, 2010), EMBASE (1980 to September 2010), Scopus (1823 to September 2010), PubMed (March 2010), LILACS (1985 to September 2010) and Iran MedEx (1998 to September 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-04-02 07:00:15 +1000" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials comparing epinephrine to placebo or another intervention involving children less than two years with acute viral bronchiolitis. Studies were included if the trials presented data for at least one quantitative outcome of interest.</P>
<P>We selected primary outcomes a priori, based on clinical relevance: rate of admission by days one and seven of presentation for outpatients, and length of stay (LOS) for inpatients. Secondary outcomes included clinical severity scores, pulmonary function, symptoms, quality of life and adverse events.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-04-25 20:21:21 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently screened the searches, applied inclusion criteria, assessed risk of bias and graded the evidence. We conducted separate analyses for different comparison groups (placebo, non-epinephrine bronchodilators, glucocorticoids) and for clinical setting (inpatient, outpatient).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-05-03 09:07:14 +1000" MODIFIED_BY="[Empty name]">
<P>We included 19 studies (2256 participants). Epinephrine versus placebo among outpatients showed a significant reduction in admissions at Day 1 (risk ratio (RR) 0.67; 95% confidence interval (CI) 0.50 to 0.89) but not at Day 7 post-emergency department visit. There was no difference in LOS for inpatients. Epinephrine versus salbutamol showed no differences among outpatients for admissions at Day 1 or 7. Inpatients receiving epinephrine had a significantly shorter LOS compared to salbutamol (mean difference -0.28; 95% CI -0.46 to -0.09). One large RCT showed a significantly shorter admission rate at Day 7 for epinephrine and steroid combined versus placebo (RR 0.65; 95% CI 0.44 to 0.95). There were no important differences in adverse events.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-04-02 07:00:46 +1000" MODIFIED_BY="[Empty name]">
<P>This review demonstrates the superiority of epinephrine compared to placebo for short-term outcomes for outpatients, particularly in the first 24 hours of care. Exploratory evidence from a single study suggests benefits of epinephrine and steroid combined for later time points. More research is required to confirm the benefits of combined epinephrine and steroids among outpatients. There is no evidence of effectiveness for repeated dose or prolonged use of epinephrine or epinephrine and dexamethasone combined among inpatients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-05-03 09:11:27 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-04-25 21:44:55 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-04-25 21:44:55 +1000" MODIFIED_BY="[Empty name]">
<P>Bronchiolitis is an acute lower respiratory tract infection (LRTI) that affects children less than two years of age (<LINK REF="REF-Klassen-1997" TYPE="REFERENCE">Klassen 1997</LINK>). It is characterized by fever, coryza, cough, expiratory wheezing, apnea in the very young, and respiratory distress (i.e. increased respiratory rate, chest wall indrawing, thoracic-abdominal asynchrony) (<LINK REF="REF-Klassen-1997" TYPE="REFERENCE">Klassen 1997</LINK>). Bronchiolitis is most commonly associated with respiratory syncytial virus (RSV) (<LINK REF="REF-Kini-2001" TYPE="REFERENCE">Kini 2001</LINK>; <LINK REF="REF-Shay-2001" TYPE="REFERENCE">Shay 2001</LINK>; <LINK REF="REF-Smyth-2006" TYPE="REFERENCE">Smyth 2006</LINK>).</P>
<P>Bronchiolitis is the most frequent acute LRTI in infants and is one of the main reasons that children younger than one year require hospitalization (<LINK REF="REF-Everard-1995" TYPE="REFERENCE">Everard 1995</LINK>; <LINK REF="REF-Klassen-1997" TYPE="REFERENCE">Klassen 1997</LINK>; <LINK REF="REF-Wright-1989" TYPE="REFERENCE">Wright 1989</LINK>). It is estimated that 11% to 12% of infants are afflicted (<LINK REF="REF-Flores-1997" TYPE="REFERENCE">Flores 1997</LINK>). Approximately 3% of infants are hospitalized with bronchiolitis and rates of hospitalization have been increasing over time (<LINK REF="REF-Langley-2003" TYPE="REFERENCE">Langley 2003</LINK>; <LINK REF="REF-Shay-1999" TYPE="REFERENCE">Shay 1999</LINK>; <LINK REF="REF-Van-Woensel-2002" TYPE="REFERENCE">Van Woensel 2002</LINK>). The prevalence and morbidity associated with bronchiolitis mean that the economic burden placed on health services is substantial (<LINK REF="REF-Hall-1999" TYPE="REFERENCE">Hall 1999</LINK>; <LINK REF="REF-Paramore-2004" TYPE="REFERENCE">Paramore 2004</LINK>; <LINK REF="REF-Pelletier-2006" TYPE="REFERENCE">Pelletier 2006</LINK>). According to a recent review the global incidence of RSV-associated bronchiolitis is a major cause of hospital admissions and mortality (<LINK REF="REF-Nair-2010" TYPE="REFERENCE">Nair 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-04-25 20:23:09 +1000" MODIFIED_BY="[Empty name]">
<P>Despite the frequency of the condition, there remains considerable controversy regarding its management (<LINK REF="REF-Mallory-2003" TYPE="REFERENCE">Mallory 2003</LINK>; <LINK REF="REF-Panitch-2003" TYPE="REFERENCE">Panitch 2003</LINK>). This has resulted in substantial practice variation both within centres and across geographic regions, reflecting the absence of clear evidence for any single treatment approach. In part, this controversy stems from the fact that superficially, infants with acute viral bronchiolitis resemble older children with asthma. For example, both groups commonly present with the symptoms of a recent viral illness, respiratory distress and wheezing. Systematic reviews have assessed the use of bronchodilators, &#946;<SUB>2</SUB> agonists, epinephrine, glucocorticoids, hypertonic saline, antibiotics, surfactant, ribavirin and chest physiotherapy (<LINK REF="REF-Bialy-2006" TYPE="REFERENCE">Bialy 2006</LINK>). All of these reviews, with the exception of treatment with nebulized hypertonic saline, have failed to show consistent and relevant effects (<LINK REF="REF-Zhang-2008" TYPE="REFERENCE">Zhang 2008</LINK>). Nebulized hypertonic saline may significantly improve some outcomes, but replication of this effect in large randomized controlled trials (RCTs) is needed (<LINK REF="REF-Zhang-2008" TYPE="REFERENCE">Zhang 2008</LINK>). While bronchodilators have proven to be of substantive benefit in children with asthma, their effects on infants with bronchiolitis have been less dramatic. Pathophysiologically, we know that bronchiolitis and asthma are, in fact, distinct conditions. There has also been a lack of consistency in determining relevant outcomes to evaluate the effectiveness of interventions and the outcomes used may not be clinically meaningful. For example, a 2% to 3% difference in hemoglobin oxygen saturation has been used as a primary outcome measure; though the relevance of this outcome is questionable.</P>
</INTERVENTION>
<THEORY MODIFIED="2011-04-25 20:23:39 +1000" MODIFIED_BY="[Empty name]">
<P>Historically, children were offered good supportive care including fluids and oxygen (<LINK REF="REF-Panitch-2003" TYPE="REFERENCE">Panitch 2003</LINK>). Clinical trials have provided conflicting evidence regarding the benefit of pharmacological interventions. Much of the debate involves the role of bronchodilators (<LINK REF="REF-Everard-1995" TYPE="REFERENCE">Everard 1995</LINK>; <LINK REF="REF-Mallory-2003" TYPE="REFERENCE">Mallory 2003</LINK>). The use of bronchodilators, though costly and widespread, is not without harm, therefore effectiveness requires rigorous review (<LINK REF="REF-Kini-2001" TYPE="REFERENCE">Kini 2001</LINK>). A systematic review by Kellner and colleagues examined the effectiveness of bronchodilators and showed modest short-term improvement in patients with mild to moderate bronchiolitis (<LINK REF="REF-Kellner-1996" TYPE="REFERENCE">Kellner 1996</LINK>). The review grouped all bronchodilators and compared these to placebo; they did not examine the relative efficacy of different bronchodilators. In a 2010 Cochrane systematic review, Gadomski et al examined the effectiveness of all bronchodilators (other than epinephrine) and found that they did not improve oxygen saturation, reduce hospital admission after outpatient treatment, shorten the duration of hospitalization or reduce the time to resolution of illness at home (<LINK REF="REF-Gadomski-2010" TYPE="REFERENCE">Gadomski 2010</LINK>). Although there were small improvements in clinical scores for outpatients, the authors cautioned that this must be weighed against the costs and adverse effects of bronchodilators (<LINK REF="REF-Gadomski-2010" TYPE="REFERENCE">Gadomski 2010</LINK>).</P>
<P>Epinephrine has a theoretical benefit because it contains alpha adrenergic properties in addition to the beta adrenergic effect. Wohl and Chernick suggested that bronchiolitis may benefit from the vasoconstricting effects and reduction of edema offered by the alpha adrenergic effect (<LINK REF="REF-Wohl-1978" TYPE="REFERENCE">Wohl 1978</LINK>). The mechanisms of different bronchodilators vary, therefore we chose to specifically investigate the efficacy of epinephrine in the treatment of bronchiolitis.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-04-25 20:24:02 +1000" MODIFIED_BY="[Empty name]">
<P>There continues to be substantial variation in the management of bronchiolitis worldwide (<LINK REF="REF-Babl-2008" TYPE="REFERENCE">Babl 2008</LINK>; <LINK REF="REF-Barben-2008" TYPE="REFERENCE">Barben 2008</LINK>; <LINK REF="REF-Christakis-2005" TYPE="REFERENCE">Christakis 2005</LINK>; <LINK REF="REF-Plint-2004" TYPE="REFERENCE">Plint 2004</LINK>), likely stemming from lack of evidence for any single approach. Several new trials have been published since the 2004 publication of this Cochrane Review (<LINK REF="REF-Hartling-2004" TYPE="REFERENCE">Hartling 2004</LINK>). Of particular interest is a multi-centre trial involving 800 children in Canada, examining epinephrine and dexamethasone, alone or combined utilizing a factorial design (<LINK REF="REF-Plint-2009" TYPE="REFERENCE">Plint 2009</LINK>). This pivotal trial adds substantially to the evidence and provides a strong signal for an update of the earlier review (<LINK REF="REF-Shojania-2007" TYPE="REFERENCE">Shojania 2007</LINK>). This trial also raises new questions about the benefit of combining epinephrine and steroids, therefore it is critical to incorporate these results along with other recently published trials to determine whether this new evidence can inform practice.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-05-03 09:07:40 +1000" MODIFIED_BY="[Empty name]">
<P>The objective of this review was to compare the effects of epinephrine (any route of administration) versus placebo or other active interventions (i.e. other bronchodilators, glucocorticoids) in infants less than two years of age with acute viral bronchiolitis. For outpatients the effects of epinephrine was measured based on the rate of admission on Day 1 and 7 and for inpatients by length of stay.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-05-03 09:08:22 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-05-03 09:08:22 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-04-25 20:24:22 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) evaluating the efficacy of epinephrine versus placebo or another active intervention in the treatment of bronchiolitis were considered for inclusion. We considered all studies regardless of language or publication status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-04-25 20:25:34 +1000" MODIFIED_BY="[Empty name]">
<P>All studies of infants and young children up to 24 months of age were considered for inclusion. We defined bronchiolitis as a first episode of wheezing, respiratory distress and clinical evidence of respiratory infection (for example, cough, coryza or fever). We included studies of inpatients or outpatients (ambulatory care or emergency department, or both). We excluded studies in the intensive care setting or with intubated or ventilated participants (or both). Patients admitted to the intensive care unit with bronchiolitis were not included as they are a distinct subset of patients which require specific focus in terms of disease description, interventions and outcomes.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-04-25 20:26:09 +1000" MODIFIED_BY="[Empty name]">
<P>We considered studies for inclusion if participants were randomized between receiving epinephrine or receiving placebo or another active intervention. We made no restrictions for dose, duration or routes of administration. Epinephrine could be administered alone or combined with co-interventions (for example, glucocorticoids), with or without a fixed study protocol.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-05-03 09:08:22 +1000" MODIFIED_BY="[Empty name]">
<P>We selected primary outcomes a priori based on clinical relevance and patient importance; secondary outcomes assessed other relevant health domains (clinical severity, pulmonary function, healthcare use, patient/parent-reported symptoms and status, and harms). We included studies if they reported numeric data on at least one primary or secondary outcome assessed within the first month after acute bronchiolitis. We considered different timings of outcome assessment, based on a priori relevance and available data.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-05-03 09:07:53 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Rate of admission by Day 1 and Day 7 for outpatients.</LI>
<LI>Length of stay for inpatients.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-05-03 09:08:22 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Change in clinical score, oxygen saturation (oximetry), respiratory rate and heart rate.</LI>
<LI>Hospital re-admissions for inpatients.</LI>
<LI>Return healthcare visits.</LI>
<LI>Length of stay for outpatients.</LI>
<LI>Pulmonary function tests.</LI>
<LI>Duration of symptoms and quality of life.</LI>
<LI>Short and long-term adverse events.</LI>
</OL>
<P>We selected the following time points and intervals for secondary outcomes: clinical scores, oxygen saturation, respiratory and heart rate, 60 and 120 minutes, 3 to 6, 6 to 12, 12 to 24, 24 to 72 hours, and 3 to 10 days; re-admissions and return visits, Days 1 to 10 and Days 11 to 30. When available we used these time points for both inpatient and outpatient outcomes. However, the majority of outpatient data are reported for the earlier time points. We also considered data on all other outcomes when reported.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-05-03 07:46:39 +1000" MODIFIED_BY="[Empty name]">
<P>We designed an inclusive search strategy as part of a comprehensive systematic review evaluating the effect of three types of interventions in bronchiolitis (steroids, epinephrine and other bronchodilators).</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-05-03 07:46:39 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2010, Issue 3) which contains the Acute Respiratory Infections Group's Specialized Register, MEDLINE Ovid Version (1950 to September Week 2, 2010), EMBASE Ovid Version (1980 to September 2010), Scopus<SUP>®</SUP> (1823 to September 2010), PubMed (March 2010), LILACS (1985 to September 2010) and IRAN MedEx (1998 to September 2010). We examined the reference lists of all selected articles for relevant studies. We developed the searches by scanning search strategies of relevant systematic reviews and examining index terms of potentially relevant studies. We applied a validated RCT filter and modified this for each database (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>). We applied no year or language restrictions. Full search strategies can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>.</P>
<P>To identify unpublished studies and those in progress we searched the following clinical trials registers on 3 March and 26 November 2009:</P>
<OL>
<LI>ClinicalTrials.gov; Current Controlled Trials;</LI>
<LI>ClinicalStudyResults.org;</LI>
<LI>Australian New Zealand Clinical Trials Registry;</LI>
<LI>IFPMA Clinical Trials Portal;</LI>
<LI>UMIN Clinical Trials Registry;</LI>
<LI>rct zoeken (<A HREF="http://www.trialregister.nl/trialreg/index.asp">http://www.trialregister.nl/trialreg/index.asp</A>) - Netherlands Trial Register - Dutch Cochrane Centre; and</LI>
<LI>ICTRP Search Portal - World Health Organization.</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-04-25 20:36:20 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the following conference proceedings: Canadian Pediatric Society, Pediatric Academic Societies and Society for Academic Emergency Medicine (2004 to 2009); European Respiratory Society (2003 to 2009); American Thoracic Society and European Society for Pediatric Research (2006 to 2009).</P>
<P>We identified additional published, unpublished and ongoing studies by handsearching reference lists of relevant reviews and included or excluded studies, as well as contacting topic specialists.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-04-25 21:50:54 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-04-25 21:48:42 +1000" MODIFIED_BY="[Empty name]">
<P>Four review authors (LB, LH, NH, RF) screened the titles, keywords and abstracts (when available) to determine if an article met the inclusion criteria. Two review authors independently screened each article and rated articles as 'include', 'exclude' or 'unclear'. One or more of the review authors retrieved the full text of all articles classified as 'include' or 'unclear' for detailed review. Two review authors (LB, LH, NH or RF) independently assessed each study using a standard inclusion/exclusion form. Disagreements were resolved by consensus or third-party adjudication.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-04-25 20:36:43 +1000" MODIFIED_BY="[Empty name]">
<P>One review author (LB, LH, HM, AM or RF) extracted data from English trials and a second review author (LB, LH, AM or RF) independently verified the data. One review author (OT) extracted data from Turkish (OT) and one review author (MK) extracted data from Farsi reports. We used a standard form that described the following: characteristics of the study (design, method of randomization, withdrawals/dropouts); participants (age, gender); intervention (type, dose, route of administration, timing and duration of therapy, co-interventions); control (agent and dose); outcomes (types of outcome measures, timing of outcomes, adverse effects); whether or not the study used an intention-to-treat protocol; funding source; and results.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-04-25 21:49:51 +1000" MODIFIED_BY="[Empty name]">
<P>We used the Cochrane 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess for potential for bias in the included studies. We pilot tested the 'Risk of bias' tool on a sample of five studies. We used results from this pilot to adapt decision rules based on the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> guidance regarding application of the tool (rules available from review authors). Two review authors (LH, LB or RF) independently evaluated the risk of bias of included trials. Differences were resolved by consensus reached after discussion. Only one review author assessed studies published in Turkish (OT) and Farsi (MK).</P>
<P>As recommended by the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), we grouped outcomes into classes with similar risks of bias for the assessment of blinding and incomplete outcome data. The classes and associated outcomes included: 1) administrative - rate of admission, length of hospitalization, hospital re-admission, return to any healthcare facility; 2) clinical scores/parameters - change in clinical scores, oxygen saturation, respiratory rate, heart rate; 3) patient-reported quality of life measures, assessment of well-being; 4) pulmonary function - forced expiratory volume, other pulmonary function tests; and 5) other - adequate fluid intake, duration of oxygen therapy, adverse events, etc.</P>
<P>For the selective outcome reporting domain, we used the search strategies described to identify trial protocols or trial registers. When these were available, we compared the stated pre-specified outcomes with the paper reported outcomes. If not available, we compared outcomes reported in the methods and results sections of the reports.</P>
<P>The overall (study level) assessment of risk of bias for each study was based on recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If one or more domains were assessed as having a high risk of bias, we rated the overall score as high. Only if all domains were rated as having a low risk of bias was the overall score considered low. We rated all other studies as unclear for overall risk of bias.</P>
<P>We chose a priori to explore the impact of summarized risk of bias at a study level by performing sensitivity analyses of the primary outcomes restricted to studies with a low overall risk of bias, whenever feasible.</P>
<SUBSECTION>
<HEADING LEVEL="4">Grading the body of evidence</HEADING>
<P>We used the Evidence-Based Practice Centers GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, based on the standard GRADE system, to assess the domain-specific and overall strength of evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Owens-2009" TYPE="REFERENCE">Owens 2009</LINK>). We evaluated the outcomes which were judged to be most relevant: length of hospital stay (LOS) or admission rate; clinical severity scores; and adverse events. We examined the following four domains: risk of bias, consistency, directness and precision.</P>
<P>We graded the overall strength of evidence as high (further research is very unlikely to change our confidence in the estimate of effect), moderate (further research may change our confidence in the estimate of effect and may change the estimate), low (further research is likely to change the confidence in the estimate of effect and is likely to change the estimate), or insufficient (evidence either is unavailable or does not permit estimation of an effect).</P>
<P>Two review authors (LH, RF) independently graded the body of evidence using GRADE guidance and decision rules adapted to the clinical and research context. For the risk of bias domain, we considered all evidence as high or medium, as we only included RCTs. For the precision domain, there is limited evidence of the minimal clinically important difference for all outcomes studied. We considered a priori the following clinical thresholds of significance, based on expert opinion: a relative reduction of 20% or more for dichotomous outcomes, and a reduction in LOS of 0.5 days or more. We used GRADE guidelines for the remaining domains (<LINK REF="REF-GRADEpro-2009" TYPE="REFERENCE">GRADEpro 2009</LINK>). All decisions were made explicitly and we calculated inter-rater agreement (available from authors). Two review authors (LH, RF) resolved discrepancies through consensus.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-04-25 21:50:54 +1000" MODIFIED_BY="[Empty name]">
<P>We pooled dichotomous variables using risk ratios (RR). We analyzed measurement scale outcomes as continuous variables. For continuous variables measured on the same scale (for example, respiratory rate), we calculated mean differences for individual studies and calculated mean differences (MD) for the pooled estimates. For continuous variables measured on different scales (for example, different clinical scores) we calculated mean differences for separate studies and calculated standardized mean differences (SMD) for the pooled estimates. We used changes from baseline for all continuous variables when available, otherwise we used unadjusted final scores. We conducted separate analyses for the different types of control groups (i.e. placebo, non-epinephrine bronchodilators, glucocorticoids) and clinical setting (i.e. inpatient or outpatient).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-04-25 20:41:32 +1000" MODIFIED_BY="[Empty name]">
<P>Some studies with more than two intervention groups were eligible to contribute with several comparisons between arms to a single pair-wise meta-analysis. We included data from these arms with no transformation when the comparisons were independent, i.e. with no intervention group in common (for example, a trial with four independent arms (1) 'epinephrine + placebo', (2) 'epinephrine + dexamethasone', (3) 'placebo + dexamethasone' and (4) 'placebo + placebo' contributed both comparisons 1 versus 4 and 2 versus 3 to the overall epinephrine versus placebo comparison). These arms are shown separately in each forest plot, with the same study identification. If needed and feasible, we pooled the active groups to avoid double-counting of the comparator group when there was more than one active group (for example, when there were two steroid groups versus placebo). No treatment groups were included twice in the same meta-analysis.</P>
<P>We extracted and included both 'at the margins' and 'inside the table' data for factorial trials whenever reported. These are shown separately in each forest plot with the same study identification (see <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK>). There were no further unit of analysis issues.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-04-25 20:42:16 +1000" MODIFIED_BY="[Empty name]">
<P>We extracted information on incomplete outcome data and we identified trials that performed adequate intention-to-treat analysis. We only included data for participants whose results were reported; we did not impute missing data for drop-outs (available case analysis). We addressed the potential impact of the missing data in the assessment of risk of bias (incomplete outcome data domain).</P>
<P>When means were not given they were estimated from graphs or imputed from medians if possible. Otherwise, the study would be excluded from the meta-analysis. Standard deviations, when not given, were computed from available data (i.e. standard errors, confidence intervals or P values). Failing this we estimated them from ranges and inter-quartile ranges, or imputed them from a similar study. To estimate standard deviations of change from baseline values, we estimated correlation at 0.5 when it was not available.</P>
<P>When data were unavailable for one of the predefined timings of outcome measurement, we used the time point closest to the planned timing, or any time point in the range. If there was more than one time point, we chose the one with the largest magnitude of change. We did not contact authors of the individual trials to obtain additional data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-04-25 20:42:29 +1000" MODIFIED_BY="[Empty name]">
<P>We quantified statistical heterogeneity using the I<SUP>2</SUP> statistic. A value greater than 50% was considered to be substantial heterogeneity (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-04-25 20:42:46 +1000" MODIFIED_BY="[Empty name]">
<P>We did not assess publication bias due to the small number of trials in each outcome, comparison and clinical setting group included in the review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-04-25 20:45:24 +1000" MODIFIED_BY="[Empty name]">
<P>We meta-analyzed quantitative results within the different comparisons when studies were consistent on clinical grounds and had available outcome data. There were no restrictions based on risk of bias. We performed meta-analyses separately for studies involving inpatients and outpatients.</P>
<P>We combined results using random-effects models regardless of heterogeneity, due to expected differences in interventions, outcomes and measurement instruments (for example, clinical scores measuring different clinical features or weighting these differently). We also calculated fixed-effects in a sensitivity analysis. We carried out meta-analyses of dichotomous outcomes using Mantel-Haenszel methods (<LINK REF="REF-Borenstein-2009" TYPE="REFERENCE">Borenstein 2009</LINK>). We used inverse variance methods for continuous outcomes and measurement scales. All results are reported with 95% CI and we used Review Manager (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-04-25 20:45:37 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to investigate heterogeneity by conducting subgroup analyses based on the protocolized use of steroids (use of steroids was part of, and defined by, the study protocol versus steroid given at the discretion of the attending physician). This subgroup was decided upon based on a recent trial suggesting a possible positive interaction ('synergism') between steroids and epinephrine. Our aim was to subgroup trials in which steroid use was fixed by protocol in all participants (epinephrine + fixed steroid versus placebo + fixed steroid), from those in which steroid use was at the discretion of the physician or not allowed ('pure' epinephrine versus placebo). Differences between these subgroups could be attributed to positive or negative (i.e. 'synergistic' or 'antagonistic') interactions between treatments when combined. We planned to perform subgroup analyses only on the review's primary outcomes.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-09-27 12:38:30 +1000" MODIFIED_BY="[Empty name]">
<P>We decided a priori to perform sensitivity analyses on primary outcome results of trials with overall low risk of bias. We also checked for differences in the direction and magnitude of primary outcome results when using fixed-effect models, as well as using pooled data from all factorial trial arms ('at the margins data').</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-05-03 09:11:16 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-05-03 07:38:41 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-05-03 07:38:34 +1000" MODIFIED_BY="[Empty name]">
<P>The search strategy identified 2387 citations from electronic databases (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). After screening titles and abstracts, 349 studies were assessed to be potentially relevant. Four additional studies were identified for further examination by contact with experts or handsearching the reference lists from previous systematic reviews.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-05-03 07:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>We reviewed the full text of 353 reports using the pre-defined inclusion criteria resulting in 301 irrelevant studies and 33 excluded studies in this review. A total of 19 reports of RCTs are included in this review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>The 19 included studies ranged in sample size from 27 to 800 and included a total of 2256 participants. For detailed information on each study refer to the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables. Nine studies involved 773 inpatients (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>) and 10 involved 1483 outpatients (<LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>). Ten studies only included children at one year of age or younger and three studies described atopic status of participants (<LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>). In all 19 studies epinephrine was administered via nebulization. Five studies used racemic epinephrine (<LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>), 12 used L-epinephrine (<LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>), and for two studies information on the type of epinephrine was not available (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>). Most trials reported administering epinephrine in multiple doses (n = 12) with all others being delivered as a single dose (n = seven). Placebo was compared to an active treatment in nine studies with eight studies reporting the use of saline (<LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>) and one study did not indicate the type of placebo used (<LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>).</P>
<P>A wide range of outcomes was reported. The primary outcomes varied across studies: clinical score (<LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK> ); length of stay (<LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>); oxygen saturation (<LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>); admission rates (<LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>); admission rates for those on home oxygen therapy (<LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>); heart rate and/or respiratory rate (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>); clinical score and respiratory rate (<LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>); and clinical score, respiratory rate and heart rate (<LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>). Secondary outcomes included: clinical score; oxygen saturation; respiratory rate; heart rate; blood pressure; activity status; time in oxygen; need for supplemental oxygen; adequate fluid intake; duration of hospitalization; rate of hospitalization; temperature; pulmonary functions; duration of symptoms; return to healthcare facility; and 'improvement' as defined by the individual trials. Most of the outcomes reported were short-term (i.e. within minutes or hours of treatment) with few studies evaluating longer-term outcomes (for example, participants' progression over several days). Due to inconsistency or lack of reporting, the following pre-defined outcomes were not meta-analyzed: quality of life (none reported), pulmonary functions (<LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>) and participant/provider report of symptoms (<LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>).</P>
<P>The majority of studies assessing clinical score used the Respiratory Distress Assessment Instrument (RDAI) (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>) with other assessments done through the modification of existing clinical scores (<LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>) and respiratory effort score (<LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>).</P>
<P>The majority (n = 16) of studies were published in English, with two of the studies published in Turkish (<LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>) and one in Farsi (<LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>). Most studies were conducted in high-income countries: Australia (<LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>); Canada (<LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>); Chile (<LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>); England (<LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>); Israel (<LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>); Turkey (<LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>) and the United States (<LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>). Five of the studies were conducted in low-income countries, including Jordan (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>); Iran (<LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>); India (<LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>); and Bangladesh (<LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-04-25 20:49:11 +1000" MODIFIED_BY="[Empty name]">
<P>For this update we revised the inclusion criteria to include only studies that defined bronchiolitis as the first episode of wheezing. As a result of this new criterion five studies included in the original review have been excluded from this update (<LINK REF="STD-Hariprakash-2003" TYPE="STUDY">Hariprakash 2003</LINK>; <LINK REF="STD-Kristjansson-1993" TYPE="STUDY">Kristjansson 1993</LINK>; <LINK REF="STD-Lowell-1987" TYPE="STUDY">Lowell 1987</LINK>; <LINK REF="STD-Ray-2002" TYPE="STUDY">Ray 2002</LINK>; <LINK REF="STD-Reijonen-1995" TYPE="STUDY">Reijonen 1995</LINK>). For detailed information on reasons for exclusion refer to the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-04-25 20:50:15 +1000" MODIFIED_BY="[Empty name]">
<P>Domain-specific and overall risk of bias assessments are detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and summarized by outcome and study in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, respectively. Of the 19 included studies 42% (n = eight) had an overall risk of bias rating of 'Unclear' (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>), 32% (n = six) a rating of 'Low' (<LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>) and 26% (n = five) a rating of 'High' (<LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomization sequence</HEADING>
<P>Twelve studies reported an adequate method of generating the randomization sequence (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>).</P>
</SUBSECTION>
<ALLOCATION MODIFIED="2010-11-05 06:52:59 +1000" MODIFIED_BY="[Empty name]">
<P>Nine studies adequately concealed the randomization sequence from the investigators (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-04-25 20:50:00 +1000" MODIFIED_BY="[Empty name]">
<P>All 19 of the trials assessed either an administrative outcome or clinical severity parameter; 12 of these trials adequately blinded participants and investigators.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-04-25 20:50:07 +1000" MODIFIED_BY="[Empty name]">
<P>Incomplete outcome reporting was adequately addressed in 11 of 13 for the review primary outcomes; 13 of 18 for clinical severity score.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-11-05 07:22:41 +1000" MODIFIED_BY="[Empty name]">
<P>Thirteen studies adequately reported outcomes in methods/protocol and results (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>), four studies had unclear reporting (<LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>), and two studies did not adequately report all outcomes in the methods/protocol and results (<LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>). We identified three studies with protocols (<LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>) that were used to assist in the assessment of selective outcome reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-04-25 20:50:15 +1000" MODIFIED_BY="[Empty name]">
<P>The studies were assessed for bias with respect to potential for inappropriate influence of funder, important imbalances in baseline characteristics, and use of a cross-over design. Twelve studies were at low risk of bias for other sources of bias (<LINK REF="STD-Abu_x002d_Shukair-2001" TYPE="STUDY">Abu-Shukair 2001</LINK>; <LINK REF="STD-Abul_x002d_Ainine-2002" TYPE="STUDY">Abul-Ainine 2002</LINK>; <LINK REF="STD-Beck-2007" TYPE="STUDY">Beck 2007</LINK>; <LINK REF="STD-Bertrand-2001" TYPE="STUDY">Bertrand 2001</LINK>; <LINK REF="STD-Bilan-2007" TYPE="STUDY">Bilan 2007</LINK>; <LINK REF="STD-Khashabi-2005a" TYPE="STUDY">Khashabi 2005a</LINK>; <LINK REF="STD-Menon-1995" TYPE="STUDY">Menon 1995</LINK>; <LINK REF="STD-Mull-2004" TYPE="STUDY">Mull 2004</LINK>; <LINK REF="STD-Patel-2002a" TYPE="STUDY">Patel 2002a</LINK>; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK>; <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK>; <LINK REF="STD-Wainwright-2003" TYPE="STUDY">Wainwright 2003</LINK>), six studies were unclear (<LINK REF="STD-Anil-2010a" TYPE="STUDY">Anil 2010a</LINK>; <LINK REF="STD-Barlas-1998a" TYPE="STUDY">Barlas 1998a</LINK>; <LINK REF="STD-John-2006" TYPE="STUDY">John 2006</LINK>; <LINK REF="STD-Kadir-2009" TYPE="STUDY">Kadir 2009</LINK>; <LINK REF="STD-Kuyucu-2004a" TYPE="STUDY">Kuyucu 2004a</LINK>; <LINK REF="STD-Okutan-1998a" TYPE="STUDY">Okutan 1998a</LINK>), and one study was inadequate due to the utilization of a cross-over study design (<LINK REF="STD-Sanchez-1993" TYPE="STUDY">Sanchez 1993</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-05-03 09:11:16 +1000" MODIFIED_BY="[Empty name]">
<P>We stratified results by comparison (i.e. epinephrine versus placebo, epinephrine versus salbutamol, epinephrine versus steroid, epinephrine and steroid versus placebo, epinephrine and steroid versus salbutamol, epinephrine versus salbutamol and ipratropium bromide) and by setting (i.e. inpatient versus outpatient). Supplementary data tables are available for strength of evidence (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) and adverse events (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Summary of findings are provided for the following comparisons: epinephrine versus placebo (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), epinephrine versus salbutamol (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>), epinephrine and steroid versus placebo (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>) and epinephrine versus steroid (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Epinephrine versus placebo</HEADING>
<P>Nine studies compared epinephrine and placebo; these comparisons involved a total of 1354 patients (677 epinephrine; 677 placebo). The studies were published between 1995 and 2010 and were conducted in Canada (n = two), the US (n = one), Australia (n = one), Turkey (n = three), England (n = one) and Iran (n = one). Three studies involved inpatients (n = 333) and six studies involved outpatients (n = 1021). Three studies used racemic epinephrine while six studies used L-epinephrine. Epinephrine was administered by nebulizer in all studies.</P>
<P>The overall risk of bias was low for three studies, unclear for five studies and high for one study. The latter study was assessed as high risk overall due to potential selective outcome reporting: a number of outcomes were reported in the results but not mentioned in the methods section of the report. Studies were rated unclear overall primarily due to unclear reporting with respect to sequence generation and allocation concealment.</P>
<SUBSECTION>
<HEADING LEVEL="4">Inpatients (three studies)</HEADING>
<P>Our primary outcome (length of stay: LOS) was reported and declared as the primary outcome in two studies. The primary outcomes for the third study were respiratory rate and heart rate. There was no statistically significant difference in LOS (mean difference (MD) -0.35; 95% confidence interval (CI) -0.87 to 0.17; two studies, 292 participants) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>There were also no differences in clinical score, oxygen saturation, respiratory rate at any of the time points measured. The only significant difference in terms of physiological measures was for heart rate at 60 minutes post-treatment, which favored placebo (MD 13.06; 95% CI 1.19 to 24.92; two studies, 225 participants) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
<P>There were no significant differences in other administrative outcomes, including hospital readmission after discharge and return visits to the emergency department (ED) or any healthcare provider.</P>
<P>One study reported on adverse events and found no occurrences of vomiting, pallor, tremor or arrhythmias.</P>
<P>There was no change in the results for LOS and clinical scores when only low risk of bias studies were included.</P>
<P>The strength of evidence was moderate for inpatient studies, i.e. there was moderate evidence suggesting no difference in length of stay or clinical score at 60 minutes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outpatients (six studies)</HEADING>
<P>Our primary outcome for outpatients (admission rate) was assessed in five studies and was declared as the primary outcome in two studies. The timing of assessment differed: <LINK REF="STD-Ralston-2005a" TYPE="STUDY">Ralston 2005a</LINK> measured admission within 24 hours of study enrolment; <LINK REF="STD-Plint-2009a" TYPE="STUDY">Plint 2009a</LINK> reported admission rates up to seven days and by Day 22 after enrolment; timing was not specified by Barlas et al. The primary outcome was clinical score in two studies and not specified in two studies. Physiological measures were commonly assessed; the timing of assessments as well as other outcomes assessed in each study are detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>The primary outcome of admission rate at Day 1 was significant in favor of epinephrine (RR 0.67; 95% CI 0.50 to 0.89; five studies; n = 995) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). However, admission rate by Day 7 was not significantly different between groups. Differences in results for admission at Day 1 were seen for subgroups that used steroids (RR 0.74; 95% CI 0.45 to 1.23; one study, 400 participants) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>) versus those that did not (RR 0.62; 95% CI 0.40 to 0.94; five studies, 595 participants) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). However, the CIs overlapped. When analyses for admission at Day 1 were restricted to trials with low risk of bias, results were no longer statistically significant (RR 0.77; 95% CI 0.56 to 1.07; three studies, 842 participants) (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>). For admission up to Day 7, results were significant when steroids were used (RR 0.67; 95% CI 0.45 to 0.98; one study; 400 participants) versus no steroid use (RR 0.90; 95% CI 0.64 to 1.26; one study; 400 participants) (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). While the point estimates differed substantially between these subgroups, the Cls overlapped.</P>
<P>Results favored epinephrine in terms of change in clinical score at 60 and 120 minutes (standardized mean difference (SMD) -0.40; 95% CI -0.58 to -0.23; five studies, n = 975; and SMD -0.73; 95% CI -1.13 to -0.33; two studies, n = 105, respectively) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). There was no significant difference between groups in oxygen saturation at 60 and 120 minutes or respiratory rate at 60 minutes. Results favored placebo in terms of change in heart rate at 60 minutes, although there was no difference between groups at 120 minutes post-treatment. There was no difference in return visits (RR 0.98; 95% CI 0.81 to 1.19; two studies, n = 800) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>Three studies reported on adverse events (n = 944). One study observed pallor (11% epinephrine, 8% placebo), vomiting (2% epinephrine, 1.5% placebo), tremors (2% epinephrine, 1% placebo) and hypertension (0.5% epinephrine, 0% placebo). However, the occurrence was not significantly different between groups. The other study found no occurrences of tachycardia, withdrawal due to worsening clinical status, or discontinuation of study medications due to adverse events.</P>
<P>The strength of evidence favoring epinephrine was rated as moderate for admissions Day 1 and low for admissions Day 7. In terms of clinical score, the strength of evidence favoring epinephrine was considered high at 60 minutes and low at 120 minutes. Details for each strength of evidence domain are detailed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epinephrine versus salbutamol</HEADING>
<P>Fifteen studies compared epinephrine versus salbutamol/albuterol; these comparisons involved 957 randomized participants (480 epinephrine; 477 salbutamol). The studies were published between 1993 and 2010 and were conducted in Canada (n = three), Turkey (n = four), the USA (n = two), Iran (n = two), Jordan (n = one), India (n = one), Israel (n = one) and Chile (n = two). Six studies involved inpatients (n = 430) and nine studies involved outpatients (n = 527). Four studies used racemic epinephrine while eight studies used L-epinephrine and in two studies the type of epinephrine was unknown. Epinephrine was administered by nebulizer in all studies.</P>
<P>'Risk of bias' was low in four studies, unclear in seven studies and high in four studies. Studies were assessed at high risk of bias due to selective outcome reporting, incomplete outcome reporting, cross-over study design and limited baseline characteristics. Many studies were unclear in their reporting of sequence generation (n = seven), allocation concealment (n = eight), and blinding (n = six).</P>
<SUBSECTION>
<HEADING LEVEL="4">Inpatients (six studies)</HEADING>
<P>Our primary outcome for inpatients (length of stay) was reported in four studies and declared as the primary outcome in one study. The primary outcomes for one study were respiratory rate, heart rate and clinical score. The remaining studies (n = four) did not specify a primary outcome. The other outcomes assessed are detailed the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>There was a statistically significant difference in the primary outcome of length of stay favoring epinephrine (MD -0.28; 95% CI -0.46 to -0.09; four studies, 261 participants) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). However, the implications of this result need to be interpreted in light of the above findings showing no difference for epinephrine versus placebo. The result was not significant when restricted to one trial at low risk of bias.</P>
<P>There were significant differences favoring epinephrine for change in clinical score at both 60 minutes and 120 minutes post-treatment (SMD -0.79; 95% CI -1.45 to -0.13; four studies, 248 participants; and SMD -0.52; 95% CI -0.86 to -0.18; one study, 140 participants, respectively) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Change in oxygen saturation was significant and favored epinephrine at 60 minutes. However, there was no difference between groups at 120 minutes based on data from one study. There was a significant difference favoring epinephrine in change in respiratory rate at 60 minutes but not 120 minutes. There were no significant differences in heart rate at 60 minutes or 120 minutes. Further, there were no significant differences in hospital readmissions after discharge.</P>
<P>Two studies reported on adverse events. One study found no cases of pallor, vomiting or tremors (n = 46). The second study (n = 30) reported no cases of tremor, increased blood pressure after nebulization or tachycardia among the epinephrine group; the authors did not report on adverse events for the salbutamol group.</P>
<P>The strength of evidence for inpatients was moderate for length of stay and low for clinical score, however the findings varied by outcome. There were no differences for overall length of stay, while results favored epinephrine in terms of clinical score at 60 and 120 minutes. Details for each strength of evidence domain are detailed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outpatients (nine studies)</HEADING>
<P>Our primary outcome for outpatients (admission rate) was assessed in seven studies, and was declared as the primary outcome in one study. The primary outcome for the remaining studies was clinical score (n = three), oxygen saturation (n = one), respiratory rate (n = one) or not specified (n = three). The other outcomes assessed in each study are detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>The primary outcomes of admission rate at Day 1 and Day 7 were not significantly different between treatment groups (RR 0.67; 95% CI 0.41 to 1.09; seven studies, n = 444 and RR 1.05; 95% CI 0.71 to 1.54, two studies; n = 212, respectively) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Clinical score and heart rate were compared at 60 and 120 minutes, 12 to 24 hours, and 3 to 10 days post-treatment. Respiratory rate was assessed at 60 and 120 minutes, 12 to 24 hours, and &gt; 24 hours. Significant differences were found favoring epinephrine for clinical score at 3 to 10 days and respiratory rate at 60 minutes and &gt; 24 hours. Oxygen saturation was assessed at 60 and 120 minutes but no differences were found. Return visits to any healthcare facility was not significantly different between groups overall or for the two time points measured (i.e. 2 to 10 days, 10 to 30 days).</P>
<P>Three studies reported on adverse events. One study (n = 66) reported on pallor (one epinephrine, zero albuterol), vomiting (one epinephrine, five albuterol), and tremors (zero epinephrine, zero albuterol). The second study (n = 40) reported cases of tachycardia (zero epinephrine, two albuterol) but reported no cases of withdrawal due to worsening clinical status or discontinuation of study medications due to adverse events. The third study (n = 186) reported no cases of tremor or increased heart rate in the epinephrine or albuterol groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epinephrine versus steroid</HEADING>
<P>Two studies compared steroids and epinephrine; these comparisons involved a total of 444 patients (230 steroid; 214 epinephrine). One study examined prednisolone (n = 15) and budesonide (n = 15), and one study examined dexamethasone (n = 200). The studies were published in 1995 and 2009 and were conducted in Turkey and Canada. Both studies involved outpatients. There were no studies that compared steroids and epinephrine among inpatients.</P>
<P>'Risk of bias' was unclear in one study and low in the other study. The study that was rated unclear did not describe methods for sequence generation, allocation concealment and blinding, and did not report any funding source.</P>
<P>Our primary outcome for outpatients (admission rate) was assessed in both studies, and was declared as the primary outcome in one study. The primary outcome in the other study was clinical score. A variety of other outcomes were assessed and are detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>The primary outcomes of admission rate at Day 1 and Day 7 were not significantly different between groups.</P>
<P>Results favored epinephrine over steroids in terms of change in clinical score at 60 minutes (SMD 0.31; 95% CI 0.12 to 0.50; two studies, 442 participants) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). There was no significant difference for change in clinical score at 120 minutes or three to six hours, possibly due to the small numbers of participants for these comparisons. There was a significant difference in oxygen saturation at 60 minutes favoring epinephrine, but no significant difference at 120 minutes or three to six hours, again possibly due to the small numbers of participants available for comparison at these latter time points. There was no significant difference in respiratory rate at 60 minutes post-treatment. Results favored steroids in terms of change in heart rate at 60 minutes, although there was no difference between groups at 120 minutes and three to six hours post-treatment. Based on one study, there was no significant difference between groups in return visits to any healthcare facility.</P>
<P>One study reported on adverse events and noted the following reactions which did not differ substantially between groups: pallor (11% epinephrine, 7.5% dexamethasone), vomiting (2% epinephrine, 2.5% dexamethasone), tremors (2% epinephrine, 2.5% dexamethasone), and hypertension (0.5% epinephrine, 0.5% dexamethasone).</P>
<P>The strength of evidence was rated moderate among outpatient studies in terms of admissions (no difference between groups) and high for clinical score 60 minutes post-treatment (favoring epinephrine over steroids). The strength of evidence was low for clinical score at other time points due to the small number of patients and only a single study for these comparisons. Details for each strength of evidence domain are detailed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epinephrine and steroid versus placebo</HEADING>
<P>One study compared epinephrine and dexamethasone versus placebo among 399 outpatients. The study was conducted in Canada and was rated as low risk of bias. For our primary outcomes, no significant difference was observed at Day 1. However, a significant difference favoring epinephrine and dexamethasone was observed for Day 7 (RR 0.65; 95% CI 0.44 to 0.95) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). The number needed to treat for this comparison is 11 (95% CI 7 to 76).</P>
<P>A significant difference favoring epinephrine and dexamethasone was also observed for clinical score at 60 minutes. No differences were observed for respiratory rate or oxygen saturation at 60 minutes. A significant difference favoring placebo was found for heart rate at 60 minutes. The study observed the following adverse events: pallor (11.5% epi + dex; 8% placebo); vomiting (1% epi + dex; 1.5% placebo); tremor (2% epi + dex; 1% placebo); and hypertension (0% in both groups).</P>
<P>The strength of evidence for admissions at Day 1 and Day 7 was rated as low due to unknown consistency and imprecision resulting from the small number of events. The strength of evidence for clinical score at 60 minutes was considered moderate demonstrating superiority of epinephrine and dexamethasone combined. Details for each strength of evidence domain are detailed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epinephrine and steroid versus salbutamol</HEADING>
<P>One small study (n = 35) compared epinephrine and dexamethasone versus salbutamol among outpatients. The study did not evaluate our primary outcome of length of stay. The study measured clinical score at 120 minutes, 24 to 48 hours, and 3 to 10 days. The only significant difference in clinical score was at 3 to 10 days. Respiratory rate was assessed at 120 minutes, 12 to 24 hours, and &gt; 24 hours; a significant difference was observed at &gt; 24 hours. Heart rate was assessed at 120 minutes, 24 to 72 hours, and 3 to 10 days; there were no significant differences at any time point assessed. The study did not report any adverse effects.</P>
<P>The strength of evidence for admissions at Day 1 and Day 7 was insufficient. The strength of evidence for clinical score was considered low and only favored epinephrine and dexamethasone at the longest of the three time points assessed (i.e. 3 to 10 days). Details for each strength of evidence domain are detailed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Epinephrine versus salbutamol and ipratropium bromide</HEADING>
<P>One study compared epinephrine versus salbutamol and ipratropium bromide among 60 inpatients. This study did not evaluate our primary outcome of length of stay. The study measured clinical score and oxygen saturation at six to 12 hours. The only significant difference was in the clinical score which favored epinephrine. The study was at high risk of bias due to lack of blinding. The strength of evidence for this finding is considered low.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-05-03 09:11:27 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-04-25 21:01:45 +1000" MODIFIED_BY="[Empty name]">
<P>This review provides evidence of the effectiveness of epinephrine in outpatients for outcomes of most clinical relevance, specifically admission rates during the first 24 hours. This is supported by positive results for secondary outcomes, in particular short-term changes in clinical scores.</P>
<P>This review provides preliminary evidence for the effectiveness of epinephrine and dexamethasone combined for outcomes of most clinical relevance among outpatients. This is based on a single large trial with low risk of bias which demonstrated a relative risk reduction of 35%. Based on the study's baseline risk, 11 children with bronchiolitis would need to be treated to reduce one admission. These were unadjusted results from a factorial randomized controlled trial (RCT) which should be interpreted cautiously since significant findings may arise from multiple comparisons.</P>
<P>There is no evidence of effectiveness for repeated dose or prolonged use of epinephrine or epinephrine and dexamethasone combined among inpatients. While epinephrine compared to salbutamol showed a significant difference for length of stay, the finding is tempered by the fact that there were no differences in length of stay for epinephrine versus placebo.</P>
<P>The evidence shows no important differences in adverse effects with epinephrine over the short-term.</P>
<P>Although severity of illness was reported overall in many of the studies, due to variability of scales used it is difficult to assess which populations are most sensitive to these treatments. For outpatient results comparing epinephrine to placebo most of the population ranges from mild to moderate severity with some possibly severe; and for epinephrine compared to steroid the population ranges from moderate to severe.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-05-03 09:11:27 +1000" MODIFIED_BY="[Empty name]">
<P>The findings from this review add substantially to the current evidence base regarding the use of epinephrine in acute viral bronchiolitis. For this update we used revised methodology at all stages of the review, including more precise inclusion criteria and pre-defined clinically relevant primary outcomes. We also devised a new approach to analysis in order to accommodate for the use of epinephrine alone or in combination with steroids, and the presence of different comparisons. A substantial amount of new data was added, including up to 800 participants from the largest RCT performed to date in bronchiolitis. We used a comprehensive search strategy to capture all potentially relevant trials. We were unable to test for publication bias due to the small number of studies within each category of comparison, outcome and clinical setting.</P>
<P>This review included only first-time wheezers so results could be directly pertinent to infants with 'typical' viral bronchiolitis, as opposed to children with acute recurrent wheezing (i.e. episodic/viral or multiple-trigger wheeze) or a formal diagnosis of asthma. We acknowledge that there is no standard definition of bronchiolitis (<LINK REF="REF-DiTraglia-2004" TYPE="REFERENCE">DiTraglia 2004</LINK>; <LINK REF="REF-Weinberger-2003" TYPE="REFERENCE">Weinberger 2003</LINK>; <LINK REF="REF-Weinberger-2007" TYPE="REFERENCE">Weinberger 2007</LINK>), in part due to regional variation in semantics between North America and UK, which is likely to exist throughout the world. Differences in definitions are based on factors like age of the child, number of previous wheezing episodes, and acute clinical findings. For example, in the UK, 'crackles' are often key to a diagnosis of bronchiolitis, while older children with wheeze may be considered a distinct subgroup (<LINK REF="REF-Everard-2009" TYPE="REFERENCE">Everard 2009</LINK>). A first episode of wheezing may be a first manifestation of wheezing phenotypes with heterogeneous pathological, genetic, viral or environmental determinants and distinct prognosis (<LINK REF="REF-Brand-2008" TYPE="REFERENCE">Brand 2008</LINK>; <LINK REF="REF-Martinez-2005" TYPE="REFERENCE">Martinez 2005</LINK>; <LINK REF="REF-Sly-2008" TYPE="REFERENCE">Sly 2008</LINK>). However, research is still ongoing to identify simple, valid and universal discriminative and/or prognostic tools to distinguish prospectively between them (<LINK REF="REF-Brand-2008" TYPE="REFERENCE">Brand 2008</LINK>; <LINK REF="REF-Sly-2008" TYPE="REFERENCE">Sly 2008</LINK>). Our choice of bronchiolitis definition was meant to allow a pragmatic interpretation of results by clinicians in different settings, and findings are likely to be applicable to children with different bronchiolitis definitions.  </P>
<P>The applicability of the findings from this review is driven by the individual trial characteristics. There was variation between the trials in delivery of interventions including the type of epinephrine, number of administrations and dosage. We were unable to assess the impact of these variations due to the small number of studies in each comparison.</P>
<P>The effectiveness of interventions may also vary according to a number of patient factors such as age, severity or stage of illness, co-morbidities, viral etiology, and atopic status of the patient, family or both. There were insufficient data presented at the trial level to allow for comparisons within these important subgroups. Ten studies included only children less than one year of age. Seven of these studies involved inpatients, therefore there were insufficient numbers of studies within the comparative groups to examine differences with respect to younger (&lt;= 12 months) versus older (up to two years) children. The trials most often involved children without co-morbidities. Individual trials varied in terms of the disease severity of their sample ranging from mild to severe disease, although data were rarely available for these subgroups within trials. Inpatient versus outpatient status may be a proxy for severity or response to treatment which may explain the differences in effect, particularly lack of clear effect among inpatients. Further, we excluded studies in the intensive care unit (ICU) setting or involving children requiring intubation or mechanical ventilation which likely represent children with more severe disease or complicating co-morbidities. Data were not available to examine effects due to different viral etiology. In the seven studies that described the viral etiology of their participants, the majority (&gt; 50%) were positive for respiratory syncytial virus. Two studies described the atopic status of participants and found it present in approximately 10% and 13.3%; subgroup analyses at the trial level showed no important differences in effect for the trial with 10% atopy in participants.</P>
<P>Results from one trial show that a combination of epinephrine with systemic dexamethasone may have a significant and clinically relevant effect in reducing admissions of outpatients by Day 7, when compared to placebo. Caution may be advised when interpreting whether these findings are true and generalizable. Recent empirical evidence suggests that reliance on evidence from a single precise well-conducted trial is reasonable (<LINK REF="REF-Glasziou-2010" TYPE="REFERENCE">Glasziou 2010</LINK>).This was a factorial trial with methodological caveats, and interpretation of results is problematic since interaction between treatments was not anticipated. It is not clear how to handle possible additive/synergistic or subtractive/antagonistic effects at a systematic review level. These results should be considered exploratory; replication of these findings is needed to improve our confidence in the direction, precision and magnitude of the effect estimate. Further, additional research is required to assess the applicability of combination therapy to other populations, specifically inpatients, and to examine differences within the combination schemes, such as doses of steroids.</P>
<P>Results suggesting a benefit from epinephrine and dexamethasone should be balanced against incomplete data on harms. Safety concerns are expected regarding the widespread use of epinephrine and steroids in young children with viral wheezing, particularly with repeated high steroid doses (<LINK REF="REF-Bush-2009" TYPE="REFERENCE">Bush 2009</LINK>; <LINK REF="REF-Frey-2009" TYPE="REFERENCE">Frey 2009</LINK>). Our results do not suggest any serious or frequent short-term expected or unexpected harms from epinephrine or steroids in infants with bronchiolitis in the absence of co-morbidities. However, the power to detect important differences was limited due to the infrequent occurrence of events. Adverse event detection at the trial level was also heterogeneous. Current data from RCTs and observational studies in croup suggest a favorable short-term safety profile from both dexamethasone and epinephrine (<LINK REF="REF-Bjornson-2008" TYPE="REFERENCE">Bjornson 2008</LINK>; <LINK REF="REF-Zhang-2005b" TYPE="REFERENCE">Zhang 2005b</LINK>). Corticosteroids also raise long-term safety issues. Their use in prematurity for neonatal respiratory distress has been associated with effects on adrenal function, cardiovascular responses, somatic and lung growth, and neurodevelopment (<LINK REF="REF-Doyle-2010" TYPE="REFERENCE">Doyle 2010</LINK>; <LINK REF="REF-Karemaker-2008b" TYPE="REFERENCE">Karemaker 2008b</LINK>; <LINK REF="REF-Karemaker-2008a" TYPE="REFERENCE">Karemaker 2008a</LINK>; <LINK REF="REF-Onland-2008" TYPE="REFERENCE">Onland 2008</LINK>; <LINK REF="REF-Wilson_x002d_Costello-2009" TYPE="REFERENCE">Wilson-Costello 2009</LINK>). Evidence is scarce, however, regarding effects of short-term use in otherwise healthy term infants. Further pharmacoepidemiologic data are needed to permit adequate short and long-term risk-benefit assessments.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-04-25 21:03:42 +1000" MODIFIED_BY="[Empty name]">
<P>Our risk of bias and strength of evidence assessments provide clarity around the limitations of this body of evidence. Two key factors affected the strength of evidence: potential risk of bias in the included studies and sparsity of data for many of the outcomes and comparisons, which resulted in imprecise estimates and unknown consistency of estimates across studies. The trials varied in their risk of bias with six at low risk, five high and eight unclear. The domains that resulted in high overall risk of bias were selective outcome reporting in two trials, missing outcome data in one trial, and use of cross-over design in one trial which we deemed to be inappropriate for this condition. The domains that consistently contributed to unclear overall ratings were sequence generation, allocation concealment and blinding. This information provides clear direction for enhanced reporting of future trials.</P>
<P>Sparsity of data was a result of a large number of comparisons as well as variability in the choice of outcomes and timing of outcome assessments. Within trials, this also led to frequent uncertainties regarding selective outcome reporting. The message around consistency and relevance of outcomes is not new to this field. The absence of standardized, validated and patient-important outcome measures and instruments in this area has been a challenge for evidence synthesis and poses a threat to the validity of trial results. Our primary outcomes were based on the increased use of hospital services, and its clear implications for patients and families. However, there is no evidence or guidance supporting the choice of outcomes that are methodologically sound and patient-important. The diversity of primary outcomes chosen by different included trials reflects this, and caused heterogeneous sample size calculations. Timings of assessment are also important and were not standardized. Additionally, validity of admissions and length of stay is limited by inadequate reporting of hospitalization and discharge criteria, given the wide variation in bronchiolitis management. Many factors besides disease severity and treatment response may contribute to these outcomes (for example, social, family, health service related factors), and this may ultimately impact treatment effects. While most trials assessed clinical scores, the choice of instruments was inconsistent. Their compositions often encompass different disease domains, and scale structures differed, which limits comparability between results. While the Respiratory Distress Assessment Instrument (RDAI) was used in a considerable number of trials, its clinimetric properties are not well known. Importantly, responsiveness and clinically important differences have not been defined, thus limiting the clinical interpretation of findings. The heterogeneity in post-acute symptom assessment instruments, as well as the absence of any quality of life measures highlights under representation of patient-important domains. Further work is needed to define a core set of clinically important efficacy and safety outcome measures and timing of assessments, for trials and systematic reviews in this field.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-04-25 21:03:51 +1000" MODIFIED_BY="[Empty name]">
<P>Strengths of this updated review rest primarily on a revision of methods used and investigation of new hypotheses stemming from recent evidence. Some limitations have been described previously; others should also be highlighted. We did not obtain data from authors of included studies, which might have clarified risk of bias assessments and further added to reported trial characteristics and secondary outcome results. Our approach to the investigation of synergism/antagonism was exploratory, since there is scarce guidance on how to handle this issue at a systematic review level. The same holds for the use of factorial trial results in systematic reviews when interaction is observed. Limitations of subgroup analyses are well known and have been addressed. Grading of evidence was limited by the lack of evidence regarding clinically relevant differences in studied outcomes. Finally, we were unable to assess for publication bias due to the small number of studies within each outcome, comparison and patient subgroup.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-09-27 14:59:55 +1000" MODIFIED_BY="[Empty name]">
<P>The earlier version of this review published in 2004 (<LINK REF="REF-Hartling-2004" TYPE="REFERENCE">Hartling 2004</LINK>) showed "some evidence to support the use of epinephrine among outpatients." This was based on findings for clinical parameters from a small number of studies of varying internal validity. Overall the review found that the findings lacked consistency. One of the largest sources of inconsistency in the earlier review arose from the six different scoring systems used across the component studies. This resulted in statistically significant heterogeneity between studies. The present review adds substantially more data to the comparisons of interest. Further, the focus on different outcomes of clinical and patient importance (i.e. admission rates for outpatients and length of stay for inpatients) avoids over-reliance on the clinical scores and the challenges they present for interpretation. The findings from the present review increase our confidence in the effectiveness of epinephrine among outpatients. However, the lack of evidence for epinephrine among inpatients remains.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-04-25 21:04:08 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-04-25 21:04:04 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>There is evidence that epinephrine is effective for outpatients in terms of outcomes of clinical importance, including admissions within 24 hours and short-term changes in clinical scores and other clinical parameters. There were no important differences reported in adverse effects.</LI>
<LI>Combined epinephrine and high-dose systemic dexamethasone may be effective in reducing outpatient admissions in moderately severe bronchiolitis, with few short-term adverse effects. Efficacy, harms and applicability of this promising finding need to be clarified further. </LI>
<LI>There is insufficient evidence to support the use of epinephrine, with or without steroids, for the treatment of bronchiolitis among inpatients.</LI>
</OL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-04-25 21:04:08 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>A large RCT is needed to replicate and complement findings from combination therapy with epinephrine and steroids for outpatients. An additional aim could include assessing the minimum efficacious steroid dose.</LI>
<LI>The strategy of combined epinephrine and steroids could be evaluated in inpatient settings.</LI>
<LI>Data are needed to assess the long-term safety of combination treatment with epinephrine and steroids.</LI>
<LI>Future trials should use standardized sets of outcome measures in this field.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-04-25 21:04:56 +1000" MODIFIED_BY="[Empty name]">
<P>We thank Marlene Dorgan and Ellen Crumley for their assistance with searching for the initial review. We thank Dr. Metin Gulmezoglum for his assistance with translation and data extraction of the Turkish studies for the initial review. We would like to acknowledge the previous review authors Kelly Russell and Natasha Wiebe for their work on the original document.</P>
<P>The authors gratefully acknowledge the following individuals for their contributions to the most recent update: Ms. Annabritt Chisholm (article retrieval), Ms. Heather McPhee (study inclusion, quality assessment and data extraction), Ms. Nicola Hooton (study selection), Ms. Andrea Milne (screening, study inclusion, quality assessment and data extraction), Dr. Özge Tunçalp (Turkish translation), Joy Lee (Korean translation), João Franco (Spanish translation), Mohammad Karkhaneh (Farsi translation) and Paolo Valerio (Dutch translation). Finally we thank the following people for commenting on this updated review: Thiagarajan Jaiganesh, Vishal Jatana, Sara Ahronheim, Robert Ware and<B> </B>Inge Axelsson.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-09-01 08:26:58 +1000" MODIFIED_BY="[Empty name]">
<P>ACP, HP, DWJ and TPK are authors and/or co-authors on trials included in this review. No other declarations of interest are noted.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-04-25 21:04:28 +1000" MODIFIED_BY="[Empty name]">
<P>LH contributed to protocol development, searching, relevance and inclusion screening, quality assessment, data extraction, analysis and writing the review.<BR/>LB contributed to relevance and inclusion screening, quality assessment, data extraction, analysis and writing the review.<BR/>BV contributed to protocol development, analysis and editing the review.<BR/>LT contributed to the development and execution of the search strategy and editing the review.<BR/>DWJ contributed to relevance and inclusion screening, analysis and editing the review.<BR/>ACP contributed to relevance and inclusion screening, analysis and editing the review.<BR/>TPK contributed to protocol development, relevance and inclusion screening, analysis and editing the review.<BR/>HP contributed to review of protocol, interpretation of results and editing the review.<BR/>RMF contributed to protocol development, searching, relevance and inclusion screening, quality assessment, data extraction, analysis and writing the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2011-04-25 21:05:36 +1000" MODIFIED_BY="[Empty name]">
<P>We made the following changes to this 2010 update based on consultations with clinicians and authors.</P>
<OL>
<LI>We modified the inclusion criteria to include definitions of bronchiolitis that specified first episode of wheezing.</LI>
<LI>The outcome 'improvement' has been excluded.</LI>
<LI>Analyses of return visits, hospital re-admissions, risk of bias and synergies of drug combinations have been added.</LI>
<LI>Comparisons of epinephrine plus dexamethasone versus placebo, epinephrine plus dexamethasone versus salbutamol, epinephrine versus salbutamol plus ipratropium bromide have been added.</LI>
<LI>The search strategy for this review along with <I>Glucocorticoids for acute viral bronchiolitis in infants and young children</I> (<LINK REF="REF-Fernandes-2010" TYPE="REFERENCE">Fernandes 2010</LINK>) were part of a comprehensive synthesis project evaluating the effect of various interventions in bronchiolitis, i.e. bronchodilators, epinephrine and steroids.</LI>
<LI>Based on the data available in the included studies the time points from the previous review (change from baseline at 30, 60 and 90 minutes) have been modified to include the following: change from baseline at 60 minutes, 120 minutes, three to six hours, 6 to 12 hours, 12 to 24 hours, 24 to 72 hours and 3 to 10 days.</LI>
</OL>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-04-25 22:16:25 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-11-27 03:26:24 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-11-27 03:26:24 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abu_x002d_Shukair-2001" NAME="Abu-Shukair 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Shukair M, El-Tal Y, Al-Rawabdeh E</AU>
<TI>Salbutamol versus epinephrine in the treatment of acute bronchiolitis</TI>
<SO>Journal of the Bahrain Medical Society</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>3</NO>
<PG>143-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abul_x002d_Ainine-2002" NAME="Abul-Ainine 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abul-Ainine A, Luyt D</AU>
<TI>Short term effects of adrenaline in bronchiolitis: a randomised controlled trial</TI>
<SO>Archives of Diseases in Children</SO>
<YR>2002</YR>
<VL>86</VL>
<PG>276-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anil-2010a" MODIFIED="2010-10-14 08:29:11 +1000" MODIFIED_BY="[Empty name]" NAME="Anil 2010a" YEAR="2010">
<REFERENCE MODIFIED="2010-10-14 02:49:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N</AU>
<TI>High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anil-2010b" MODIFIED="2010-10-14 08:30:30 +1000" MODIFIED_BY="[Empty name]" NAME="Anil 2010b" YEAR="2010">
<REFERENCE MODIFIED="2010-10-14 08:30:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N</AU>
<TI>High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anil-2010c" MODIFIED="2010-11-27 03:26:24 +1000" MODIFIED_BY="[Empty name]" NAME="Anil 2010c" YEAR="2010">
<REFERENCE MODIFIED="2010-11-27 03:26:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anil AB, Anil M, Saglam AB, Cetin N, Bal A, Aksu N</AU>
<TI>High volume normal saline alone is as effective as nebulized salbutamol-normal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998a" MODIFIED="2010-09-27 09:27:06 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998a" YEAR="1998">
<REFERENCE MODIFIED="2010-09-27 09:27:06 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Gocmen A, Ozcelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<PG>155-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998b" MODIFIED="2010-09-27 09:27:13 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998b" YEAR="1998">
<REFERENCE MODIFIED="2010-09-27 09:27:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Gocmen A, Ozcelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<PG>155-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barlas-1998c" MODIFIED="2010-09-27 09:27:20 +1000" MODIFIED_BY="[Empty name]" NAME="Barlas 1998c" YEAR="">
<REFERENCE MODIFIED="2010-09-27 09:27:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barlas C, Kiper N, Gocmen A, Ozcelik U, Dilber E, Anadol D, et al</AU>
<TI>Racemic adrenaline and other treatment regimens in mild and moderate bronchiolitis</TI>
<SO>Cocuk Sagligi Ve Hastaliklari Dergisi</SO>
<YR>1998</YR>
<VL>41</VL>
<PG>155-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-2007" MODIFIED="2010-09-22 01:04:00 +1000" MODIFIED_BY="[Empty name]" NAME="Beck 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-09-22 01:04:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beck R, Elias N, Shoval S, Tov N, Talmon G, Godfrey S, et al</AU>
<TI>Computerized acoustic assessment of treatment efficacy of nebulized epinephrine and albuterol in RSV bronchiolitis</TI>
<SO>BMC Pediatrics</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>22</NO>
<PG>online publication</PG>
<MD>Open Access</MD>
<IDENTIFIERS MODIFIED="2010-04-08 03:18:33 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-08 03:18:33 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2431-7-22"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertrand-2001" NAME="Bertrand 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertrad P, Aranibar H, Castro E, Sanchez I</AU>
<TI>Efficacy of nebulized epinephrine versus salbutamol in hospitalised infants with bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>31</VL>
<PG>284-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bilan-2007" MODIFIED="2010-02-19 07:10:34 +1000" MODIFIED_BY="[Empty name]" NAME="Bilan 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-02-19 07:10:33 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilan N, Saiied Sadry N</AU>
<TI>Clinical efficacy of salbutamol spray in treatment of bronchiolitis</TI>
<SO>Medical Journal of Tabriz University of Medical Sciences</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-John-2006" MODIFIED="2010-02-20 02:39:15 +1000" MODIFIED_BY="[Empty name]" NAME="John 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-02-20 02:39:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>John BM, Patnaik SK, Prasad PL</AU>
<TI>Efficacy of nebulised epinephrine versus salbutamol in hospitalised children with bronchiolitis</TI>
<SO>Medical Journal Armed Forces India</SO>
<YR>2006</YR>
<VL>62</VL>
<PG>354-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kadir-2009" MODIFIED="2010-10-14 02:51:25 +1000" MODIFIED_BY="[Empty name]" NAME="Kadir 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-14 02:51:23 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kadir MA, Mollah AH, Basak R, Choudhury AM, Ahmed S</AU>
<TI>Comparative efficacy of combined nebulized salbutamol with ipratropium bromide and nebulized adrenaline to treat children with acute bronchiolitis</TI>
<SO>Mymensingh Medical Journal</SO>
<YR>2009</YR>
<VL>18</VL>
<PG>208-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khashabi-2005a" MODIFIED="2010-03-27 06:11:07 +1000" MODIFIED_BY="[Empty name]" NAME="Khashabi 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-02-19 06:54:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khashabi J</AU>
<TI>Comparison of the efficacy of nebulized L-epinephrine, salbutamol and normal saline in acute bronchiolitis: a randomized clinical trial</TI>
<SO>Medical Journal of the Islamic Republic of Iran</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>2</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khashabi-2005b" MODIFIED="2010-04-08 02:32:51 +1000" MODIFIED_BY="[Empty name]" NAME="Khashabi 2005b" YEAR="">
<REFERENCE MODIFIED="2010-04-08 02:32:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khashabi J</AU>
<TI>Comparison of the efficacy of nebulized L-epinephrine, salbutamol and normal saline in acute bronchiolitis: a randomized clinical trial</TI>
<SO>Medical Journal of the Islamic Republic of Iran</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>2</NO>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyucu-2004a" MODIFIED="2010-04-08 02:01:50 +1000" MODIFIED_BY="[Empty name]" NAME="Kuyucu 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyucu S, Unal S, Kuyucu N, Yilgor E</AU>
<TI>Additive effects of dexamethasone in nebulized salbutamol or l-epinephrine treated infants with acute bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<PG>539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyucu-2004b" MODIFIED="2010-04-08 02:33:05 +1000" MODIFIED_BY="[Empty name]" NAME="Kuyucu 2004b" YEAR="">
<REFERENCE MODIFIED="2010-04-08 02:33:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyucu S, Unal S, Kuyucu N, Yilgor E</AU>
<TI>Additive effects of dexamethasone in nebulized salbutamol or l-epinephrine treated infants with acute bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<PG>539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyucu-2004c" MODIFIED="2010-04-08 02:33:09 +1000" MODIFIED_BY="[Empty name]" NAME="Kuyucu 2004c" YEAR="">
<REFERENCE MODIFIED="2010-04-08 02:33:09 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyucu S, Unal S, Kuyucu N, Yilgor E</AU>
<TI>Additive effects of dexamethasone in nebulized salbutamol or l-epinephrine treated infants with acute bronchiolitis</TI>
<SO>Pediatrics International</SO>
<YR>2004</YR>
<VL>46</VL>
<PG>539-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menon-1995" NAME="Menon 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menon K, Sutcliffe T, Klassen TP</AU>
<TI>A randomised trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<PG>1004-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mull-2004" MODIFIED="2010-09-22 01:06:11 +1000" MODIFIED_BY="[Empty name]" NAME="Mull 2004" YEAR="2002">
<REFERENCE MODIFIED="2010-09-22 01:06:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mull CC, Scarfone RJ, Ferri LR, Carlin T, Salvaggio C, Bechtel KA, et al</AU>
<TI>A randomized trial of nebulized epinephrine vs albuterol in the emergency department treatment of bronchiolitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<NO>2</NO>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okutan-1998a" MODIFIED="2010-04-08 00:46:16 +1000" MODIFIED_BY="[Empty name]" NAME="Okutan 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okutan V, Akin R, Kurekci AE, Yanik A, Ozcan O, Gokcay E</AU>
<TI>Effectiveness of nebulised adrenaline and salbutamol in the treatment of infants with bronchiolitis</TI>
<SO>Bulletin of Gulhane Military Medical Academy</SO>
<YR>1998</YR>
<VL>40</VL>
<PG>199-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okutan-1998b" MODIFIED="2010-04-08 02:33:22 +1000" MODIFIED_BY="[Empty name]" NAME="Okutan 1998b" YEAR="">
<REFERENCE MODIFIED="2010-04-08 02:33:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okutan V, Akin R, Kurekci AE, Yanik A, Ozcan O, Gokcay E</AU>
<TI>Effectiveness of nebulised adrenaline and salbutamol in the treatment of infants with bronchiolitis</TI>
<SO>Bulletin of Gulhane Military Medical Academy</SO>
<YR>1998</YR>
<VL>40</VL>
<PG>199-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2002a" MODIFIED="2010-02-19 06:29:41 +1000" MODIFIED_BY="[Empty name]" NAME="Patel 2002a" YEAR="2001">
<REFERENCE MODIFIED="2010-02-19 06:29:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Patel H, Platt RW, Pekeles GS, Ducharme F</AU>
<TI>A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<NO>6</NO>
<PG>818-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2002b" MODIFIED="2010-02-19 06:30:40 +1000" MODIFIED_BY="[Empty name]" NAME="Patel 2002b" YEAR="2001">
<REFERENCE MODIFIED="2010-02-19 06:30:40 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Patel H, Platt RW, Pekeles GS, Ducharme F</AU>
<TI>A randomized, controlled trial of the effectiveness of nebulized therapy with epinephrine compared with albuterol and saline in infants hospitalized for acute viral bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<NO>6</NO>
<PG>818-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Plint-2009a" MODIFIED="2010-09-22 01:06:50 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009a" YEAR="2009">
<REFERENCE MODIFIED="2010-09-22 01:06:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>20</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2009b" MODIFIED="2010-09-22 01:07:01 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009b" YEAR="2009">
<REFERENCE MODIFIED="2010-09-22 01:07:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>20</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2009c" MODIFIED="2010-09-22 01:07:14 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009c" YEAR="2009">
<REFERENCE MODIFIED="2010-09-22 01:07:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>20</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plint-2009d" MODIFIED="2010-09-22 01:07:26 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009d" YEAR="2009">
<REFERENCE MODIFIED="2010-09-22 01:07:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>20</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralston-2005a" MODIFIED="2010-09-22 01:08:17 +1000" MODIFIED_BY="[Empty name]" NAME="Ralston 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-09-22 01:08:17 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ralston S, Hartenberger C, Anaya T, Qualls C, William KH</AU>
<TI>Randomized, placebo-controlled trial of albuterol and epinephrine at equipotent beta-2 agonist doses in acute bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>292-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ralston-2005b" MODIFIED="2010-09-22 01:08:24 +1000" MODIFIED_BY="[Empty name]" NAME="Ralston 2005b" YEAR="">
<REFERENCE MODIFIED="2010-09-22 01:08:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ralston S, Hartenberger C, Anaya T, Qualls C, William KH</AU>
<TI>Randomized, placebo-controlled trial of albuterol and epinephrine at equipotent beta-2 agonist doses in acute bronchiolitis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2005</YR>
<VL>40</VL>
<PG>292-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-1993" NAME="Sanchez 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V</AU>
<TI>Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>122</VL>
<PG>145-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wainwright-2003" NAME="Wainwright 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Wainwright C, Altamirano L, Cheney M, et al. A multi-centre randomised controlled double blind trial of nebulised adrenaline in infants with &lt;br&gt;bronchiolitis. N Engl J Med 2003;349:27-35.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wainwright C, Altamirano L, Cheney M, Cheney J, Barber S, Price D, et al</AU>
<TI>A multi-centre randomised controlled double blind trial of nebulised adrenaline in infants with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<PG>27-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-10-14 01:18:30 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Altamirano-2002" MODIFIED="2010-03-05 08:03:39 +1000" MODIFIED_BY="[Empty name]" NAME="Altamirano 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 07:58:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altamirano L</AU>
<TI>A multi-centre randomised controlled double-blind trial of nebulised adrenaline in infants with bronchiolitis</TI>
<SO>Respirology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>A52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altinel-2003" MODIFIED="2010-03-05 08:03:45 +1000" MODIFIED_BY="[Empty name]" NAME="Altinel 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 08:00:12 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altinel N, Karadag B, Pekun F, Dagli E</AU>
<TI>Efficacy of nebulised adrenaline and salbutamol on mild to moderate bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl 45</NO>
<PG>A1438</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1993" MODIFIED="2010-09-27 09:29:03 +1000" MODIFIED_BY="[Empty name]" NAME="Carter 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-09-27 09:29:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter ER, Moffitt DR</AU>
<TI>Nebulized salbutamol versus racemic epinephrine in the treatment of infants with bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1993</YR>
<VL>123</VL>
<NO>3</NO>
<PG>491-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carvajal-2001" MODIFIED="2010-03-05 08:10:49 +1000" MODIFIED_BY="[Empty name]" NAME="Carvajal 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 08:10:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carvajal CC</AU>
<TI>Natural epinephrine in bronchiolitis</TI>
<SO>Revista Espanola de Pediatria</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>342</NO>
<PG>497-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frohna-2009" MODIFIED="2010-10-14 01:17:19 +1000" MODIFIED_BY="[Empty name]" NAME="Frohna 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-14 01:17:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frohna JG, Frey U</AU>
<TI>Combination of epinephrine and dexamethasone may reduce hospitalization in children with bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>2009</YR>
<VL>155</VL>
<PG>761-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grewal-2009" MODIFIED="2010-03-05 08:12:53 +1000" MODIFIED_BY="[Empty name]" NAME="Grewal 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-03-05 08:12:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grewal S, Ali S, McConnell D, Vandermeer B, Klassen T</AU>
<TI>A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2009</YR>
<VL>163</VL>
<NO>11</NO>
<PG>1007-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guill-2003" MODIFIED="2010-03-05 08:13:53 +1000" MODIFIED_BY="[Empty name]" NAME="Guill 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 08:13:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guill MF</AU>
<TI>Question from the clinician: racemic epinephrine for bronchiolitis</TI>
<SO>Pediatrics in Review</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>8</NO>
<PG>284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gurkan-2004" MODIFIED="2010-03-05 08:15:58 +1000" MODIFIED_BY="[Empty name]" NAME="Gurkan 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-03-05 08:15:56 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gurkan F, Tuzun H, Ece A, Haspolat K, Bosnak M, Dikici B</AU>
<TI>Comparison of treatments with nebulised salbutamol and epinephrine in acute bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>A2163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hariprakash-2003" MODIFIED="2010-09-27 09:29:36 +1000" MODIFIED_BY="[Empty name]" NAME="Hariprakash 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-09-27 09:29:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hariprakash S, Alexander J, Carroll W</AU>
<TI>Randomized controlled trial of nebulized adrenaline in acute bronchiolitis</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-2003" MODIFIED="2010-03-05 08:17:30 +1000" MODIFIED_BY="[Empty name]" NAME="King 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 08:17:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King TM, Perovitz-Bichell K, Rowe PC, Lehmann HP</AU>
<TI>Is epinephrine efficacious in the treatment of bronchiolitis?</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2003</YR>
<VL>157</VL>
<NO>10</NO>
<PG>965-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klassen-2003" MODIFIED="2010-03-05 08:19:02 +1000" MODIFIED_BY="[Empty name]" NAME="Klassen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 08:19:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP</AU>
<TI>In infants with bronchiolitis, is epinephrine more effective than placebo in improving clinical outcomes, as measured by clinical score, oxygen saturation and respiratory rate? Part B: clinical commentary</TI>
<SO>Paediatrics and Child Health</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>10</NO>
<PG>630</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kristjansson-1993" MODIFIED="2010-02-18 09:06:39 +1000" MODIFIED_BY="[Empty name]" NAME="Kristjansson 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-02-18 09:06:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kristjansson S, Lodrup Carlsen KC, Wennergren G, Strannegard I-L, Carlsen K-H</AU>
<TI>Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers</TI>
<SO>Archives of Diseases of Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>650-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langley-2005" MODIFIED="2010-07-06 06:17:15 +1000" MODIFIED_BY="[Empty name]" NAME="Langley 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-06 06:17:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, Smith MB, LeBland JC, Joudrey H, Ojah CR, Pianosi P</AU>
<TI>Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled trial</TI>
<SO>BMC Pediatrics</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>7</NO>
<PG>online publication</PG>
<MD>Open Access</MD>
<IDENTIFIERS MODIFIED="2010-04-08 03:17:34 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-08 03:17:34 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/1471-2431-5-7"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez-Andreu-2002" MODIFIED="2010-03-05 08:27:00 +1000" MODIFIED_BY="[Empty name]" NAME="Lopez Andreu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 08:26:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez Andreu JA, Ruiz Garcia V, Roques Serradilla JM</AU>
<TI>Nebulized epinephrine in acute bronchiolitis. Is there enough evidence?</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>4</NO>
<PG>362-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lowell-1987" MODIFIED="2010-02-18 09:12:34 +1000" MODIFIED_BY="[Empty name]" NAME="Lowell 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-02-18 09:12:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lowell DI, Lister G, Von Koss H, McCarthy P</AU>
<TI>Wheezing in infants: the response to epinephrine</TI>
<SO>Pediatrics</SO>
<YR>1987</YR>
<VL>79</VL>
<PG>939-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinon_x002d_Torres-2002" MODIFIED="2010-03-05 08:28:46 +1000" MODIFIED_BY="[Empty name]" NAME="Martinon-Torres 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 08:28:44 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinón-Torres F, Rodriguez Núñez A, Martinón Sánchez JM</AU>
<TI>Bronchiolitis and epinephrine: reviewing the evidence</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>4</NO>
<PG>363-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meates-2002" MODIFIED="2010-03-05 08:03:52 +1000" MODIFIED_BY="[Empty name]" NAME="Meates 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 08:02:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meates M</AU>
<TI>Does nebulised adrenaline (epinephrine) reduce admission rate in bronchiolitis?</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>6</NO>
<PG>548-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mesquita-2009" MODIFIED="2010-10-14 01:15:07 +1000" MODIFIED_BY="[Empty name]" NAME="Mesquita 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-14 01:15:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mesquita PM, Castro-Rodriquez JA, Heinichen L, Farina E, Iramain R</AU>
<TI>Single oral dose of dexamethasone in outpatients with bronchiolitis: a placebo controlled trial</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>2009</YR>
<VL>37</VL>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Misra-2003" MODIFIED="2010-03-05 08:29:52 +1000" MODIFIED_BY="[Empty name]" NAME="Misra 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 08:29:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Misra S, Stevermer JJ</AU>
<TI>Nebulized epinephrine does not help bronchiolitis</TI>
<SO>Journal of Family Practice</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>11</NO>
<PG>845-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okutan-2002" MODIFIED="2010-03-05 08:06:10 +1000" MODIFIED_BY="[Empty name]" NAME="Okutan 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-03-05 08:06:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okutan V, Kurekci AE, Akin R, Yanik A, Ozcan O, Gokcay E</AU>
<TI>Nebulized adrenaline vs. salbutamol in wheeze associated respiratory infections</TI>
<SO>Indian Pediatrics</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>12</NO>
<PG>1170-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patel-2001" MODIFIED="2010-03-05 08:30:56 +1000" MODIFIED_BY="[Empty name]" NAME="Patel 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-03-05 08:30:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel H</AU>
<TI>Randomized, controlled trial of extended-use epinephrine in infants with bronchiolitis</TI>
<SO>Pediatric Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>4</NO>
<PG>239A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-2002" MODIFIED="2010-02-18 09:13:57 +1000" MODIFIED_BY="[Empty name]" NAME="Ray 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-02-18 09:13:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray MS, Singh V</AU>
<TI>Comparison of nebulized adrenaline versus salbutamol in wheeze associated respiratory tract infection in infants</TI>
<SO>Indian Pediatrics</SO>
<YR>2002</YR>
<VL>39</VL>
<PG>12-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reijonen-1995" MODIFIED="2010-02-18 09:15:34 +1000" MODIFIED_BY="[Empty name]" NAME="Reijonen 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-02-18 09:15:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reijonen T, Korppi M, Pitkakangas S, Tenhola S, Remes K</AU>
<TI>The clinical efficacy of nebulized racemic epinephrine and albuterol in acute bronchiolitis</TI>
<SO>Archives of Pediatric and Adolescent Medicine</SO>
<YR>1995</YR>
<VL>149</VL>
<PG>686-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rusconi-1996" MODIFIED="2010-09-27 09:30:31 +1000" MODIFIED_BY="[Empty name]" NAME="Rusconi 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-09-27 09:30:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rusconi F, Sideri S</AU>
<TI>Efficacy of epinephrine with salbutamol in treatment of acute bronchiolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>128</VL>
<NO>3</NO>
<PG>441-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saseen-2004" MODIFIED="2010-09-27 09:30:45 +1000" MODIFIED_BY="[Empty name]" NAME="Saseen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-09-27 09:30:45 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saseen JJ</AU>
<TI>Epinephrine is efficacious for outpatient treatment of bronchiolitis</TI>
<SO>Journal of Family Practice</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>3</NO>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schumacher-2010" MODIFIED="2010-10-14 01:18:30 +1000" MODIFIED_BY="[Empty name]" NAME="Schumacher 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-14 01:18:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schumacher DJ</AU>
<TI>No significant improvement in bronchiolitis seen with hypertonic saline plus epinephrine</TI>
<SO>Journal of Pediatrics</SO>
<YR>2010</YR>
<VL>156</VL>
<PG>858-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simsek-2005" MODIFIED="2010-09-22 01:10:03 +1000" MODIFIED_BY="[Empty name]" NAME="Simsek 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-09-22 01:10:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simsek PO, Aslan AT, Kiper N, Yalcin E, Dogru D, Ozcelik U, et al</AU>
<TI>A randomized trial of the effectiveness of nebulized therapy with epinephrine compared with salbutamol in the treatment of acute viral bronchiolitis</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>A865</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tal-2006" MODIFIED="2010-09-27 09:31:01 +1000" MODIFIED_BY="[Empty name]" NAME="Tal 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-09-27 09:31:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tal G, Cesar K, Oron A, Houri S, Ballin A, Mandelberg A</AU>
<TI>Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience</TI>
<SO>Israel Medical Association Journal</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>3</NO>
<PG>169-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valverde-2005" MODIFIED="2010-03-05 08:38:36 +1000" MODIFIED_BY="[Empty name]" NAME="Valverde 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 08:38:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valverde MJ, Escribano MA</AU>
<TI>Treatment of bronchiolitis: use of nebulized epinephrine</TI>
<SO>Anales de Pediatria</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>2</NO>
<PG>179-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Aerde-2003" MODIFIED="2010-03-05 08:39:38 +1000" MODIFIED_BY="[Empty name]" NAME="Van Aerde 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-03-05 08:39:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Aerde T, Klassen T</AU>
<TI>In infants with bronchiolitis, is epinephrine more effective than placebo in improving clinical outcomes, as measured by clinical score, oxygen saturation and respiratory rate? Part A: Evidence-based answer and summary</TI>
<SO>Paediatrics and Child Health</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>10</NO>
<PG>629-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walsh-2008" MODIFIED="2010-03-05 08:41:12 +1000" MODIFIED_BY="[Empty name]" NAME="Walsh 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-03-05 08:41:11 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh P, Caldwell J, McQuillan KK, Friese S, Robbins D, Rothenberg SJ</AU>
<TI>Comparison of nebulized epinephrine to albuterol in bronchiolitis</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>4</NO>
<PG>305-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waseem-2006" MODIFIED="2010-03-05 08:41:48 +1000" MODIFIED_BY="[Empty name]" NAME="Waseem 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-03-05 08:41:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waseem M</AU>
<TI>Use of racemic epinephrine in bronchiolitis: what is the emergency physician's perspective?</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>4</NO>
<PG>1114-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2010-03-05 08:07:40 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-03-05 08:07:37 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Sanguebsche LS</AU>
<TI>The safety of nebulization with 3 to 5 ml of adrenaline (1:1000) in children: an evidence based review</TI>
<SO>Jornal de Pediatria</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>3</NO>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-02-18 09:05:30 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-04-25 22:16:25 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-04-25 22:16:25 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Babl-2008" MODIFIED="2010-09-22 01:17:07 +1000" MODIFIED_BY="[Empty name]" NAME="Babl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Babl FE, Sheriff N, Neutze J, Borland M, Oakley E</AU>
<TI>Bronchiolitis management in pediatric emergency departments in Australia and New Zealand: a PREDICT study</TI>
<SO>Pediatric Emergency Care</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>10</NO>
<PG>656-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barben-2008" MODIFIED="2010-09-22 01:17:17 +1000" MODIFIED_BY="[Empty name]" NAME="Barben 2008" TYPE="JOURNAL_ARTICLE">
<AU>Barben J, Kuehni CE, Trachsel D, HammerJ, Swiss Paediatric Respiratory Research Group</AU>
<TI>Management of acute bronchiolitis: can evidence based guidelines alter clinical practice</TI>
<SO>Thorax</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>12</NO>
<PG>1103-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bialy-2006" MODIFIED="2010-06-03 03:13:29 +1000" MODIFIED_BY="[Empty name]" NAME="Bialy 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bialy L, Smith M, Bourke T, Becker L</AU>
<TI>The Cochrane Library and bronchiolitis: an umbrella review</TI>
<SO>Evidence Based Child Health: A Cochrane Review Journal</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>4</NO>
<PG>939-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjornson-2008" MODIFIED="2011-03-16 01:40:13 +1000" MODIFIED_BY="[Empty name]" NAME="Bjornson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bjornson CL, Johnson DW</AU>
<TI>Croup</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<NO>9609</NO>
<PG>329-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borenstein-2009" MODIFIED="2010-11-17 15:43:10 +1000" MODIFIED_BY="[Empty name]" NAME="Borenstein 2009" TYPE="BOOK_SECTION">
<AU>Borenstein M, Hedges LV, Higgins JPT, Rothstein HR</AU>
<TI>Chapter 37: Further methods for dichotomous data</TI>
<SO>Introduction to Meta-Analysis</SO>
<YR>2009</YR>
<PG>331-9</PG>
<PB>Wiley</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brand-2008" MODIFIED="2011-03-15 06:21:47 +1000" MODIFIED_BY="[Empty name]" NAME="Brand 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A, et al</AU>
<TI>Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<VL>32</VL>
<PG>1096-110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bush-2009" MODIFIED="2011-04-25 21:30:36 +1000" MODIFIED_BY="[Empty name]" NAME="Bush 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bush A</AU>
<TI>Practice imperfect - treatment for wheezing in preschoolers</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<PG>409-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christakis-2005" MODIFIED="2010-09-22 01:17:30 +1000" MODIFIED_BY="[Empty name]" NAME="Christakis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM</AU>
<TI>Variation in inpatients diagnostic testing and management of bronchiolitis</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>4</NO>
<PG>878-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiTraglia-2004" MODIFIED="2011-04-12 13:06:36 +1000" MODIFIED_BY="[Empty name]" NAME="DiTraglia 2004" TYPE="JOURNAL_ARTICLE">
<AU>DiTraglia J</AU>
<TI>Bronchiolitis</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2004</YR>
<VL>158</VL>
<NO>7</NO>
<PG>707-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2010" MODIFIED="2011-04-12 13:07:08 +1000" MODIFIED_BY="[Empty name]" NAME="Doyle 2010" TYPE="JOURNAL_ARTICLE">
<AU>Doyle LW, Ehrenkranz RA, Halliday HL</AU>
<TI>Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review</TI>
<SO>Neonatology</SO>
<YR>2010</YR>
<VL>98</VL>
<NO>4</NO>
<PG>289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Everard-1995" MODIFIED="2011-04-12 13:07:26 +1000" MODIFIED_BY="[Empty name]" NAME="Everard 1995" TYPE="JOURNAL_ARTICLE">
<AU>Everard ML</AU>
<TI>Bronchiolitis: origins and optimal management</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>6</NO>
<PG>885-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Everard-2009" MODIFIED="2011-03-15 06:23:24 +1000" MODIFIED_BY="[Empty name]" NAME="Everard 2009" TYPE="JOURNAL_ARTICLE">
<AU>Everard ML</AU>
<TI>Acute bronchiolitis and croup</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>2009</YR>
<VL>56</VL>
<PG>119-xi</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandes-2010" MODIFIED="2011-04-12 13:07:40 +1000" MODIFIED_BY="[Empty name]" NAME="Fernandes 2010" TYPE="COCHRANE_REVIEW">
<AU>Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al</AU>
<TI>Glucocorticoids for acute viral bronchiolitis in infants and young children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2011-04-12 13:07:40 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-12 13:07:40 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004878.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flores-1997" NAME="Flores 1997" TYPE="JOURNAL_ARTICLE">
<AU>Flores G, Horwitz RI</AU>
<TI>Efficacy of B2-agonists in bronchiolitis: a reappraisal and meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<NO>2</NO>
<PG>233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frey-2009" MODIFIED="2011-04-25 21:30:52 +1000" MODIFIED_BY="[Empty name]" NAME="Frey 2009" TYPE="JOURNAL_ARTICLE">
<AU>Frey U, von Mutius E</AU>
<TI>The challenge of managing wheezing in infants</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>360</NO>
<PG>2130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gadomski-2010" MODIFIED="2010-11-17 14:26:29 +1000" MODIFIED_BY="[Empty name]" NAME="Gadomski 2010" TYPE="COCHRANE_REVIEW">
<AU>Gadomski AM, Brower M</AU>
<TI>Bronchodilators for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2010-09-28 02:54:07 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-28 02:54:07 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001266.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" MODIFIED="2011-04-25 22:15:57 +1000" MODIFIED_BY="[Empty name]" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JNV, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glasziou-2010" MODIFIED="2011-04-25 21:31:08 +1000" MODIFIED_BY="[Empty name]" NAME="Glasziou 2010" TYPE="JOURNAL_ARTICLE">
<AU>Glasziou PP, Shepperd S, Brassey J</AU>
<TI>Can we rely on the best trial? A comparison of individual trials and systematic reviews</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>23</NO>
<PG>online publication</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2009" MODIFIED="2011-04-25 21:31:20 +1000" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2009" TYPE="OTHER">
<AU>The GRADE Working Group; Schünemann H, Brozek J, Oxman A, eds</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendation</TI>
<SO>Version 3.2</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2011-04-25 21:31:30 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1999" MODIFIED="2011-04-25 21:31:51 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hall CB</AU>
<TI>Respiratory syncytial virus: a continuing culprit and conundrum</TI>
<SO>Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>135</VL>
<PG>S2-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2010-03-04 06:41:30 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-04-25 21:31:58 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-04-25 21:32:09 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT and Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karemaker-2008a" MODIFIED="2011-03-16 01:45:03 +1000" MODIFIED_BY="[Empty name]" NAME="Karemaker 2008a" TYPE="JOURNAL_ARTICLE">
<AU>Karemaker R, Kavelaars A, ter Wolbeek M, Tersteeg-Kamperman M, Baerts W, Veen S, et al</AU>
<TI>Neonatal dexamethasone treatment for chronic lung disease of prematurity alters the hypothalamus-pituitary-adrenal axis and immune system activity at school age</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>121</VL>
<NO>4</NO>
<PG>e870-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karemaker-2008b" MODIFIED="2011-04-12 13:08:38 +1000" MODIFIED_BY="[Empty name]" NAME="Karemaker 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Karemaker R, Karemaker JM, Kavelaars A, Tersteeg-Kamperman M, Baerts W, Veen S, et al</AU>
<TI>Effects of neonatal dexamethasone treatment on the cardiovascular stress response of children at school age</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>5</NO>
<PG>978-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kellner-1996" MODIFIED="2011-04-25 22:16:11 +1000" MODIFIED_BY="[Empty name]" NAME="Kellner 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kellner JD, Ohlsson A, Gadomski AM, Wang EEL</AU>
<TI>Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis</TI>
<SO>Archives of Pediatric and Adolescent Medicine</SO>
<YR>1996</YR>
<VL>150</VL>
<PG>1166-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kini-2001" NAME="Kini 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kini NM, Robbins JM, Kirschbaum MS, Frisbee SJ, Kotagal UR</AU>
<TI>Inpatient care for uncomplicated bronchiolitis</TI>
<SO>Archives of Pediatric and Adolescent Medicine</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>12</NO>
<PG>1323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klassen-1997" NAME="Klassen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Klassen TP</AU>
<TI>Recent advances in the treatment of bronchiolitis and laryngitis</TI>
<SO>Pediatric Clinics of North America</SO>
<YR>1997</YR>
<VL>44</VL>
<NO>1</NO>
<PG>249-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97210729"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Langley-2003" MODIFIED="2010-07-06 05:41:42 +1000" MODIFIED_BY="[Empty name]" NAME="Langley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, LeBlanc JC, Smith B, Wang EE</AU>
<TI>Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>188</VL>
<PG>1764-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mallory-2003" NAME="Mallory 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mallory MD, Shay DK, Garrett J, Bordley WC</AU>
<TI>Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>1</NO>
<PG>e45-e51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinez-2005" MODIFIED="2011-03-15 06:24:39 +1000" MODIFIED_BY="[Empty name]" NAME="Martinez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Martinez FD</AU>
<TI>Heterogeneity of the association between lower respiratory illness in infancy and subsequent asthma</TI>
<SO>Proceedings of the American Thoracic Society</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nair-2010" MODIFIED="2010-09-01 03:47:44 +1000" MODIFIED_BY="[Empty name]" NAME="Nair 2010" TYPE="JOURNAL_ARTICLE">
<AU>Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al</AU>
<TI>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<PG>1545-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Onland-2008" MODIFIED="2011-03-16 01:46:00 +1000" MODIFIED_BY="[Empty name]" NAME="Onland 2008" TYPE="JOURNAL_ARTICLE">
<AU>Onland W, De Jaegere AP, Offringa M, van Kaam AH</AU>
<TI>Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>122</VL>
<NO>1</NO>
<PG>92-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owens-2009" MODIFIED="2010-09-22 01:13:18 +1000" MODIFIED_BY="[Empty name]" NAME="Owens 2009" TYPE="JOURNAL_ARTICLE">
<AU>Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al</AU>
<TI>AHRQ Series Paper 5: Grading the strength of a body of evidence when comparing medical interventions?Agency for Healthcare Research and Quality and the Effective Health-Care Program</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2009</YR>
<VL>63</VL>
<NO>5</NO>
<PG>513-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Panitch-2003" MODIFIED="2011-04-25 21:33:40 +1000" MODIFIED_BY="[Empty name]" NAME="Panitch 2003" TYPE="JOURNAL_ARTICLE">
<AU>Panitch HB</AU>
<TI>Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>Suppl 2</NO>
<PG>87-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paramore-2004" MODIFIED="2010-07-06 05:45:23 +1000" MODIFIED_BY="[Empty name]" NAME="Paramore 2004" TYPE="JOURNAL_ARTICLE">
<AU>Paramore LC, Ciuryla V, Ciesla G, Liu L</AU>
<TI>Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases</TI>
<SO>Pharmacoeconomics</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>275-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pelletier-2006" MODIFIED="2010-07-06 05:44:26 +1000" MODIFIED_BY="[Empty name]" NAME="Pelletier 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pelletier AJ, Mansbach JM, Camargo CA Jr</AU>
<TI>Direct medical costs of bronchiolitis hospitalizations in the United States</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>2418-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plint-2004" MODIFIED="2010-09-01 08:58:10 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2004" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Wiebe N, Bulloch B, Pusic M, Joubert G, et al</AU>
<TI>Practice variation among pediatric emergency departments in the treatment of bronchiolitis</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>4</NO>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plint-2009" MODIFIED="2011-04-25 21:34:27 +1000" MODIFIED_BY="[Empty name]" NAME="Plint 2009" TYPE="JOURNAL_ARTICLE">
<AU>Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al</AU>
<TI>Epinephrine and dexamethasone in children with bronchiolitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>20</NO>
<PG>2079-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-04-12 13:31:34 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5.1 (RevMan)</TI>
<YR>2011</YR>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-1999" NAME="Shay 1999" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ</AU>
<TI>Bronchiolitis-associated hospitalizations among US children, 1980-1996</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<NO>15</NO>
<PG>1440-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shay-2001" MODIFIED="2011-04-25 22:16:25 +1000" MODIFIED_BY="[Empty name]" NAME="Shay 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ</AU>
<TI>Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children 1979-1997</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>183</VL>
<PG>16-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shojania-2007" MODIFIED="2010-09-22 01:20:31 +1000" MODIFIED_BY="[Empty name]" NAME="Shojania 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shojania KG, Sampson M, Ansari MT, Doucette S, Moher D</AU>
<TI>How quickly do systematic reviews go out of date? A survival analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>147</VL>
<NO>4</NO>
<PG>224-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sly-2008" MODIFIED="2011-03-15 06:26:33 +1000" MODIFIED_BY="[Empty name]" NAME="Sly 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sly PD, Boner AL, Bjorksten B, Bush A, Custovic A, Eigenmann PA, et al</AU>
<TI>Early identification of atopy in the prediction of persistent asthma in children</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9643</NO>
<PG>1100-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smyth-2006" MODIFIED="2010-06-03 02:52:35 +1000" MODIFIED_BY="[Empty name]" NAME="Smyth 2006" TYPE="JOURNAL_ARTICLE">
<AU>Smyth R, Openshaw P</AU>
<TI>Bronchiolitis</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>312-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Woensel-2002" MODIFIED="2010-07-06 05:43:12 +1000" MODIFIED_BY="[Empty name]" NAME="Van Woensel 2002" TYPE="JOURNAL_ARTICLE">
<AU>van Woensel JB, van Aalderen WM, Kneyber MC, Heijnen ML, Kimpen JL</AU>
<TI>Bronchiolitis hospitalisations in the Netherlands from 1991 to 1999</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2002</YR>
<VL>86</VL>
<PG>370-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberger-2003" MODIFIED="2011-03-16 01:49:16 +1000" MODIFIED_BY="[Empty name]" NAME="Weinberger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger M</AU>
<TI>Corticosteroids for first-time young wheezers: current status of the controversy</TI>
<SO>Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>143</VL>
<NO>6</NO>
<PG>700-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberger-2007" MODIFIED="2011-03-16 01:50:10 +1000" MODIFIED_BY="[Empty name]" NAME="Weinberger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger M</AU>
<TI>Should corticosteroids be used for first-time young wheezers?</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2007</YR>
<VL>119</VL>
<NO>3</NO>
<PG>567-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson_x002d_Costello-2009" MODIFIED="2011-03-16 01:47:06 +1000" MODIFIED_BY="[Empty name]" NAME="Wilson-Costello 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wilson-Costello D, Walsh MC, Langer JC, Guillet R, Laptook AR, Stoll BJ, et al</AU>
<TI>of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>123</VL>
<NO>3</NO>
<PG>e430-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wohl-1978" NAME="Wohl 1978" TYPE="JOURNAL_ARTICLE">
<AU>Wohl MEB, Chernick V</AU>
<TI>State of the art: bronchiolitis</TI>
<SO>American Review of Respiratory Diseases</SO>
<YR>1978</YR>
<VL>118</VL>
<PG>759-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-1989" MODIFIED="2010-11-10 03:13:22 +1000" MODIFIED_BY="[Empty name]" NAME="Wright 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wright AL, Taussig LM, Ray CG</AU>
<TI>The Tucson children's respiratory study: II. lower respiratory tract illness in the first year of life</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1989</YR>
<VL>129</VL>
<PG>1232-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2005b" MODIFIED="2011-04-12 13:10:40 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Sanguebsche LS</AU>
<TI>The safety of nebulization with 3 to 5 ml of adrenaline (1:1000) in children: an evidence based review</TI>
<TO>Seguranca de nebulizacao com 3 a 5 ml de adrenalina (1:1000) em criancas: uma revisao baseada em evidencia</TO>
<SO>Jornal de Pediatria</SO>
<YR>2005</YR>
<VL>81</VL>
<NO>3</NO>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2008" MODIFIED="2010-09-22 01:20:57 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" TYPE="COCHRANE_REVIEW">
<AU>Zhang L, Mendoza-Sassi RA, Wainwright C</AU>
<TI>Nebulized hypertonic saline solution for acute bronchiolitis in infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2010-09-22 01:20:57 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-22 01:20:57 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006458.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-04-12 13:11:39 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hartling-2004" MODIFIED="2011-04-12 13:11:39 +1000" MODIFIED_BY="[Empty name]" NAME="Hartling 2004" TYPE="COCHRANE_REVIEW">
<AU>Hartling L, Wiebe N, Russell K, Patel H, Klassen TP</AU>
<TI>Epinephrine for bronchiolitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-04-12 13:11:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-12 13:11:39 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003123.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-05-03 09:11:46 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-05-03 09:11:46 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:50 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, controlled trial. No withdrawals reported<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:06:38 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Jordan, inpatients<BR/>140 inpatients &lt; 18 months with acute bronchiolitis</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 68<BR/>Age, mean: 7.4 months<BR/>Males, N (%): 46 (68)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 72<BR/>Age, mean: 7.1 months<BR/>Males, N (%): 50 (70)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:08:56 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: salbutamol (0.03 ml/kg of 5 mg/ml solution diluted with 0.9% saline to total 3 ml)</P>
<P>
<I>Group 2</I>: 3 ml of 1:1000 epinephrine. Administered at 0 and 30 min via nebulizer with continuous flow of oxygen at 6 L/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:09:29 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome*</I>
<BR/>SaO<SUB>2</SUB>, respiratory rate, heart rate, adverse events, clinical score (RDAI)</P>
<P>*Outcomes measured at baseline, 30, 60, 120 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:08:56 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:52 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial. No withdrawals reported<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:09:43 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in England, inpatients<BR/>38 children (between 30 days to 1 year) admitted with clinical diagnosis of moderately severe acute bronchiolitis (within the first 4 days of illness); first-time wheezers only</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 19<BR/>Age: &lt; 6 months, N (%): 14 (73.7), &gt; 6 months, N (%): 5 (26.3)<BR/>Males, N (%): 10 (42.6)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 19<BR/>Age: &lt; 6 months, N (%): 13 (68.4), &gt; 6 months, N (%): 6 (31.6)<BR/>Males, N (%): 8 (42.1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:08:25 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: single dose (3 ml) of levo-adrenaline (3 mg)</P>
<P>
<I>Group 2</I>: 0.9% saline placebo</P>
<P>Treatments nebulized in 100% oxygen at 6 L/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:08:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Respiratory rate, heart rate</P>
<P>
<I>Secondary outcome</I>
<BR/>SaO<SUB>2</SUB>, clinical score (RDAI), activity status</P>
<P>Outcomes measured at 20 minutes pre-treatment, baseline, and 20, 40, 60 minutes post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:08:50 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: PARI Medical Ltd provided nebulizer<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:10:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anil-2010a">
<CHAR_METHODS MODIFIED="2010-11-17 14:14:47 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled trial. No withdrawals reported<BR/>Parallel design, single-centre, 5 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:09:56 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Turkey, outpatients<BR/>186 children (between 6 weeks to 24 months) admitted with first episode of acute bronchiolitis and a clinical severity score between 1 and 9 (mild to moderate)</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 38<BR/>Age, mean ± SD: 10.4 ± 5.7 months<BR/>Males, N (%): 26 (68.4)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 39<BR/>Age, mean ± SD: 9.4 ± 5.0 months<BR/>Males, N (%): 29 (74.3)</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 36<BR/>Age, mean ± SD: 9.0 ± 6.2 months<BR/>Males, N (%): 20 (55.5)</P>
<P>
<I>Group 4</I>
<BR/>Sample size: 36<BR/>Age, mean ± SD: 9.7 ± 6.2 months<BR/>Males, N (%): 23 (63.8)</P>
<P>
<I>Group 5</I>
<BR/>Sample size: 37<BR/>Age, mean ± SD: 9.1 ± 4.4<BR/>Males, N (%): 22 (59.4)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-14 04:41:00 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: inhalation of epinephrine, 1.5 mg, diluted to 4 ml with 0.9% saline</P>
<P>
<I>Group 2</I>: inhalation of epinephrine, 1.5 mg, diluted to 4 ml with 3% saline</P>
<P>
<I>Group 3</I>: inhalation of salbutamol, 2.5 mg, diluted to 4 ml with 0.9% saline</P>
<P>
<I>Group 4</I>: inhalation of salbutamol, 2.5 mg, diluted to 4 ml with 3% saline</P>
<P>
<I>Group 5</I>: inhalation of 4 ml 0.9% saline</P>
<P>Treatments nebulized in 100% oxygen at 6 L/min, 2 doses administered at 0 and 30 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:10:02 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Clinical severity score, SaO<SUB>2</SUB>, HR, admissions from ED, number of readmissions of those discharged from ED, tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
<P>Outcomes measured prior to each drug administration (0 and 30 minutes), 60 and 120 minutes post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-25 21:10:07 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not specified<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine (Group 1) versus salbutamol (Group 3)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-14 08:32:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anil-2010b">
<CHAR_METHODS MODIFIED="2010-10-14 08:32:18 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-14 08:32:21 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-14 08:32:22 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-14 08:32:23 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-10-14 08:32:38 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine (Group 2) versus salbutamol (Group 4)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-19 02:40:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anil-2010c">
<CHAR_METHODS MODIFIED="2010-11-19 02:39:42 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-19 02:39:42 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-19 02:39:43 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-19 02:39:44 +1000" MODIFIED_BY="[Empty name]">
<P>See Anil 2010a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-19 02:40:12 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine (Group 1) versus placebo (Group 5)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:10:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998a">
<CHAR_METHODS MODIFIED="2010-09-27 10:09:39 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial. No withdrawals reported<BR/>Parallel design, single-centre, multi-arm (6)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:10:40 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Turkey, outpatients<BR/>90 children (less than 24 months of age) presenting to emergency outpatient clinic with first episode of wheezing and clinical score between 4 and 10 (mild to moderate)</P>
<P>
<I>Group 1 to 6 (all participants)</I>
<BR/>Sample size: 15 (total 90)<BR/>Age, mean ± SD: 8.52 ± 0.59 months<BR/>Males, N (%): 50 (56)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:10:53 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: placebo - mist tent (nebulized)<BR/>
</P>
<P>
<I>Group 2</I>: albuterol (nebulized); 0.15 mg/kg; every hour during the first 4 h</P>
<P>
<I>Group 3</I>: prednisolone (IV); 2 mg/kg; single dose</P>
<P>
<I>Group 4</I>: albuterol + prednisolone (nebulized + I); 0.15 mg/kg (alb) + 2 mg/kg (pre); single dose for both interventions</P>
<P>
<I>Group 5</I>: racemic adrenaline (epinephrine) (nebulized); 0.1 ml/kg; every 2 h during the first 4 h</P>
<P>
<I>Group 6</I>: budesonide (nebulized); 0.5 mg; single dose</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:10:58 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Hospital admission, SaO<SUB>2</SUB>*, heart rate*, observation period, number improved with initial tx, and additional tx</P>
<P>*Outcomes measured at baseline, 60, 120 minutes and 4 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:11:18 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: Turkish<BR/>This study contributed to the following comparison: epinephrine versus placebo (Barlas 1998a); epinephrine versus salbutamol (Barlas 1998b); and epinephrine versus steroid (prednisolone + budesonide) (Barlas 1998c)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:12:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998b">
<CHAR_METHODS MODIFIED="2010-09-27 10:11:51 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:11:54 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:11:57 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:12:01 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:12:43 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparison: epinephrine versus placebo (Barlas 1998a); epinephrine versus salbutamol (Barlas 1998b); and epinephrine versus steroid (prednisolone + budesonide) (Barlas 1998c)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:13:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barlas-1998c">
<CHAR_METHODS MODIFIED="2010-09-27 10:13:02 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:13:06 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:13:08 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:13:10 +1000" MODIFIED_BY="[Empty name]">
<P>See Barlas 1998a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:13:54 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparison: epinephrine versus placebo (Barlas 1998a); epinephrine versus salbutamol (Barlas 1998b); and epinephrine versus steroid (prednisolone + budesonide) (Barlas 1998c)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beck-2007">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:53 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled trial. No withdrawals reported<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:12:32 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Israel, outpatients (emergency department)<BR/>27 children (2 to 12 months of age) presenting to emergency department with first episode of respiratory distress and RSV-positive</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 12<BR/>Age, mean ± SD: 4.9 ± 0.8 months<BR/>Males, N (%): 8 (66.7)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 15<BR/>Age, mean ± SD: 4 ± 1.35 months<BR/>Males, N (%): 11 (77.3)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:12:41 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: epinephrine (1 mg diluted in 2 ml 0.9% saline)</P>
<P>
<I>Group 2</I>: albuterol (2.5 mg diluted in 2.5 ml 0.9% saline)</P>
<P>Via nebulizer at 0.4 ml/min in 5L/min O<SUB>2</SUB> flow. Single treatment of interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:14:48 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Clinical score*, respiratory rate*, heart rate*, acoustic breath sounds, computerized wheeze rate, computerized crackle count</P>
<P>*Outcomes measured at baseline, 10, 30 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:14:59 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: government<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:13:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bertrand-2001">
<CHAR_METHODS MODIFIED="2010-09-27 10:15:46 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled trial<BR/>Two participants (one per group) had worsening of clinical condition and were transferred to PICU; these participants were excluded from analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:13:02 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Chile, inpatients<BR/>30 children (less than 1 year of age) admitted with acute bronchiolitis (first episode of wheezing)</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 14<BR/>Age, mean ± SD: 3.7 ± 0.6 months<BR/>Males, N (%): 7 (50)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 16<BR/>Age, mean ± SD: 3.9 ± 0.4 months<BR/>Males, N (%): 9 (56)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:13:19 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: salbutamol (0.5 ml (2.5 mg) + 3.5 ml 0.9% saline)</P>
<P>
<I>Group 2</I>: epinephrine (0.5 ml (0.5 mg) + 3.5 ml saline)</P>
<P>Via nebulizer. Interventions administered every 2 to 4 h during hospitalization; measurements done at baseline, 24 and 36 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:16:21 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Clinical score (60 min, 24 and 36 hours), SaO<SUB>2</SUB>, respiratory rate*, heart rate*, duration of oxygen therapy, length of hospital stay, hospital re-admission (2 weeks after discharge), adverse events, blood pressure</P>
<P>*Outcomes measured at baseline, 24 and 36 hours<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:16:45 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bilan-2007">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:54 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial. No withdrawals reported<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:13:51 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Iran, inpatients<BR/>100 children (2 to 12 months of age) admitted to hospital with bronchiolitis with lower respiratory tract infection, fever, rhinitis, tachypnea, wheezing and dyspnea</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 50<BR/>Age, mean ± SD: 6 ± 4 months<BR/>Males, N (%): 30 (60)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 50<BR/>Age, mean ± SD: 5 ± 3.6 months<BR/>Males, N (%): 28 (56)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:17:44 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: salbutamol (2 puffs via spacer every 4 hours)</P>
<P>
<I>Group 2</I>: epinephrine (1/1000 0.2 mg/kg with 3.5 cc saline via spray)</P>
<P>Interventions administered every 4 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:17:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Length of stay and return to normal feeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:18:01 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: Farsi<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-John-2006">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:54 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial. No withdrawals reported<BR/>Parallel design, single-centre, 2 arms<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:14:20 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in India, inpatients<BR/>30 children (2 to 12 months of age) diagnosed with bronchiolitis based on history of coryza and/or fever followed by respiratory distress; moderately severe to severe bronchiolitis with respiratory distress with difficulty in feeding, nasal flare, chest retractions, and hypoxia requiring supplemental oxygen</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 15<BR/>Age, mean ± SD: 6.67 ± 3.01 months<BR/>Males, N (%): 10 (66.7)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 15<BR/>Age, mean ± SD: 6.73 ± 2.95 months<BR/>Males, N (%): 9 (60)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:14:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: epinephrine (0.5 ml/kg; maximum of 2.5 ml with 3 ml saline via nebulizer)</P>
<P>
<I>Group 2</I>: salbutamol (0.15 mg/kg with 3 ml saline via nebulizer)</P>
<P>Interventions administered at 0, 30, 60 minutes and then 4-hourly until child was stable</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:14:36 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Length of stay, clinical score (RDAI)*, SaO<SUB>2</SUB>*, respiratory rate*, heart rate*</P>
<P>*Outcomes measured at baseline, 10, 40 and 70 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:18:59 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kadir-2009">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:55 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial. No withdrawals reported<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:14:50 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Bangladesh, inpatients<BR/>60 children (less than 2 years of age) with acute bronchiolitis presenting with respiratory distress and wheeze following an attack of coryza with evidence of hyperinflation on chest x-ray, hypoxemia and clinical score &gt; 4</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 30<BR/>Age: 28 (93%) in first year, 2 (7%) in second year<BR/>Males, N (%): 21 (70)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 30<BR/>Age: 24 (80%) in first year, 6 (20%) in second year<BR/>Males, N (%): 21 (70)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-14 06:32:19 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: combined salbutamol (0.15 mg/kg) and ipratropium bromide (250 &#956;g in 1 ml)</P>
<P>
<I>Group 2</I>: L-adrenaline (0.01 ml/kg of 1:1000 dilutions)</P>
<P>Interventions nebulized and administered at 0 and 6 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-14 06:34:06 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>MRDAI (Modified Respiratory Distress Assessment Instrument), SaO<SUB>2</SUB>, respiratory rate, coryza, respiratory distress, cyanosis, ronchi, crepitation, evidence of hyperinflation on chest x-ray, white blood cell counts<BR/>
</P>
<P>Outcomes measured at baseline and 30 min after each tx</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-25 21:15:02 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol + ipratropium bromide</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:15:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khashabi-2005a">
<CHAR_METHODS MODIFIED="2011-04-25 21:15:09 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind trial. No withdrawals reported<BR/>Parallel design, single-centre, multi-arm (3)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-04 06:34:24 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Iran, outpatients (emergency department)<BR/>72 children (2 to 24 months of age) presenting to emergency department with a diagnosis of viral bronchiolitis, including: acute viral lower respiratory tract infection; fever; rhinitis; tachypnea; expiratory wheezing; increased respiratory effort; and mild to moderate severity bronchiolitis</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 24<BR/>Age, mean: 8.9 months<BR/>Males, N (%): 5 (20.8)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 24<BR/>Age, mean: 10.5 months<BR/>Males, N (%): 6 (25)</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 24<BR/>Age, mean: 7.9 months<BR/>Males, N (%): 9 (37.5)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:15:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: epinephrine (0.1 ml/kg of 1:10000 solution + saline to 5 ml)</P>
<P>
<I>Group 2</I>: salbutamol (0.15 mg/kg + saline to 5 ml)</P>
<P>
<I>Group 3</I>: placebo (5 ml saline)</P>
<P>Administered via nebulizer in 8 L/min O<SUB>2</SUB> flow, 3 doses at 20-minute intervals</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:15:39 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Clinical score (RDAI)*, SaO<SUB>2</SUB>*, respiratory rate*, number ready to go home at end of treatment</P>
<P>*Outcomes measured at baseline, 10, 20, 30 and 40 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-25 21:15:44 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus placebo (Khashabi 2005a) and epinephrine versus salbutamol (Khashabi 2005b)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:15:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khashabi-2005b">
<CHAR_METHODS MODIFIED="2010-09-27 10:20:25 +1000" MODIFIED_BY="[Empty name]">
<P>See Khashabi 2005a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:20:31 +1000" MODIFIED_BY="[Empty name]">
<P>See Khashabi 2005a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:20:34 +1000" MODIFIED_BY="[Empty name]">
<P>See Khashabi 2005a</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:20:35 +1000" MODIFIED_BY="[Empty name]">
<P>See Khashabi 2005a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-25 21:15:54 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus placebo (Khashabi 2005a) and epinephrine versus salbutamol (Khashabi 2005b)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-03 09:11:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyucu-2004a">
<CHAR_METHODS MODIFIED="2011-05-03 09:11:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind controlled study; not ITT for follow-up outcomes (21 patients did not attend follow-up visits at 24 hours or Day 5 and were not included in analysis)<BR/>Parallel design, single-centre, multi-arm (4)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:16:23 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Turkey, outpatients<BR/>69 children (2 to 21 months) attending pediatric outpatient clinic or ED with first episode of wheezing</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 26<BR/>Age, mean ± SD: 7.2 ± 0.8 months</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 24<BR/>Age, mean ± SD: 7.9 ± 1.0 months</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 19<BR/>Age, mean ± SD: 9.6 ± 1.3 months</P>
<P>
<I>Group 4</I>
<BR/>Sample size: 21<BR/>Age, mean ± SD: 9.9 ± 1.7 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 22:11:05 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: epinephrine + dexamethasone (3 ml (3 mg) of 1:1000 L-epinephrine + 0.6 mg/kg of dexamethasone)</P>
<P>
<I>Group 2</I>: salbutamol + dexamethasone (0.15 mg/kg of 1 mg/ml solution of salbutamol added to 0.9% saline to total 3 ml + 0.6 mg/kg of dexamethasone)</P>
<P>
<I>Group 3</I>: epinephrine + placebo (3 ml (3 mg) of 1:1000 L-epinephrine)</P>
<P>
<I>Group 4</I>: salbutamol + placebo (0.15 mg/kg of 1 mg/ml solution of salbutamol added to 0.9% saline solution to make a total of 3 ml)</P>
<P>3 doses administered to each participant</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:16:58 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Respiratory rate*, heart rate*, clinical score* (RDAI)</P>
<P>
<I>Secondary outcome</I>
<BR/>Additional medication, follow-up rate, adverse events</P>
<P>*Outcomes measured at baseline, 120 minutes, 24 hours, 5 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:22:31 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: English<BR/>This study contributed to the following comparisons:epinephrine versus salbutamol (Kuyucu 2004a and Kuyucu 2004b); epinephrine + steroid versus salbutamol (Kuyucu 2004c)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:23:22 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyucu-2004b">
<CHAR_METHODS MODIFIED="2010-09-27 10:22:44 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:22:49 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:23:09 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus salbutamol (Kuyucu 2004a and Kuyucu 2004b); epinephrine + steroid versus salbutamol (Kuyucu 2004c)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:23:16 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:23:22 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:24:10 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyucu-2004c">
<CHAR_METHODS MODIFIED="2010-09-27 10:23:36 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:23:40 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:24:00 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus salbutamol (Kuyucu 2004a and Kuyucu 2004b); epinephrine + steroid versus salbutamol (Kuyucu 2004c)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:24:05 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:24:10 +1000" MODIFIED_BY="[Empty name]">
<P>See Kuyucu 2004a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Menon-1995">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:56 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized centrally by pharmacy using table of random numbers; controlled trial; double-blind. One participant excluded after randomization (did not meet inclusion criteria); no withdrawals reported<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:24:36 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Canada, outpatients<BR/>42 children (between 6 weeks and 1 year) presenting to emergency department with first episode of wheezing</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 21</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:18:14 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: salbutamol (0.3 ml of 5 mg/ml solution + 2.7 ml of 0.9% saline)</P>
<P>
<I>Group 2</I>: L-epinephrine (3 ml of 1:1000)</P>
<P>Via nebulizer. One inhalation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:24:48 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>SaO<SUB>2</SUB>*</P>
<P>
<I>Secondary outcome</I>
<BR/>Clinical score (RDAI)*, heart rate*, respiratory rate*, length of stay in ED or hospital, admission to hospital</P>
<P>*Outcomes measured at baseline, 30, 60, 90 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:25:00 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: other<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mull-2004">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled trial. Seven participants excluded after enrolment; no withdrawals or losses to follow up<BR/>Parallel design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:18:58 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in USA, outpatients<BR/>66 moderately ill children (between 0 to 12 months) presenting to emergency department of a tertiary care centre with first-time episode of acute wheezing</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 34<BR/>Age, mean ± SD: 4.7 ± 2.6 months<BR/>Males, N (%): 19 (55.9)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 32<BR/>Age, mean ± SD: 4.1 ± 2.0 months<BR/>Males, N (%): 17 (53.1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:19:10 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: nebulized 2.25% racemic epinephrine (0.9 mg/kg)</P>
<P>
<I>Group 2</I>: nebulized 0.5% albuterol (0.15 mg/kg) (n = 32) with 2 ml of 0.9% isotonic sodium chloride solution</P>
<P>Delivered via face mask with continuous flow of 100% oxygen at 6 L/min in 3 doses at 0, 30 and 60 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:26:02 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Clinical score (RDAI)*, respiratory rate*</P>
<P>
<I>Secondary outcome</I>
<BR/>SaO<SUB>2</SUB>*, hospitalization rate, adverse events, hospital re-admission, return to physician, 72-hour relapse rate, time well enough to go home</P>
<P>*Outcomes measured at baseline, 30, 60, 90, 120, 150 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:26:18 +1000" MODIFIED_BY="[Empty name]">
<P>Funded in part by Nephron Pharmaceuticals Company<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:20:00 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okutan-1998a">
<CHAR_METHODS MODIFIED="2011-04-25 21:20:00 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized trial. Participants were sedated with oral chloral hydrate (80 mg/kg) and kept in supine position. After 1 hour (or after the child was asleep) pulse oximeter was fitted and clinical scoring made. Extent of follow up or whether ITT analysis done unknown<BR/>Parallel design, single-centre, multi-arms (3)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:19:32 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Turkey, outpatients<BR/>45 children (ages 3 to 18 months)</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 16<BR/>Age, mean ± SD: 7.8 ± 4.1 months</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 19<BR/>Age, mean ± SD: 7.7 ± 3.8 months</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 10<BR/>Age, mean ± SD: 9 ± 5.8 months</P>
<P>Males, % (total): 28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:19:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: epinephrine (0.2 mg/kg; 1 mg/ml; 3 ml)</P>
<P>
<I>Group 2</I>: salbutamol (0.15 mg/kg; 2.5 mg/2.5 ml; 3 ml)</P>
<P>
<I>Group 3</I>: placebo (0.9% NaCl; 3 ml)</P>
<P>Number and timing of doses unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:19:54 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Respiratory rate, pulse rate, clinical score (RDAI), SaO<SUB>2</SUB>, arterial BP</P>
<P>Outcomes measured at 15, 30, 45, 60 and 120 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:27:15 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: not mentioned<BR/>Language of publication: Turkish<BR/>This study contributed to the following comparisons: epinephrine versus placebo (Okutan 1998a); epinephrine versus salbutamol (Okutan 1998b)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:27:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okutan-1998b">
<CHAR_METHODS MODIFIED="2010-09-27 10:27:23 +1000" MODIFIED_BY="[Empty name]">
<P>See Okutan 1998a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:27:27 +1000" MODIFIED_BY="[Empty name]">
<P>See Okutan 1998a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:27:45 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus placebo (Okutan 1998a); epinephrine versus salbutamol (Okutan 1998b)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:27:50 +1000" MODIFIED_BY="[Empty name]">
<P>See Okutan 1998a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:27:54 +1000" MODIFIED_BY="[Empty name]">
<P>See Okutan 1998a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:20:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-2002a">
<CHAR_METHODS MODIFIED="2011-04-25 21:20:15 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind study. Intention-to-treat analysis performed; 10 participants withdrew (epi = 1, sal = 4, pla = 5)<BR/>Parallel design, single-centre, multi-arm (3)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:20:33 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Canada, inpatients<BR/>149 hospitalized infants with moderate-severe bronchiolitis (ages 0 to 12 months), who were previously well, were randomized into 3 treatment groups</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 50<BR/>Age, mean ± SD: 4.2 ± 3.1 months<BR/>Males, N (%): 28 (56)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 51<BR/>Age, mean ± SD: 3.9 ± 2.9 months<BR/>Males, N (%): 35 (69)</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 48<BR/>Age, mean ± SD: 4.7 ± 2.9 months<BR/>Males, N (%): 25 (52)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:20:41 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: racemic epinephrine (0.03 ml/kg/dose of a 2.25% solution)</P>
<P>
<I>Group 2</I>: saline placebo (0.03 ml/kg/dose of 0.9% sodium chloride)</P>
<P>
<I>Group 3</I>: salbutamol (0.03 ml/kg/dose of a 5 mg/ml solution)</P>
<P>Treatment administered every 1 to 6 h for 10 to 15 min via nebulizer with continuous flow 100% oxygen at 6 to 7 L/min, frequency changes at the discretion of medical team</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:20:47 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Length of stay</P>
<P>
<I>Secondary outcome</I>
<BR/>SaO<SUB>2</SUB>,* clinical score (RDAI), hospital or ICU readmission**, return to healthcare facility**, adequate fluid intake*, medication requirements*</P>
<P>* Outcomes measured 2 times per day<BR/>**Outcomes measured 7 days after discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:29:22 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: other<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus placebo (Patel 2002a); epinephrine versus salbutamol (Patel 2002b)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:29:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-2002b">
<CHAR_METHODS MODIFIED="2010-09-27 10:29:52 +1000" MODIFIED_BY="[Empty name]">
<P>See Patel 2002a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:29:59 +1000" MODIFIED_BY="[Empty name]">
<P>50 infants received epinephrine (0.03 ml/kg/dose of a 2.25% solution) and 51 were given salbutamol (0.03 ml/kg/dose of a 5 mg/ml solution)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-05-03 09:11:46 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009a">
<CHAR_METHODS MODIFIED="2011-04-25 21:21:34 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled trial<BR/>Data were not available on the primary outcome for 3 participants (one each of epinephrine&#8211;dexamethasone, epinephrine and dexamethasone groups); these participants were not included in the intention-to-treat analysis. Because of a pharmacy error, a total of 23 participants in the epinephrine&#8211;dexamethasone group and 23 participants in the placebo-dexamethasone group received dexamethasone at 80% of the planned dose; these participants were included in the analysis<BR/>Factorial design, multi-centre (8), multi-arm (4)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:21:40 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Canada, outpatients (emergency department)<BR/>797 children (6 to 24 months) presenting to the emergency department with bronchiolitis and a RDAI score between 4 and 15 (mild to severe), and first episode wheezing associated with upper respiratory tract infection</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 200<BR/>Age, median: 5 months<BR/>Males, N (%): 124 (62)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 199<BR/>Age, median: 5 months<BR/>Males, N (%): 122 (61.3)</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 200<BR/>Age, median: 5 months<BR/>Males, N (%): 127 (63.5)</P>
<P>
<I>Group 4</I>
<BR/>Sample size: 201<BR/>Age, median: 5 months<BR/>Males, N (%): 120 (59.7)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:21:57 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: epinephrine + dexamethasone</P>
<P>
<I>Group 2</I>: epinephrine + placebo</P>
<P>
<I>Group 3</I>: dexamethasone + placebo</P>
<P>
<I>Group 4</I>: placebo + placebo</P>
<P>Dosages as follows: epi: 3 ml in 1:1000 saline; dex: 1.0 mg/kg weight (max 10 mg) then 0.6 mg/kg (max 10 mg) after ED. Mode of administration for epinephrine was nebulized in O<SUB>2</SUB> flow 8 L/min, and dexamethasone was oral. Two doses of treatment administered at 30 minutes apart; oral dexamethasone after first nebulization of epinephrine in ED, followed by 5 once daily doses of oral dexamethasone after leaving ED</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-03 09:11:46 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Hospital admission at Day 7 and 22</P>
<P>
<I>Secondary outcome</I>
<BR/>Length of stay for those admitted, SaO<SUB>2</SUB>, respiratory rate, heart rate, return to healthcare facility (within 22 days), duration of symptoms (22 days), temperature, adverse events</P>
<P>* Outcomes measured at baseline, 30 and 60 minutes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:32:43 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: government<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus placebo (Plint 2009a and Plint 2009b); epinephrine versus dexamethasone (Plint 2009c); epinephrine + dexamethasone versus placebo (Plint 2009d)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:34:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009b">
<CHAR_METHODS MODIFIED="2010-09-27 10:33:03 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:33:12 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:34:29 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus placebo (Plint 2009a and Plint 2009b); epinephrine versus dexamethasone (Plint 2009c); epinephrine + dexamethasone versus placebo (Plint 2009d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:33:15 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:33:18 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:22:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009c">
<CHAR_METHODS MODIFIED="2010-09-27 10:33:22 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:33:24 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:22:31 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus placebo (Plint 2009a and Plint 2009b); epinephrine versus dexamethasone (Plint 2009c); epinephrine + dexamethasone versus placebo (Plint 2009d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:33:27 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:33:30 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:36:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plint-2009d">
<CHAR_METHODS MODIFIED="2010-09-27 10:33:34 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:33:36 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:36:08 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus placebo (Plint 2009a and Plint 2009b); epinephrine versus dexamethasone (Plint 2009c); epinephrine + dexamethasone versus placebo (Plint 2009d)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:33:38 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:33:40 +1000" MODIFIED_BY="[Empty name]">
<P>See Plint 2009a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:24:29 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ralston-2005a">
<CHAR_METHODS MODIFIED="2010-09-28 01:20:55 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled trial. No withdrawals reported<BR/>Parallel design, single-centre, multi-arm (3)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:23:14 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in USA, outpatients (emergency department)<BR/>65 children (6 weeks to 24 months) with mild to moderate bronchiolitis (first episode of wheezing) presenting to urgent care clinic</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 25<BR/>Age, mean ± SD: 7.3 ± 5.1 months<BR/>Males, N (%): 15 (60)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 23<BR/>Age, mean ± SD: 7.7 ± 6.0 months<BR/>Males, N (%): 15 (65)</P>
<P>
<I>Group 3</I>
<BR/>Sample size: 17<BR/>Age, mean ± SD: 7.9 ± 5.2 months<BR/>Males, N (%): 6 (35)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:24:29 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: 0.9% saline placebo</P>
<P>
<I>Group 2</I>: racemic albuterol (salbutamol) sulfate (5 mg)</P>
<P>
<I>Group 3</I>: racemic epinephrine (5 mg)</P>
<P>All drugs given in 3 ml nebulized doses via mask with continuous flow of oxygen at 6 L/min. Study drug given at 0 and 30 min. Third dose given at 60 min if RDAI score &gt; 8 or room air oxygen saturation &lt; 90%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:37:21 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Hospital admission or received home oxygen</P>
<P>
<I>Secondary outcome</I>
<BR/>Clinical score (RDAI) (measured at 60 minutes if 2 doses, 90 minutes if 3 doses), adverse events (heart rate &gt; 200, withdrawal from study due to deteriorating status, discontinuation due to side effects)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:37:45 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: Dept HHS/NIH/NCRR/GCRC (USA); American Academy of Pediatrics<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus placebo (Ralston 2005a); epinephrine versus salbutamol (Ralston 2005b)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-27 10:38:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ralston-2005b">
<CHAR_METHODS MODIFIED="2010-09-27 10:38:12 +1000" MODIFIED_BY="[Empty name]">
<P>See Ralston 2005a</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-27 10:38:18 +1000" MODIFIED_BY="[Empty name]">
<P>See Ralston 2005a</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-09-27 10:38:44 +1000" MODIFIED_BY="[Empty name]">
<P>This study contributed to the following comparisons: epinephrine versus placebo (Ralston 2005a); epinephrine versus salbutamol (Ralston 2005b)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-09-27 10:38:20 +1000" MODIFIED_BY="[Empty name]">
<P>See Ralston 2005a</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:38:22 +1000" MODIFIED_BY="[Empty name]">
<P>See Ralston 2005a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 21:25:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sanchez-1993">
<CHAR_METHODS MODIFIED="2010-11-17 14:22:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, controlled trial, double-blind, cross-over study. Results from cross-over arms not differentiated in the analysis. 8 participants did not complete study because of inadequate sedation or technical problems; they were excluded from the analysis<BR/>Cross-over design, single-centre, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:24:49 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Canada, inpatients<BR/>32 inpatients (less than 1 year of age) with diagnosis of acute bronchiolitis. All patients being treated with inhaled salbutamol. Mild to moderate cases</P>
<P>
<I>Group 1 and 2</I>
<BR/>Sample size: 32<BR/>Age, mean ± SEM (range): 4.6 ± 0.5 (1 to 10) months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:25:04 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: albuterol (0.03 ml/kg of 5 mg/ml solution diluted to total of 2 ml in 0.9% NaCl)</P>
<P>
<I>Group 2</I>: racemic epinephrine (0.1 ml/kg of 2.25% solution diluted to total 2 ml in 0.9% NaCl)</P>
<P>Via nebulizer. One inhalation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:25:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Not specified</P>
<P>
<I>Secondary outcome</I>
<BR/>Length of stay, clinical score (12-point scale)*, SaO<SUB>2</SUB>*, respiratory rate*; heart rate*. Pulmonary mechanics measured under sedation: tidal volume; minute ventilation; inspiratory, expiratory and total pulmonary resistance; duration of inspiration as fraction of total breath duration; dynamic compliance</P>
<P>*Outcomes measured at baseline and 20 to 30 minutes post-treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:39:56 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: pharmaceutical and other<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus salbutamol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-04-25 22:13:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wainwright-2003">
<CHAR_METHODS MODIFIED="2011-04-25 22:13:57 +1000" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled, double-blind study. No withdrawals reported. Data analyzed on an intention-to-treat basis<BR/>Parallel design, multi-centre (4), 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-04-25 21:25:44 +1000" MODIFIED_BY="[Empty name]">
<P>Conducted in Australia, inpatients<BR/>194 inpatients (less than 1 year of age) with clinical diagnosis of bronchiolitis; first-time wheezing only; mild, moderate and severe cases included</P>
<P>
<I>Group 1</I>
<BR/>Sample size: 99<BR/>Age, mean ± SD: 4.52 ± 3.01 months<BR/>Males, N (%): 70 (70.7)</P>
<P>
<I>Group 2</I>
<BR/>Sample size: 95<BR/>Age, mean ± SD: 4.35 ± 2.95 months<BR/>Males, N (%): 61 (64.2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-04-25 21:25:54 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Group 1</I>: adrenaline (isomer epinephrine) (4 ml 1%)</P>
<P>
<I>Group 2</I>: placebo (4 ml normal saline)</P>
<P>Three doses administered at 4-hour intervals within 24 hours after admission to hospital. Treatment nebulized with oxygen flow at 6 L/min</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-04-25 21:25:57 +1000" MODIFIED_BY="[Empty name]">
<P>
<I>Primary outcome</I>
<BR/>Length of stay and time to be ready for discharge</P>
<P>
<I>Secondary outcome</I>
<BR/>Respiratory rate*, heart rate*, hospital readmission at 1 month, chest recession, time in oxygen, highest oxygen flow rates, need for supplemental parenteral fluids, blood pressure</P>
<P>*Outcomes measured at 30 and 60 minutes after each dose</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-09-27 10:40:57 +1000" MODIFIED_BY="[Empty name]">
<P>Funding: none<BR/>Language of publication: English<BR/>This study contributed to the following comparisons: epinephrine versus placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AE: adverse events<BR/>BP: blood pressure<BR/>d/c: discharge<BR/>ED: emergency department<BR/>epi: epinephrine<BR/>h: hour<BR/>HR: heart rate<BR/>ICU: Intensive Care Unit<BR/>ITT: intention-to-treat<BR/>IV: intravenous<BR/>LOS: length of stay<BR/>min: minute<BR/>NaCl: sodium chloride<BR/>O<SUB>2</SUB>:<SUB> </SUB>oxygen<BR/>PICU: Pediatric Intensive Care Unit<BR/>pla: placebo<BR/>RDAI: Respiratory Distress Assessment Index<BR/>RR: respiratory rate<BR/>RSV: respiratory syncytial virus<BR/>NS: not specified<BR/>sal: salbutamol<BR/>SaO<SUB>2</SUB>: oxygen saturation<BR/>SD: standard deviation<BR/>SEM: standard error of the mean<BR/>tx: treatment</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-10-14 01:19:12 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:45:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altamirano-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:45:51 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:45:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altinel-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:45:52 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:58:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carter-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:58:51 +1000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:45:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carvajal-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:45:53 +1000" MODIFIED_BY="[Empty name]">
<P>Study is not randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-14 01:18:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frohna-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-14 01:18:47 +1000" MODIFIED_BY="[Empty name]">
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:45:55 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grewal-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:45:55 +1000" MODIFIED_BY="[Empty name]">
<P>Used saline as intervention not epinephrine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:48:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guill-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:48:01 +1000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:45:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gurkan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:45:56 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:45:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hariprakash-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:45:58 +1000" MODIFIED_BY="[Empty name]">
<P>Recurrent wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:48:18 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-King-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:48:18 +1000" MODIFIED_BY="[Empty name]">
<P>Comment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:48:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klassen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:48:32 +1000" MODIFIED_BY="[Empty name]">
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kristjansson-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:05 +1000" MODIFIED_BY="[Empty name]">
<P>Not first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Langley-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:08 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:10:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lopez-Andreu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:10:02 +1000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:09 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lowell-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:09 +1000" MODIFIED_BY="[Empty name]">
<P>Not first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:53:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinon_x002d_Torres-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:53:42 +1000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:30:07 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meates-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:30:07 +1000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-14 01:19:06 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mesquita-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-14 01:19:06 +1000" MODIFIED_BY="[Empty name]">
<P>Protocolized use of epinephrine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:29:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Misra-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:29:50 +1000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:47:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Okutan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:47:36 +1000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patel-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:11 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:12 +1000" MODIFIED_BY="[Empty name]">
<P>First or second episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reijonen-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:13 +1000" MODIFIED_BY="[Empty name]">
<P>Not first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:01:47 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rusconi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:01:47 +1000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:29:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saseen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:29:14 +1000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-14 01:19:12 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schumacher-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-14 01:19:12 +1000" MODIFIED_BY="[Empty name]">
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:14 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simsek-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:14 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:15 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tal-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:15 +1000" MODIFIED_BY="[Empty name]">
<P>Used saline as intervention not epinephrine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:17:28 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Valverde-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:17:28 +1000" MODIFIED_BY="[Empty name]">
<P>Letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:48:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Aerde-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:48:51 +1000" MODIFIED_BY="[Empty name]">
<P>Commentary</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-27 10:48:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walsh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-27 10:48:17 +1000" MODIFIED_BY="[Empty name]">
<P>Unclear if first episode of wheezing</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 08:51:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Waseem-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 08:51:40 +1000" MODIFIED_BY="[Empty name]">
<P>Editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-05 09:14:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-05 09:14:32 +1000" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-02-18 09:05:30 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-04-25 21:22:53 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-11-19 02:40:28 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:21:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:34:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:15:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:16:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-19 02:40:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:40:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:17:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:19:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:53:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:58:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:48:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-04 05:40:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>Lottery method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 04:16:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:59:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 10:17:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:37:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:34:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:34:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:40:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:45:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 06:03:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 01:39:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:51:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:18:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:25:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:32:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:33:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:34:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:28:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:45:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:31:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:34:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-19 02:40:29 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:21:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 10:56:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:15:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:17:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-19 02:40:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:40:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:17:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:19:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:53:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:58:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:50:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 10:57:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 04:16:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:59:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 10:17:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:37:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:34:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:34:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:40:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:48:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 06:03:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 01:39:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:23:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:18:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:25:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:32:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:33:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:34:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:28:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:45:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:31:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:34:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-25 21:22:53 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.05" NO="5">
<NAME>Other outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4">
<NAME>Pulmonary function outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Administrative outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Clinical scores and other symptoms/clinical outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Patient reported outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-19 09:23:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-02-19 09:32:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION>
<P>RDAI; oxygen saturation; respiratory rate; heart rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-02-19 09:23:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-19 09:23:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-02-19 09:35:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION>
<P>Adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-02-19 09:36:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION>
<P>RDAI; oxygen saturation; respiratory rate; heart rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-02-19 09:36:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION>
<P>Adverse events; activity status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 14:17:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>Admissions from ED, number of readmissions of those discharged from ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-17 14:17:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>Clinical severity score, SaO<SUB>2</SUB>, HR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-11-17 14:17:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>Tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-17 14:17:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>Admissions from ED, number of readmissions of those discharged from ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-17 14:17:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>Clinical severity score, SaO<SUB>2</SUB>, HR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-10-16 02:18:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-11-17 14:18:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>Tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-19 02:40:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>Admissions from ED, number of readmissions of those discharged from ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-19 02:40:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>Clinical severity score, SaO<SUB>2</SUB>, HR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-11-19 02:41:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>Tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:11:28 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>Hospital admission, observation period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-04-25 21:11:53 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, HR, clinical score, no. improved with initial tx, additional tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:12:48 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>Hospital admission, observation period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-04-25 21:12:01 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, HR, clinical score, no. improved with initial tx, additional tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:13:58 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>Hospital admission, observation period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2011-04-25 21:12:07 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, HR, clinical score, no. improved with initial tx, additional tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-02-26 08:56:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION>
<P>RR, HR, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-27 10:15:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION>
<P>Acoustic breath sounds</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-09-27 10:15:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION>
<P>Computerized wheeze rate, computerized crackle count</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-26 08:58:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>LOS, hospital re-admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-02-26 08:59:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-02-26 08:59:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>AE, duration O<SUB>2</SUB> therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:18:08 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>LOS, hospital re-admission (2 weeks after d/c)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-03 05:57:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-03-03 05:57:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>AE, duration O<SUB>2</SUB> therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-04 05:43:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>LOS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-04 05:41:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-03-04 05:43:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>Adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-11-05 04:17:02 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION>
<P>MRDAI, SaO<SUB>2</SUB>, respiratory rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-11-05 04:16:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-03 06:00:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-09-27 10:20:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION>
<P>Number ready to go home at end of tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-06 10:18:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-09-27 10:21:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION>
<P>Number ready to go home at end of tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-02 06:39:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 06:38:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2011-04-25 21:17:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>Additional medication, follow-up rate, AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 00:34:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2011-04-25 21:17:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>Additional medication, follow-up rate, AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 00:34:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2011-04-25 21:17:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>Additional medication, follow-up rate, AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:18:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION>
<P>Hospital admission, LOS, return to healthcare facility (24 h after d/c)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 06:43:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-03-02 06:43:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:26:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>Hospital admission, time to d/c, re-admission to hospital, relapse rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 06:48:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>RR, SaO<SUB>2</SUB>, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:26:26 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>Return to physician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Mull-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-03-02 06:46:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-03 06:03:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-03 06:03:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP,<B> </B>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-07 01:39:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 01:39:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP,<B> </B>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:20:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>Hospital or ICU readmission, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 07:23:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:29:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>Medication requirements</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-03-02 06:52:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-09-27 10:29:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>Adequate fluid intake</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:21:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>Hospital or ICU readmission, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 02:18:52 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:30:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>Medication requirements</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-09-27 10:30:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>Adequate fluid intake</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:22:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 07:27:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:32:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-03-02 07:27:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:22:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 02:33:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:34:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-07-07 02:31:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-07-07 02:33:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:22:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 02:33:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:35:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-07-07 02:32:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-07-07 02:34:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-25 21:22:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 02:34:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-09-27 10:36:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-07-07 02:32:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-07-07 02:34:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:37:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION>
<P>Hospital admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 07:30:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION>
<P>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-03-04 05:53:51 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-03-08 09:35:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION>
<P>AE; home oxygen management</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-09-27 10:38:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION>
<P>Hospital admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-07-07 02:45:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION>
<P>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-07-07 02:45:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-07-07 02:45:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-07-07 02:46:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION>
<P>AE; home oxygen management</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-02 07:32:40 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>LOS, hospital re-admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 07:32:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-09-27 10:40:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>Pulmonary tests</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-02 07:36:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION>
<P>LOS, time ready for discharge, hospital readmission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-03-02 07:37:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION>
<P>RR, HR, BP, respiratory effort score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-03-02 07:34:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-03-02 07:34:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2010-09-27 10:41:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION>
<P>Supplemental O<SUB>2</SUB>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-04-25 21:22:41 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Clinical scores and other symptoms/clinical outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.05" NO="5">
<NAME>Other outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Administrative outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4">
<NAME>Pulmonary function outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>Patient reported outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-19 09:23:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-19 09:35:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION>
<P>RDAI; oxygen saturation; respiratory rate; heart rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-02-19 09:23:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-02-19 09:23:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-02-19 09:35:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION>
<P>Adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-19 09:37:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION>
<P>RDAI; oxygen saturation; respiratory rate; heart rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-02-19 09:37:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION>
<P>Adverse events; activity status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 14:17:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>Admissions from ED, number of readmissions of those discharged from ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-17 14:17:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>Clinical severity score, SaO<SUB>2</SUB>, HR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-11-17 14:17:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>Tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-17 14:18:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>Admissions from ED, number of readmissions of those discharged from ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-17 14:18:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>Clinical severity score, SaO<SUB>2</SUB>, HR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-10-16 02:18:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2011-04-25 21:10:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>Tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-19 02:41:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>Admissions from ED, number of readmissions of those discharged from ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-19 02:41:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>Clinical severity score, SaO<SUB>2</SUB>, HR</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-11-19 02:41:49 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>Tremor, study withdrawal due to worsening symptoms, discontinuation of any study drug due to side effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-27 10:11:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>Hospital admission, observation period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-04-25 21:11:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, HR, clinical score, no. improved with initial tx, additional tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-27 10:12:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>Hospital admission, observation period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-04-25 21:12:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, HR, clinical score, no. improved with initial tx, additional tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-27 10:14:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>Hospital admission, observation period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2011-04-25 21:12:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, HR, clinical score, no. improved with initial tx, additional tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-26 08:56:50 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION>
<P>RR, HR, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-09-27 10:15:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION>
<P>Acoustic breath sounds</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-09-27 10:15:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION>
<P>Computerized wheeze rate, computerized crackle count</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-26 08:59:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>LOS, hospital re-admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-26 09:00:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-02-26 09:00:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION>
<P>AE, duration O<SUB>2</SUB> therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-02-26 08:57:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:14:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>LOS, hospital re-admission (2 weeks after d/c)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-03 05:58:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-03-03 05:58:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-03-03 05:58:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION>
<P>AE, duration O<SUB>2</SUB> therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-04 05:43:13 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>LOS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-04 05:43:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-03-04 05:44:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-03-04 05:44:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION>
<P>Adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-14 06:35:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION>
<P>MRDAI, SaO<SUB>2</SUB>, respiratory rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-11-05 04:16:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-03 06:01:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-09-27 10:20:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION>
<P>Number ready to go home at end of tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 03:19:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 03:20:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-09-27 10:21:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION>
<P>Number ready to go home at end of tx</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 06:39:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2011-04-25 21:17:09 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>Additional medication, follow-up rate, AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 00:35:26 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2011-04-25 21:17:41 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>Additional medication, follow-up rate, AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 00:35:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2011-04-25 21:17:51 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>Additional medication, follow-up rate, AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:18:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION>
<P>Hospital admission, LOS, return to healthcare facility (24 h after d/c)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 06:44:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-03-02 06:44:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-11-05 07:32:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>Hospital admission, time to d/c, re-admission to hospital, relapse rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-11-05 07:32:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>RR, SaO<SUB>2</SUB>, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-11-05 07:32:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>Return to physician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Mull-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-11-05 07:32:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-03 06:04:24 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-03 06:04:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP,<B> </B>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 01:40:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 01:40:23 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, BP,<B> </B>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:21:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>Hospital or ICU readmission, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 07:23:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-09-27 10:29:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>Medication requirements</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-09-27 10:29:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION>
<P>Adequate fluid intake</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:21:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>Hospital or ICU readmission, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 02:19:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-09-27 10:30:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>Medication requirements</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-09-27 10:30:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION>
<P>Adequate fluid intake</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:22:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 07:27:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-09-27 10:32:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-03-02 07:28:02 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:22:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 02:33:10 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-09-27 10:34:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-07 02:33:15 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-07-07 02:33:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-25 21:22:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>Hospital admission,<B> </B>LOS, return to healthcare facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 02:34:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, temperature, RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-09-27 10:35:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>Duration of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-07 02:32:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-07-07 02:34:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION>
<P>AE</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-07-07 02:34:33 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 02:34:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-07 02:34:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" RESULT="UNKNOWN" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-07-07 02:34:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-27 10:37:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION>
<P>Hospital admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 07:30:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION>
<P>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-07 02:46:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-03-08 09:35:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION>
<P>AE; home oxygen management</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-27 10:38:51 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION>
<P>Hospital admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-07 02:46:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION>
<P>RDAI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-07 02:45:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-07-07 02:45:29 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-07-07 02:46:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION>
<P>AE; home oxygen management</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-02 07:32:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>LOS, hospital re-admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 07:33:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>SaO<SUB>2</SUB>, RR, HR, clinical score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-09-27 10:40:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION>
<P>Pulmonary tests</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-02 07:37:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION>
<P>LOS, time ready for discharge, hospital readmission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-02 07:37:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION>
<P>RR, HR, BP, respiratory effort score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-03-02 07:34:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2010-03-02 07:34:10 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2010-09-27 10:41:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION>
<P>Supplemental O<SUB>2</SUB>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-11-19 02:42:00 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:22:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:35:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:17:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:18:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-19 02:42:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:41:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:18:22 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:33:53 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:54:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:57:55 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:51:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 04:17:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:37:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:34:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:34:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:40:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:45:46 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 06:04:36 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 01:40:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:52:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:20:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:26:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:33:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:34:09 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:34:41 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:28:56 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:46:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:35:24 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-11-19 02:42:02 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:22:32 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abu_x002d_Shukair-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-19 09:35:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abul_x002d_Ainine-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:17:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-16 02:18:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-19 02:42:02 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anil-2010c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:42:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:18:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 09:33:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barlas-1998c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:54:16 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beck-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-26 08:57:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bertrand-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 05:51:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bilan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-John-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-05 04:17:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kadir-2009">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 06:00:05 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-06 10:18:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khashabi-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:37:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:35:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 00:35:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuyucu-2004c">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:40:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menon-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:45:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mull-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-03 06:04:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998a">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 01:40:33 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Okutan-1998b">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 06:52:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:20:07 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patel-2002b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:26:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:33:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:34:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009c">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:34:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Plint-2009d">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:28:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 02:46:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ralston-2005b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:31:48 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sanchez-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-02 07:35:30 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wainwright-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-04-25 21:28:59 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-04-25 21:27:49 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-03-16 08:54:33 +1000" MODIFIED_BY="[Empty name]">Epinephrine versus placebo for acute viral bronchiolitis</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Epinephrine versus placebo for acute viral bronchiolitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with acute viral bronchiolitis<BR/>
<B>Settings:</B> outpatients and inpatients<BR/>
<B>Intervention:</B> epinephrine versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Epinephrine versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions at enrollment or &lt; 24 hours (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.5 to 0.89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>995<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>185 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
<BR/>(92 to 165)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>190 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>127 per 1000</B>
<BR/>(95 to 169)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions overall up to 7 days (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.81 </B>
<BR/>(0.63 to 1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>875<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>251 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>203 per 1000</B>
<BR/>(158 to 259)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>255 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
<BR/>(161 to 263)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (inpatients only)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (inpatients only) in the intervention groups was<BR/>
<B>0.35 lower</B>
<BR/>(0.87 lower to 0.17 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>292<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-04-25 21:28:28 +1000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-11-17 14:51:15 +1000" MODIFIED_BY="[Empty name]">Epinephrine versus salbutamol/albuterol for acute viral bronchiolitis</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Epinephrine versus salbutamol/albuterol for acute viral bronchiolitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with acute viral bronchiolitis<BR/>
<B>Settings:</B> outpatients and inpatients<BR/>
<B>Intervention:</B> epinephrine versus salbutamol/albuterol<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Epinephrine versus salbutamol/albuterol</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions at enrollment or &lt; 24 hours (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.41 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>444<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>225 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>151 per 1000</B>
<BR/>(92 to 245)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>89 per 1000</B>
<BR/>(55 to 145)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions overall up to 7 days (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.05 </B>
<BR/>(0.71 to 1.54)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>212<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>262 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>275 per 1000</B>
<BR/>(186 to 403)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>175 per 1000</B>
<BR/>(119 to 257)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Length of stay (inpatients only)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean length of stay (inpatients only) in the intervention groups was<BR/>
<B>0.28 lower</B>
<BR/>(0.46 to 0.09 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>261<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-04-25 21:28:44 +1000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2010-09-27 10:49:38 +1000" MODIFIED_BY="[Empty name]">Epinephrine and steroid versus placebo for acute viral bronchiolitis</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Epinephrine and steroid versus placebo for acute viral bronchiolitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with acute viral bronchiolitis<BR/>
<B>Settings:</B> outpatients<BR/>
<B>Intervention:</B> epinephrine and steroid versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Epinephrine and steroid versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions at enrollment or &lt; 24 hours (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.4 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>401<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>179 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<BR/>(72 to 186)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>179 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<BR/>(72 to 186)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions overall up to 7 days (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.44 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>400<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>264 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>169 per 1000</B>
<BR/>(116 to 251)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>264 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>169 per 1000</B>
<BR/>(116 to 251)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2011-04-25 21:28:59 +1000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2010-09-27 10:50:08 +1000" MODIFIED_BY="[Empty name]">Epinephrine versus steroid for acute viral bronchiolitis</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Epinephrine versus steroid for acute viral bronchiolitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with acute viral bronchiolitis<BR/>
<B>Settings:</B> outpatients<BR/>
<B>Intervention:</B> epinephrine versus steroid<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Epinephrine versus steroid</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.12 </B>
<BR/>(0.66 to 1.88)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>444<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>136 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>152 per 1000</B>
<BR/>(90 to 256)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>73 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>82 per 1000</B>
<BR/>(48 to 137)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Admissions overall up to 7 days (outpatients only)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.08 </B>
<BR/>(0.77 to 1.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>399<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>236 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>255 per 1000</B>
<BR/>(182 to 359)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium-risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>236 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>255 per 1000</B>
<BR/>(182 to 359)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-05-03 09:12:56 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-05-03 09:12:56 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-07 08:04:48 +1000" MODIFIED_BY="[Empty name]">GRADE strength of evidence</TITLE>
<TABLE COLS="10" ROWS="27">
<TR>
<TH ROWSPAN="2">
<P>
<B>Population</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Outcome</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Number of studies</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Number of participants</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>
<B>GRADE domains</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Strength of evidence</B>
</P>
</TH>
<TH ROWSPAN="2">
<P>
<B>Intervention favored</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>Risk of bias</B>
</P>
</TH>
<TH>
<P>
<B>Consistency</B>
</P>
</TH>
<TH>
<P>
<B>Directness</B>
</P>
</TH>
<TH>
<P>
<B>Precision</B>
</P>
</TH>
</TR>
<TR>
<TH COLSPAN="10">
<P>Epinephrine versus placebo</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Inpatient</P>
</TD>
<TD>
<P>Length of stay</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>292</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (60 minutes)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>232</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>Outpatient</P>
</TD>
<TD>
<P>Admissions (Day 1)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>920</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TD>
<P>Admissions (up to Day 7)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>800</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (60 minutes)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>900</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>precise</P>
</TD>
<TD>
<P>high</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (120 minutes)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TH COLSPAN="10">
<P>Epinephrine versus salbutamol</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Inpatient</P>
</TD>
<TD>
<P>Length of stay</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>261</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>precise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (60 minutes)</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>148</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>inconsistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>precise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (120 minutes)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>140</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="6">
<P>Outpatient</P>
</TD>
<TD>
<P>Admissions (Day 1)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>444</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Admissions (up to Day 7)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>212</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (60 minutes)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>397</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>precise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (120 minutes)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>356</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>consistent</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>precise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (12 to 24 hours)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (3 to 10 days)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>69</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>epinephrine</P>
</TD>
</TR>
<TR>
<TH COLSPAN="10">
<P>Epinephrine + dexamethasone versus placebo</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Outpatient</P>
</TD>
<TD>
<P>Admissions (Day 1)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>401</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Admissions (up to Day 7)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>401</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>epinephrine + dexamethasone</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (60 minutes)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>399</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>precise</P>
</TD>
<TD>
<P>moderate</P>
</TD>
<TD>
<P>epinephrine + dexamethasone</P>
</TD>
</TR>
<TR>
<TH COLSPAN="10">
<P>Epinephrine + dexamethasone versus salbutamol</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Outpatient</P>
</TD>
<TD>
<P>Clinical score (120 minutes)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (12 to 24 hours)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>no difference</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical score (3 to 10 days)</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>medium</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>direct</P>
</TD>
<TD>
<P>imprecise</P>
</TD>
<TD>
<P>low</P>
</TD>
<TD>
<P>epinephrine + dexamethasone</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-04-25 21:29:41 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-07-07 08:55:54 +1000" MODIFIED_BY="[Empty name]">Adverse events</TITLE>
<TABLE COLS="8" ROWS="20">
<TR>
<TH VALIGN="BOTTOM">
<P>Comparison</P>
</TH>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>Adverse event</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Total (N)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Results</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Number of events/total (%)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Notes</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="19">
<P>Epi versus placebo</P>
<P>Epi versus salbutamol</P>
</TD>
<TD ROWSPAN="5">
<P>Cardiovascular</P>
</TD>
<TD ROWSPAN="3">
<P>Arrhythmias</P>
</TD>
<TD ROWSPAN="3">
<P>111</P>
</TD>
<TD>
<P>Ralston 2005</P>
</TD>
<TD>
<P>1) saline placebo</P>
<P>2) racemic albuterol sulfate</P>
<P>3) racemic epi</P>
</TD>
<TD>
<P>0/25 (0)</P>
<P>2/23 (9)</P>
<P>0/17 (0)</P>
</TD>
<TD>
<P>tachycardia</P>
</TD>
</TR>
<TR>
<TD>
<P>Bertrand 2001</P>
</TD>
<TD>
<P>1) salbutamol</P>
<P>2) epi</P>
</TD>
<TD>
<P>NR</P>
<P>0/16 (0)</P>
</TD>
<TD>
<P>tachycardia</P>
</TD>
</TR>
<TR>
<TD>
<P>John 2006</P>
</TD>
<TD>
<P>1) epi</P>
<P>2) salbutamol</P>
</TD>
<TD>
<P>0/15 (0)</P>
<P>0/15 (0)</P>
</TD>
<TD>
<P>tachyarrhythmia</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>Hypertension /</P>
<P>others</P>
</TD>
<TD ROWSPAN="2">
<P>54</P>
</TD>
<TD>
<P>Bertrand 2001</P>
</TD>
<TD>
<P>1) salbutamol</P>
<P>2) epi</P>
</TD>
<TD>
<P>NR</P>
<P>0/16 (0)</P>
</TD>
<TD>
<P>hypertension</P>
</TD>
</TR>
<TR>
<TD>
<P>Abul-Ainine 2002</P>
</TD>
<TD>
<P>1) levo-adrenaline</P>
<P>2) saline placebo</P>
</TD>
<TD>
<P>0/19 (0)</P>
<P>0/19 (0)</P>
</TD>
<TD>
<P>vomiting, pallor, tremor, arrhythmia</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="14">
<P>General</P>
</TD>
<TD ROWSPAN="6">
<P>Tremor</P>
</TD>
<TD ROWSPAN="6">
<P>981</P>
</TD>
<TD>
<P>Anil 2010</P>
</TD>
<TD>
<P>1) epi + 0.9% saline</P>
<P>2) epi + 3% saline</P>
<P>3) salbutamol + 0.9% saline</P>
<P>4) salbutamol + 3% saline</P>
</TD>
<TD>
<P>0/38 (0)</P>
<P>0/39 (0)</P>
<P>0/36 (0)</P>
<P>0/36 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kuyucu 2004</P>
</TD>
<TD>
<P>1) epi + dex</P>
<P>2) salbutamol + dex</P>
<P>3) epi + placebo</P>
<P>4) salbutamol + placebo</P>
</TD>
<TD>
<P>0/23 (0)</P>
<P>0/23 (0)</P>
<P>0/11 (0)</P>
<P>0/12 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>1) epi + dex</P>
<P>2) epi + placebo</P>
<P>3) placebo + dex</P>
<P>4) placebo + placebo</P>
</TD>
<TD>
<P>4/200 (2)</P>
<P>4/199 (2)</P>
<P>5/200 (2.5)</P>
<P>2/201 (1)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mull 2004</P>
</TD>
<TD>
<P>1) racemic epi</P>
<P>2) albuterol sulfate</P>
</TD>
<TD>
<P>0/34 (0)</P>
<P>0/32 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bertrand 2001</P>
</TD>
<TD>
<P>1) salbutamol</P>
<P>2) epi</P>
</TD>
<TD>
<P>NR</P>
<P>0/16 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>John 2006</P>
</TD>
<TD>
<P>1) epi</P>
<P>2) salbutamol</P>
</TD>
<TD>
<P>0/15 (0)</P>
<P>0/15 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>Pallor / flushing</P>
</TD>
<TD ROWSPAN="4">
<P>965</P>
</TD>
<TD>
<P>Kuyucu 2004</P>
</TD>
<TD>
<P>1) epi + dex</P>
<P>2) salbutamol + dex</P>
<P>3) epi + placebo</P>
<P>4) salbutamol + placebo</P>
</TD>
<TD>
<P>0/23 (0)</P>
<P>0/23 (0)</P>
<P>0/11 (0)</P>
<P>0/12 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>1) epi + dex</P>
<P>2) epi + placebo</P>
<P>3) placebo + dex</P>
<P>4) placebo + placebo</P>
</TD>
<TD>
<P>23/200 (11.5)</P>
<P>22/199 (11.1)</P>
<P>15/200 (7.5)</P>
<P>16/201 (8)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>John 2006</P>
</TD>
<TD>
<P>1) epi</P>
<P>2) salbutamol</P>
</TD>
<TD>
<P>0/15 (0)</P>
<P>0/15 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Mull 2004</P>
</TD>
<TD>
<P>1) racemic epi</P>
<P>2) albuterol sulfate</P>
</TD>
<TD>
<P>1/34 (3)</P>
<P>0/32 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>Vomiting</P>
</TD>
<TD ROWSPAN="3">
<P>935</P>
</TD>
<TD>
<P>Mull 2004</P>
</TD>
<TD>
<P>1) racemic epi</P>
<P>2) albuterol sulfate</P>
</TD>
<TD>
<P>1/34 (3)</P>
<P>5/32 (15.6)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kuyucu 2004</P>
</TD>
<TD>
<P>1) epi + dex</P>
<P>2) salbutamol + dex</P>
<P>3) epi + placebo</P>
<P>4) salbutamol + placebo</P>
</TD>
<TD>
<P>0/23 (0)</P>
<P>0/23 (0)</P>
<P>0/11 (0)</P>
<P>0/12 (0)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Plint 2009</P>
</TD>
<TD>
<P>1) epi + dex</P>
<P>2) epi + placebo</P>
<P>3) placebo + dex</P>
<P>4) placebo + placebo</P>
</TD>
<TD>
<P>2/200 (1)</P>
<P>4/199 (2)</P>
<P>5/200 (2.5)</P>
<P>3/201 (1.5)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Agitation / others</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>John 2006</P>
</TD>
<TD>
<P>1) epi</P>
<P>2) salbutamol</P>
</TD>
<TD>
<P>0/15 (0)</P>
<P>0/15 (0)</P>
</TD>
<TD>
<P>irritability</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Dex: dexamethasone<BR/>Epi: epinephrine<BR/>NR: not reported</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-04-25 21:36:58 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-04-25 21:36:24 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Epinephrine versus placebo</NAME>
<DICH_OUTCOME CHI2="3.7580339178850943" CI_END="0.8945861592496404" CI_START="0.5042693865427138" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6716490257079353" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.04837782537642485" LOG_CI_START="-0.29733739642371604" LOG_EFFECT_SIZE="-0.1728576109000704" METHOD="MH" MODIFIED="2011-04-25 21:34:59 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4397416768218908" P_Q="1.0" P_Z="0.006495013537948431" Q="0.0" RANDOM="YES" SCALE="8.092923526092896" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="502" WEIGHT="100.0" Z="2.721684411590029">
<NAME>Admissions at enrollment or &lt; 24 hours (outpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-19 03:37:22 +1000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.0" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2010-07-07 10:09:02 +1000" MODIFIED_BY="[Empty name]" ORDER="1005" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.9897728000213852"/>
<DICH_DATA CI_END="0.8188911803881171" CI_START="0.24121747666632606" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.08677380629442545" LOG_CI_START="-0.6175912299282995" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.3118047822311618" STUDY_ID="STD-Khashabi-2005a" TOTAL_1="24" TOTAL_2="24" VAR="0.09722222222222224" WEIGHT="21.997195494352823"/>
<DICH_DATA CI_END="1.2263276620874919" CI_START="0.44887535301113846" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="0.08860652468814063" LOG_CI_START="-0.3478742403215002" LOG_EFFECT_SIZE="-0.1296338578166798" MODIFIED="2010-03-27 04:41:12 +1000" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.25639096198129574" STUDY_ID="STD-Plint-2009a" TOTAL_1="200" TOTAL_2="200" VAR="0.06573632538569424" WEIGHT="32.53324879463142"/>
<DICH_DATA CI_END="1.2735836706277128" CI_START="0.5198157979538948" EFFECT_SIZE="0.8136515912897823" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.10502748208192542" LOG_CI_START="-0.2841505257970233" LOG_EFFECT_SIZE="-0.08956152185754895" MODIFIED="2010-03-27 04:41:26 +1000" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.2286050882903031" STUDY_ID="STD-Plint-2009b" TOTAL_1="199" TOTAL_2="201" VAR="0.052260286392217276" WEIGHT="40.922397794898494"/>
<DICH_DATA CI_END="2.6886548360778675" CI_START="0.12869660939834135" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.4295350519784423" LOG_CI_START="-0.8904328947349901" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2010-07-07 09:19:17 +1000" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.7753557058461846" STUDY_ID="STD-Ralston-2005a" TOTAL_1="17" TOTAL_2="25" VAR="0.6011764705882352" WEIGHT="3.557385116095872"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7531412190883429" CI_END="1.031960327574538" CI_START="0.6290384321190133" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8056939285277696" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.01366300170336188" LOG_CI_START="-0.201322819821301" LOG_EFFECT_SIZE="-0.0938299090589696" METHOD="MH" MODIFIED="2011-04-02 07:06:44 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.41620818991528774" P_Q="1.0" P_Z="0.08711053129714964" Q="0.0" RANDOM="YES" SCALE="2.49" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="437" TOTAL_2="438" WEIGHT="100.0" Z="1.7108406603190978">
<NAME>Admissions overall up to 7 days (outpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0633374162851426" CI_START="0.421245232429462" EFFECT_SIZE="1.1359649122807018" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4861948355137586" LOG_CI_START="-0.37546500135216254" LOG_EFFECT_SIZE="0.05536491708079807" MODIFIED="2010-11-19 03:39:41 +1000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.5061432534600242" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" VAR="0.2561809930230983" WEIGHT="6.225122999740548"/>
<DICH_DATA CI_END="0.9818605899855746" CI_START="0.4526553453489503" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="51" LOG_CI_END="-0.007950171376024993" LOG_CI_START="-0.3442323467353376" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.19753381442967494" STUDY_ID="STD-Plint-2009a" TOTAL_1="200" TOTAL_2="200" VAR="0.03901960784313726" WEIGHT="40.870687326626914"/>
<DICH_DATA CI_END="1.2587847653076298" CI_START="0.6373506903494038" EFFECT_SIZE="0.8957049397933061" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" LOG_CI_END="0.09995147813785611" LOG_CI_START="-0.19562153944643484" LOG_EFFECT_SIZE="-0.04783503065428937" MODIFIED="2011-04-02 07:06:39 +1000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.17362105363904626" STUDY_ID="STD-Plint-2009b" TOTAL_1="199" TOTAL_2="201" VAR="0.03014427026673258" WEIGHT="52.90418967363254"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.28438811076589665" CI_END="0.16861804840406736" CI_START="-0.8650328501699125" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.34820740088292257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2011-03-03 08:15:59 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5938394792219424" P_Q="1.0" P_Z="0.18666428897148368" Q="0.0" RANDOM="YES" SCALE="1.2282712714158073" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="143" UNITS="" WEIGHT="100.0" Z="1.3205115301933505">
<NAME>Length of stay (inpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7592145453566523" CI_START="-1.0512145453566522" EFFECT_SIZE="-0.1459999999999999" ESTIMABLE="YES" MEAN_1="2.492" MEAN_2="2.638" MODIFIED="2011-03-03 08:15:59 +1000" MODIFIED_BY="[Empty name]" ORDER="285" SD_1="2.583" SD_2="1.958" SE="0.46185264244489643" STUDY_ID="STD-Patel-2002a" TOTAL_1="50" TOTAL_2="48" WEIGHT="32.597533039025755"/>
<CONT_DATA CI_END="0.18351487225186713" CI_START="-1.0755148722518666" EFFECT_SIZE="-0.44599999999999973" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.896" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="334" SD_1="2.179" SD_2="2.29" SE="0.3211869591571069" STUDY_ID="STD-Wainwright-2003" TOTAL_1="99" TOTAL_2="95" WEIGHT="67.40246696097425"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.955297441429002" CI_END="-0.29659224650314114" CI_START="-0.6179479843705167" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.45727011543682894" ESTIMABLE="YES" I2="29.685676985707346" I2_Q="54.1511134437113" ID="CMP-001.04" MODIFIED="2010-11-19 06:33:34 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.19112106546402285" P_Q="0.13971664249820093" P_Z="2.4354514772312782E-8" Q="2.181078048149107" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.015904055872203747" TOTALS="SUB" TOTAL_1="543" TOTAL_2="537" UNITS="" WEIGHT="200.0" Z="5.577824521885685">
<NAME>Clinical score - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.935547327493859" CI_END="-0.22780273812979" CI_START="-0.5793454531781154" DF="5" EFFECT_SIZE="-0.4035740956539527" ESTIMABLE="YES" I2="27.9076363565565" ID="CMP-001.04.01" MODIFIED="2010-11-19 06:20:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2254781113248554" P_Z="6.791785457602221E-6" STUDIES="6" TAU2="0.012489591162140162" TOTAL_1="490" TOTAL_2="485" WEIGHT="100.00000000000001" Z="4.50011141585645">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.19287879329224" CI_START="-0.716554799481159" EFFECT_SIZE="-0.2618380030944595" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.5" MODIFIED="2010-11-19 06:20:23 +1000" MODIFIED_BY="[Empty name]" ORDER="195" SD_1="1.153" SD_2="1.114" SE="0.23200262860616191" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" WEIGHT="12.128008609481808"/>
<CONT_DATA CI_END="-0.013340665850994582" CI_START="-1.5026952233018163" EFFECT_SIZE="-0.7580179445764055" ESTIMABLE="YES" MEAN_1="-1.93" MEAN_2="-0.54" MODIFIED="2010-07-07 10:09:36 +1000" MODIFIED_BY="[Empty name]" ORDER="1006" SD_1="1.589" SD_2="1.96" SE="0.3799443686717359" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.127703969077919"/>
<CONT_DATA CI_END="-0.4133699075014853" CI_START="-1.6221320056961757" EFFECT_SIZE="-1.0177509565988305" ESTIMABLE="YES" MEAN_1="-7.5" MEAN_2="-2.7" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="338" SD_1="4.0" SD_2="5.2" SE="0.30836334435970547" STUDY_ID="STD-Khashabi-2005a" TOTAL_1="24" TOTAL_2="24" WEIGHT="7.476156938606389"/>
<CONT_DATA CI_END="0.10361388100210744" CI_START="-1.5317882502950597" EFFECT_SIZE="-0.7140871846464761" ESTIMABLE="YES" MEAN_1="-1.09" MEAN_2="-0.1" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="335" SD_1="1.26" SD_2="1.47" SE="0.41720208743553716" STUDY_ID="STD-Okutan-1998a" TOTAL_1="16" TOTAL_2="10" WEIGHT="4.311330931640028"/>
<CONT_DATA CI_END="-0.10283318796108776" CI_START="-0.49804242949102806" EFFECT_SIZE="-0.3004378087260579" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.75" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="337" SD_1="2.58" SD_2="2.4" SE="0.10082053666478066" STUDY_ID="STD-Plint-2009a" TOTAL_1="199" TOTAL_2="199" WEIGHT="35.501606700961474"/>
<CONT_DATA CI_END="-0.1389095393738656" CI_START="-0.5346948869501741" EFFECT_SIZE="-0.33680221316201986" ESTIMABLE="YES" MEAN_1="-2.45" MEAN_2="-1.65" MODIFIED="2010-03-27 04:51:42 +1000" MODIFIED_BY="[Empty name]" ORDER="243" SD_1="2.32" SD_2="2.42" SE="0.10096750519351702" STUDY_ID="STD-Plint-2009b" TOTAL_1="198" TOTAL_2="200" WEIGHT="35.455192850232386"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.09852658329140183" CI_END="-0.33393577419848697" CI_START="-1.1265823414733742" DF="1" EFFECT_SIZE="-0.7302590578359306" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2010-11-19 06:33:34 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7536050316774041" P_Z="3.0454985967000845E-4" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="3.6113988550112843">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="-0.2240851555509945" CI_START="-1.1574929221708539" EFFECT_SIZE="-0.6907890388609241" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.8" MODIFIED="2010-11-19 06:33:34 +1000" MODIFIED_BY="[Empty name]" ORDER="196" SD_1="1.2" SD_2="0.748" SE="0.23811860166371948" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" WEIGHT="72.11346206253603"/>
<CONT_DATA CI_END="-0.08182418593874308" CI_START="-1.5828296831453663" EFFECT_SIZE="-0.8323269345420546" ESTIMABLE="YES" MEAN_1="-3.53" MEAN_2="-1.27" MODIFIED="2010-07-07 10:11:00 +1000" MODIFIED_BY="[Empty name]" ORDER="1007" SD_1="2.74" SD_2="2.54" SE="0.38291660179635006" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" WEIGHT="27.88653793746397"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8462383139560798" CI_END="0.3979077214699888" CI_START="-0.4863327095568614" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04421249404343629" ESTIMABLE="YES" I2="45.8358115287283" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2010-09-27 09:37:58 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1742217149157409" P_Q="1.0" P_Z="0.8446113455957036" Q="0.0" RANDOM="YES" SCALE="2.1156595036266372" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.05382036262088191" TOTALS="SUB" TOTAL_1="118" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="0.1959984930596224">
<NAME>Clinical score - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8462383139560798" CI_END="0.3979077214699888" CI_START="-0.4863327095568614" DF="1" EFFECT_SIZE="-0.04421249404343629" ESTIMABLE="YES" I2="45.8358115287283" ID="CMP-001.05.01" MODIFIED="2010-09-27 09:37:58 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1742217149157409" P_Z="0.8446113455957036" STUDIES="2" TAU2="0.05382036262088191" TOTAL_1="118" TOTAL_2="114" WEIGHT="100.0" Z="0.1959984930596224">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.9260778831359306" CI_START="-0.35297576966280997" EFFECT_SIZE="0.28655105673656034" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-3.9" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="342" SD_1="8.282" SD_2="7.41" SE="0.32629519289327574" STUDY_ID="STD-Abul_x002d_Ainine-2002" TOTAL_1="19" TOTAL_2="19" WEIGHT="31.745419721959287"/>
<CONT_DATA CI_END="0.08414582671872328" CI_START="-0.4802491480533585" EFFECT_SIZE="-0.1980516606673176" ESTIMABLE="YES" MEAN_1="-0.483" MEAN_2="-0.2" MODIFIED="2010-07-07 09:28:03 +1000" MODIFIED_BY="[Empty name]" ORDER="341" SD_1="1.538" SD_2="1.293" SE="0.14398095557468332" STUDY_ID="STD-Wainwright-2003" TOTAL_1="99" TOTAL_2="95" WEIGHT="68.2545802780407"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="19.798024793221913" CI_END="1.049435884965636" CI_START="-0.21476908945181816" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4173333977569089" ESTIMABLE="YES" I2="69.69394642815999" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-03-03 07:50:34 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0030081494256520847" P_Q="0.3567468362594469" P_Z="0.1956556882596677" Q="0.8493130095675896" RANDOM="YES" SCALE="2.9" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.42336664112618355" TOTALS="SUB" TOTAL_1="527" TOTAL_2="527" UNITS="" WEIGHT="200.0" Z="1.2940281769199427">
<NAME>Oxygen saturation - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.746002689803404" CI_END="1.3581436114771077" CI_START="-0.1429295644626457" DF="4" EFFECT_SIZE="0.607607023507231" ESTIMABLE="YES" I2="74.59672731676676" ID="CMP-001.06.01" MODIFIED="2010-11-19 06:36:26 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0033796383892618076" P_Z="0.11257714087658792" STUDIES="5" TAU2="0.47988052817595833" TOTAL_1="474" TOTAL_2="475" WEIGHT="100.00000000000001" Z="1.5867152939858435">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.1795662683607554" CI_START="-1.3795662683607555" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.0" MODIFIED="2010-11-19 06:36:26 +1000" MODIFIED_BY="[Empty name]" ORDER="197" SD_1="1.552" SD_2="1.873" SE="0.39774520068219343" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" WEIGHT="22.981121356353043"/>
<CONT_DATA CI_END="2.531093105958966" CI_START="-0.13109310595896595" EFFECT_SIZE="1.2" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="0.2" MODIFIED="2010-07-07 10:11:40 +1000" MODIFIED_BY="[Empty name]" ORDER="1008" SD_1="1.72" SD_2="1.99" SE="0.6791416150798987" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" WEIGHT="15.581360828576738"/>
<CONT_DATA CI_END="5.134306888404939" CI_START="0.8656931115950606" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="2.5" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="354" SD_1="3.9" SD_2="3.64" SE="1.0889520956711856" STUDY_ID="STD-Khashabi-2005a" TOTAL_1="24" TOTAL_2="24" WEIGHT="8.803421595686187"/>
<CONT_DATA CI_END="0.7939932793088224" CI_START="-0.21399327930882228" EFFECT_SIZE="0.29000000000000004" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-1.02" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="351" SD_1="2.56" SD_2="2.57" SE="0.2571441533029469" STUDY_ID="STD-Plint-2009a" TOTAL_1="199" TOTAL_2="199" WEIGHT="26.85666080199694"/>
<CONT_DATA CI_END="1.424656572664221" CI_START="0.2553434273357792" EFFECT_SIZE="0.8400000000000001" ESTIMABLE="YES" MEAN_1="0.07" MEAN_2="-0.77" MODIFIED="2010-03-27 05:09:31 +1000" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="2.7" SD_2="3.23" SE="0.29829965105273226" STUDY_ID="STD-Plint-2009b" TOTAL_1="198" TOTAL_2="200" WEIGHT="25.777435417387103"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3892792385374872" CI_END="1.125441261243993" CI_START="-1.2193088586440246" DF="1" EFFECT_SIZE="-0.04693379870001576" ESTIMABLE="YES" I2="58.14637385741004" ID="CMP-001.06.02" MODIFIED="2010-11-19 06:37:18 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12217012825386686" P_Z="0.9374594281921179" STUDIES="2" TAU2="0.4186538917733525" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.07846341862140684">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.37018326079317243" CI_START="-1.5701832607931725" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.2" MODIFIED="2010-11-19 06:37:18 +1000" MODIFIED_BY="[Empty name]" ORDER="198" SD_1="2.427" SD_2="1.825" SE="0.49500055533971754" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" WEIGHT="53.91114989166799"/>
<CONT_DATA CI_END="1.7721611542509557" CI_START="-0.5721611542509555" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.07" MEAN_2="0.47" MODIFIED="2010-07-07 10:11:58 +1000" MODIFIED_BY="[Empty name]" ORDER="1009" SD_1="1.25" SD_2="1.95" SE="0.5980523945831725" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" WEIGHT="46.08885010833202"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7636467668008368" CI_START="-1.563646766800837" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2011-03-03 07:51:02 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5004819746389986" Q="0.0" RANDOM="YES" SCALE="2.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.6737315963773088">
<NAME>Oxygen saturation - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7636467668008368" CI_START="-1.563646766800837" DF="0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2010-09-27 09:38:57 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5004819746389986" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.6737315963773088">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.7636467668008368" CI_START="-1.563646766800837" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.1" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="356" SD_1="1.33" SD_2="2.22" SE="0.5937082395286515" STUDY_ID="STD-Abul_x002d_Ainine-2002" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.688605168463576" CI_END="0.647101923372869" CI_START="-7.095753442401051" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.224325759514091" ESTIMABLE="YES" I2="86.38400326605552" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2010-09-27 09:39:12 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="6.462689157891166E-4" P_Q="1.0" P_Z="0.10260374266548519" Q="0.0" RANDOM="YES" SCALE="8.87" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.49743612403338" TOTALS="SUB" TOTAL_1="421" TOTAL_2="423" UNITS="" WEIGHT="99.99999999999999" Z="1.6323596566215122">
<NAME>Respiratory rate - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.688605168463576" CI_END="0.647101923372869" CI_START="-7.095753442401051" DF="2" EFFECT_SIZE="-3.224325759514091" ESTIMABLE="YES" I2="86.38400326605552" ID="CMP-001.08.01" MODIFIED="2010-09-27 09:39:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.462689157891166E-4" P_Z="0.10260374266548519" STUDIES="3" TAU2="9.49743612403338" TOTAL_1="421" TOTAL_2="423" WEIGHT="99.99999999999999" Z="1.6323596566215122">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-5.7477381391004805" CI_START="-15.452261860899522" EFFECT_SIZE="-10.600000000000001" ESTIMABLE="YES" MEAN_1="-17.8" MEAN_2="-7.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="358" SD_1="9.0" SD_2="8.13" SE="2.4756892979531986" STUDY_ID="STD-Khashabi-2005a" TOTAL_1="24" TOTAL_2="24" WEIGHT="24.968079419930703"/>
<CONT_DATA CI_END="1.1045259111483559" CI_START="-2.584525911148356" EFFECT_SIZE="-0.7400000000000002" ESTIMABLE="YES" MEAN_1="-4.04" MEAN_2="-3.3" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="357" SD_1="9.17" SD_2="9.6" SE="0.9411019415140998" STUDY_ID="STD-Plint-2009a" TOTAL_1="199" TOTAL_2="199" WEIGHT="37.57670606519675"/>
<CONT_DATA CI_END="1.0792692535472437" CI_START="-2.679269253547244" EFFECT_SIZE="-0.8000000000000003" ESTIMABLE="YES" MEAN_1="-3.68" MEAN_2="-2.88" MODIFIED="2010-03-27 05:12:51 +1000" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="8.89" SD_2="10.2" SE="0.9588284623445532" STUDY_ID="STD-Plint-2009b" TOTAL_1="198" TOTAL_2="200" WEIGHT="37.45521451487253"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.571444575589307" CI_START="-2.9714445755893064" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2011-04-25 21:35:14 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.3416698869313973" Q="0.0" RANDOM="YES" SCALE="8.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.9508709794985423">
<NAME>Respiratory rate - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.571444575589307" CI_START="-2.9714445755893064" DF="0" EFFECT_SIZE="2.8000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2011-04-25 21:35:14 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3416698869313973" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="0.9508709794985423">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="8.571444575589307" CI_START="-2.9714445755893064" EFFECT_SIZE="2.8000000000000003" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-4.4" MODIFIED="2010-07-07 09:20:48 +1000" MODIFIED_BY="[Empty name]" ORDER="360" SD_1="9.6" SD_2="8.52" SE="2.944668688360462" STUDY_ID="STD-Abul_x002d_Ainine-2002" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.426747714706313" CI_END="9.51245690662642" CI_START="5.248836730485088" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="7.380646818555754" ESTIMABLE="YES" I2="22.20015127467177" I2_Q="54.71926841486234" ID="CMP-001.10" MODIFIED="2011-04-25 21:35:26 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.26687977511716143" P_Q="0.1372570596646131" P_Z="1.1553315970503715E-11" Q="2.208444883713466" RANDOM="YES" SCALE="26.35085429133134" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="2.1870056859108336" TOTALS="SUB" TOTAL_1="503" TOTAL_2="503" UNITS="" WEIGHT="200.0" Z="6.785689789127169">
<NAME>Heart rate - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.2351661705757393" CI_END="10.063253962738594" CI_START="5.62706706964201" DF="3" EFFECT_SIZE="7.845160516190302" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" MODIFIED="2011-04-25 21:35:26 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5250550851832062" P_Z="4.143922495227498E-12" STUDIES="4" TAU2="0.0" TOTAL_1="450" TOTAL_2="451" WEIGHT="100.0" Z="6.93218407393815">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="9.796099428311354" CI_START="-2.7960994283113534" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="2.0" MODIFIED="2010-11-19 06:37:33 +1000" MODIFIED_BY="[Empty name]" ORDER="199" SD_1="14.703" SD_2="13.089" SE="3.2123546544600727" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" WEIGHT="12.411278522540384"/>
<CONT_DATA CI_END="15.520122399712145" CI_START="0.4798776002878551" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="-1.6" MODIFIED="2010-07-07 10:12:29 +1000" MODIFIED_BY="[Empty name]" ORDER="1010" SD_1="13.63" SD_2="5.92" SE="3.8368676460536575" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.699811817787294"/>
<CONT_DATA CI_END="12.447680001431017" CI_START="5.472319998568984" EFFECT_SIZE="8.96" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="-3.76" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="363" SD_1="17.8" SD_2="17.7" SE="1.779461270177101" STUDY_ID="STD-Plint-2009a" TOTAL_1="199" TOTAL_2="199" WEIGHT="40.44700933051645"/>
<CONT_DATA CI_END="11.617481647545894" CI_START="4.462518352454104" EFFECT_SIZE="8.04" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="-3.24" MODIFIED="2010-03-27 05:16:55 +1000" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="17.6" SD_2="18.8" SE="1.8252792784788976" STUDY_ID="STD-Plint-2009b" TOTAL_1="198" TOTAL_2="200" WEIGHT="38.44190032915588"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3825686316177508" CI_END="9.474442314791542" CI_START="-5.9622772257716" DF="1" EFFECT_SIZE="1.7560825445099708" ESTIMABLE="YES" I2="27.670860083821317" ID="CMP-001.10.02" MODIFIED="2010-11-19 06:37:39 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23966429633492103" P_Z="0.6556468419328441" STUDIES="2" TAU2="10.32809318456614" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.4459313433887053">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="10.990156588475585" CI_START="-2.3901565884755867" EFFECT_SIZE="4.3" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="2.7" MODIFIED="2010-11-19 06:37:39 +1000" MODIFIED_BY="[Empty name]" ORDER="200" SD_1="16.687" SD_2="12.648" SE="3.4134079203733783" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" WEIGHT="70.55651093182837"/>
<CONT_DATA CI_END="8.413637907411356" CI_START="-17.093637907411356" EFFECT_SIZE="-4.34" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="4.47" MODIFIED="2010-07-07 10:12:47 +1000" MODIFIED_BY="[Empty name]" ORDER="1011" SD_1="13.47" SD_2="21.3" SE="6.507077685105657" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" WEIGHT="29.443489068171633"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4990915682952304" CI_END="24.921552109336538" CI_START="1.192661916185818" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="13.057107012761177" ESTIMABLE="YES" I2="71.42115373427613" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2010-09-27 09:39:51 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.06140262882372638" P_Q="1.0" P_Z="0.031006640257267373" Q="0.0" RANDOM="YES" SCALE="26.35085429133134" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="53.160336346909624" TOTALS="SUB" TOTAL_1="112" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="2.1569874763619743">
<NAME>Heart rate - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.4990915682952304" CI_END="24.921552109336538" CI_START="1.192661916185818" DF="1" EFFECT_SIZE="13.057107012761177" ESTIMABLE="YES" I2="71.42115373427613" ID="CMP-001.11.01" MODIFIED="2010-09-27 09:39:51 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06140262882372638" P_Z="0.031006640257267373" STUDIES="2" TAU2="53.160336346909624" TOTAL_1="112" TOTAL_2="113" WEIGHT="100.0" Z="2.1569874763619743">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="17.02482737924345" CI_START="-4.6248273792434516" EFFECT_SIZE="6.2" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="-3.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="366" SD_1="16.02" SD_2="17.97" SE="5.522972597776443" STUDY_ID="STD-Abul_x002d_Ainine-2002" TOTAL_1="19" TOTAL_2="19" WEIGHT="43.79881146823065"/>
<CONT_DATA CI_END="25.201962621318657" CI_START="11.600037378681344" EFFECT_SIZE="18.401" ESTIMABLE="YES" MEAN_1="12.243" MEAN_2="-6.158" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="365" SD_1="25.02" SD_2="22.34" SE="3.469942649438347" STUDY_ID="STD-Wainwright-2003" TOTAL_1="93" TOTAL_2="94" WEIGHT="56.20118853176935"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.43368145212777387" CI_END="1.8580590795579819" CI_START="0.04585032832971466" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2918777464174699" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.26905951887081236" LOG_CI_START="-1.3386575500425364" LOG_EFFECT_SIZE="-0.5347990155858621" METHOD="MH" MODIFIED="2010-09-27 09:40:17 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.5101880442424807" P_Q="0.5166979356615296" P_Z="0.19225255081687517" Q="0.4204794238013254" RANDOM="YES" SCALE="185.31902742930964" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="143" WEIGHT="100.0" Z="1.3039443690477592">
<NAME>Hospital readmissions (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.588862895176131" CI_START="0.007276904523359407" DF="0" EFFECT_SIZE="0.13725490196078435" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.4131090510354411" LOG_CI_START="-2.1380533232028" LOG_EFFECT_SIZE="-0.8624721360836795" MODIFIED="2010-09-27 09:40:11 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.18510115097697666" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="48" WEIGHT="39.71394619344918" Z="1.3252110813982085">
<NAME>2 to 10 days</NAME>
<DICH_DATA CI_END="2.588862895176131" CI_START="0.007276904523359407" EFFECT_SIZE="0.13725490196078433" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4131090510354411" LOG_CI_START="-2.1380533232028" LOG_EFFECT_SIZE="-0.8624721360836795" MODIFIED="2010-03-27 07:07:38 +1000" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="1.4985654070849643" STUDY_ID="STD-Patel-2002a" TOTAL_1="50" TOTAL_2="48" VAR="2.245698279311725" WEIGHT="39.71394619344918"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.204395558731752" CI_START="0.04423301396297422" DF="0" EFFECT_SIZE="0.4797979797979798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.7163702975832295" LOG_CI_START="-1.3542534675285962" LOG_EFFECT_SIZE="-0.3189415849726834" MODIFIED="2010-09-27 09:40:17 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5459813078763776" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="95" WEIGHT="60.28605380655081" Z="0.6037929538443416">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="5.204395558731752" CI_START="0.04423301396297422" EFFECT_SIZE="0.4797979797979798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7163702975832295" LOG_CI_START="-1.3542534675285962" LOG_EFFECT_SIZE="-0.3189415849726834" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="1.2162946493796296" STUDY_ID="STD-Wainwright-2003" TOTAL_1="99" TOTAL_2="95" VAR="1.4793726741095161" WEIGHT="60.28605380655081"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7561238820011775" CI_END="1.1936099486174918" CI_START="0.8101836560898019" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9833835834078583" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="192" I2="43.05640904669791" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.07686242994400344" LOG_CI_START="-0.09141652212701251" LOG_EFFECT_SIZE="-0.007277046091504536" METHOD="MH" MODIFIED="2011-03-03 07:51:43 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.1851088397959636" P_Q="1.0" P_Z="0.8653930240025814" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00844613936870366" TOTALS="YES" TOTAL_1="399" TOTAL_2="401" WEIGHT="100.0" Z="0.16951315750014653">
<NAME>Return visits (ED or any healthcare provider) - (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7561238820011775" CI_END="1.1936099486174918" CI_START="0.8101836560898019" DF="1" EFFECT_SIZE="0.9833835834078583" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="192" I2="43.05640904669791" ID="CMP-001.13.01" LOG_CI_END="0.07686242994400344" LOG_CI_START="-0.09141652212701251" LOG_EFFECT_SIZE="-0.007277046091504536" MODIFIED="2010-09-27 09:40:40 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1851088397959636" P_Z="0.8653930240025814" STUDIES="2" TAU2="0.00844613936870366" TOTAL_1="399" TOTAL_2="401" WEIGHT="100.0" Z="0.16951315750014653">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="1.0898548701113089" CI_START="0.736998851077132" EFFECT_SIZE="0.8962264150943396" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="106" LOG_CI_END="0.03736866921929441" LOG_CI_START="-0.13253318917113932" LOG_EFFECT_SIZE="-0.04758225997592246" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.0998011926463037" STUDY_ID="STD-Plint-2009a" TOTAL_1="200" TOTAL_2="200" VAR="0.009960278053624625" WEIGHT="53.08423156284768"/>
<DICH_DATA CI_END="1.3584326767555979" CI_START="0.8782473272194166" EFFECT_SIZE="1.0922636438003974" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="86" LOG_CI_END="0.13303811986981032" LOG_CI_START="-0.056383163227511" LOG_EFFECT_SIZE="0.038327478321149654" MODIFIED="2010-03-27 05:21:28 +1000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.11126699934184008" STUDY_ID="STD-Plint-2009b" TOTAL_1="199" TOTAL_2="201" VAR="0.01238034514253704" WEIGHT="46.91576843715233"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.385092968154275" CI_START="0.7570437682585991" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.024" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.14147892444837346" LOG_CI_START="-0.12087901116874951" LOG_EFFECT_SIZE="0.010299956639811961" METHOD="MH" MODIFIED="2011-03-03 07:52:37 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.8776939884067037" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="48" WEIGHT="100.0" Z="0.15389314608586277">
<NAME>Return visits (ED or any healthcare provider) - (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.385092968154275" CI_START="0.7570437682585991" DF="0" EFFECT_SIZE="1.024" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="0.14147892444837346" LOG_CI_START="-0.12087901116874951" LOG_EFFECT_SIZE="0.010299956639811961" MODIFIED="2010-09-27 09:41:04 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8776939884067037" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="48" WEIGHT="100.0" Z="0.15389314608586277">
<NAME>2 to 10 days</NAME>
<DICH_DATA CI_END="1.385092968154275" CI_START="0.7570437682585991" EFFECT_SIZE="1.024" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="30" LOG_CI_END="0.14147892444837346" LOG_CI_START="-0.12087901116874951" LOG_EFFECT_SIZE="0.010299956639811961" MODIFIED="2010-03-27 07:08:04 +1000" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.15411035007422438" STUDY_ID="STD-Patel-2002a" TOTAL_1="50" TOTAL_2="48" VAR="0.02374999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7580339178850943" CI_END="0.8945861592496404" CI_START="0.5042693865427138" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6716490257079352" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.04837782537642485" LOG_CI_START="-0.29733739642371604" LOG_EFFECT_SIZE="-0.17285761090007046" METHOD="MH" MODIFIED="2011-04-25 21:36:01 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.4397416768218908" P_Q="0.5813620033355757" P_Z="0.006495013537948424" Q="0.30403808866255455" RANDOM="YES" SCALE="156.34471434465257" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="493" TOTAL_2="502" WEIGHT="100.0" Z="2.7216844115900294">
<NAME>Admissions at enrollment or &lt; 24 hours (outpatients only) - subgroup analysis 'synergism'</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2263276620874919" CI_START="0.44887535301113846" DF="0" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.08860652468814063" LOG_CI_START="-0.3478742403215002" LOG_EFFECT_SIZE="-0.1296338578166798" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2443388334141371" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="200" WEIGHT="32.533248794631426" Z="1.1642102601798117">
<NAME>Protocolized use of steroid</NAME>
<DICH_DATA CI_END="1.2263276620874919" CI_START="0.44887535301113846" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="0.08860652468814063" LOG_CI_START="-0.3478742403215002" LOG_EFFECT_SIZE="-0.1296338578166798" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.25639096198129574" STUDY_ID="STD-Plint-2009a" TOTAL_1="200" TOTAL_2="200" VAR="0.06573632538569424" WEIGHT="32.533248794631426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.534010981143815" CI_END="0.9407703836950072" CI_START="0.40447233065361055" DF="3" EFFECT_SIZE="0.6168594570102748" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="62" I2="15.11062031196568" ID="CMP-001.15.02" LOG_CI_END="-0.026516363036949736" LOG_CI_START="-0.39311118247066007" LOG_EFFECT_SIZE="-0.20981377275380492" MODIFIED="2010-11-19 03:42:00 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3163778684290959" P_Z="0.0248646955098" STUDIES="5" TAU2="0.03237928903170653" TOTAL_1="293" TOTAL_2="302" WEIGHT="67.46675120536858" Z="2.2434983598140525">
<NAME>No protocolized use of steroid</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-19 03:42:00 +1000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.0" STUDY_ID="STD-Anil-2010c" TOTAL_1="38" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5475015595668227" CI_START="0.008011050351928473" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40611445855130324" LOG_CI_START="-2.0963105385798166" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2010-07-07 10:13:18 +1000" MODIFIED_BY="[Empty name]" ORDER="1012" O_E="0.0" SE="1.469936830518334" STUDY_ID="STD-Barlas-1998a" TOTAL_1="15" TOTAL_2="15" VAR="2.1607142857142856" WEIGHT="0.9897728000213853"/>
<DICH_DATA CI_END="0.8188911803881171" CI_START="0.24121747666632606" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.08677380629442545" LOG_CI_START="-0.6175912299282995" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.3118047822311618" STUDY_ID="STD-Khashabi-2005a" TOTAL_1="24" TOTAL_2="24" VAR="0.09722222222222224" WEIGHT="21.997195494352827"/>
<DICH_DATA CI_END="1.2735836706277128" CI_START="0.5198157979538948" EFFECT_SIZE="0.8136515912897823" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.10502748208192542" LOG_CI_START="-0.2841505257970233" LOG_EFFECT_SIZE="-0.08956152185754895" MODIFIED="2010-03-27 05:25:56 +1000" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.2286050882903031" STUDY_ID="STD-Plint-2009b" TOTAL_1="199" TOTAL_2="201" VAR="0.052260286392217276" WEIGHT="40.9223977948985"/>
<DICH_DATA CI_END="2.6886548360778675" CI_START="0.12869660939834135" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.4295350519784423" LOG_CI_START="-0.8904328947349901" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2010-07-07 09:21:17 +1000" MODIFIED_BY="[Empty name]" ORDER="373" O_E="0.0" SE="0.7753557058461846" STUDY_ID="STD-Ralston-2005a" TOTAL_1="17" TOTAL_2="25" VAR="0.6011764705882352" WEIGHT="3.557385116095873"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19984084611472536" CI_END="1.0686817690953496" CI_START="0.5561048001352152" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7709079462626636" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.028848400717454994" LOG_CI_START="-0.2548433562030148" LOG_EFFECT_SIZE="-0.11299747774277985" METHOD="MH" MODIFIED="2010-09-27 09:42:17 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9049095014747481" P_Q="1.0" P_Z="0.11844131799008462" Q="0.0" RANDOM="YES" SCALE="156.34471434465257" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="426" WEIGHT="99.99999999999999" Z="1.561349466927248">
<NAME>Admissions at enrollment or &lt; 24 hours (outpatients only) only low overall RoB</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2263276620874919" CI_START="0.44887535301113846" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" LOG_CI_END="0.08860652468814063" LOG_CI_START="-0.3478742403215002" LOG_EFFECT_SIZE="-0.1296338578166798" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.25639096198129574" STUDY_ID="STD-Plint-2009a" TOTAL_1="200" TOTAL_2="200" VAR="0.06573632538569424" WEIGHT="42.243822992174024"/>
<DICH_DATA CI_END="1.2735836706277128" CI_START="0.5198157979538948" EFFECT_SIZE="0.8136515912897823" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.10502748208192542" LOG_CI_START="-0.2841505257970233" LOG_EFFECT_SIZE="-0.08956152185754895" MODIFIED="2010-03-27 05:31:14 +1000" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.2286050882903031" STUDY_ID="STD-Plint-2009b" TOTAL_1="199" TOTAL_2="201" VAR="0.052260286392217276" WEIGHT="53.136978104329216"/>
<DICH_DATA CI_END="2.6886548360778675" CI_START="0.12869660939834135" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.4295350519784423" LOG_CI_START="-0.8904328947349901" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2010-07-07 09:21:28 +1000" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.7753557058461846" STUDY_ID="STD-Ralston-2005a" TOTAL_1="17" TOTAL_2="25" VAR="0.6011764705882352" WEIGHT="4.619198903496752"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.262850709492858" CI_END="1.0463668918339462" CI_START="0.5880609599721422" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7844281476941894" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="104" I2="20.814076241713078" I2_Q="20.696741914002" ID="CMP-001.17" LOG_CI_END="0.019683989656320358" LOG_CI_START="-0.23057765146253825" LOG_EFFECT_SIZE="-0.10544683090310895" METHOD="MH" MODIFIED="2011-04-25 21:36:14 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.261112275022344" P_Q="0.26146534260528775" P_Z="0.09860645710911652" Q="1.2609822397404915" RANDOM="YES" SCALE="2.49" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00908988721622842" TOTALS="YES" TOTAL_1="399" TOTAL_2="401" WEIGHT="100.0" Z="1.651647371367013">
<NAME>Admissions overall up to 7 days (outpatients only) - subgroup analysis 'synergism'</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9818605899855746" CI_START="0.45265534534895024" DF="0" EFFECT_SIZE="0.6666666666666665" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="51" I2="0.0" ID="CMP-001.17.01" LOG_CI_END="-0.007950171376024993" LOG_CI_START="-0.34423234673533765" LOG_EFFECT_SIZE="-0.17609125905568135" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04010784942830801" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="200" WEIGHT="44.91930019064425" Z="2.052636452542743">
<NAME>Protocolized use of steroid</NAME>
<DICH_DATA CI_END="0.9818605899855746" CI_START="0.4526553453489503" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="51" LOG_CI_END="-0.007950171376024993" LOG_CI_START="-0.3442323467353376" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.19753381442967494" STUDY_ID="STD-Plint-2009a" TOTAL_1="200" TOTAL_2="200" VAR="0.03901960784313726" WEIGHT="44.91930019064425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2587847653076298" CI_START="0.6373506903494038" DF="0" EFFECT_SIZE="0.8957049397933061" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.09995147813785611" LOG_CI_START="-0.19562153944643484" LOG_EFFECT_SIZE="-0.04783503065428937" MODIFIED="2010-03-27 05:35:52 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5258234506569633" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="201" WEIGHT="55.08069980935574" Z="0.6343944250935545">
<NAME>No protocolized use of steroid</NAME>
<DICH_DATA CI_END="1.2587847653076298" CI_START="0.6373506903494038" EFFECT_SIZE="0.8957049397933061" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="53" LOG_CI_END="0.09995147813785611" LOG_CI_START="-0.19562153944643484" LOG_EFFECT_SIZE="-0.04783503065428937" MODIFIED="2010-03-27 05:35:42 +1000" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.17362105363904626" STUDY_ID="STD-Plint-2009b" TOTAL_1="199" TOTAL_2="201" VAR="0.03014427026673258" WEIGHT="55.08069980935574"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7592145453566523" CI_START="-1.0512145453566522" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1459999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2010-09-27 09:42:48 +1000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.751912836147093" Q="0.0" RANDOM="YES" SCALE="1.2282712714158073" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="48" UNITS="" WEIGHT="100.0" Z="0.31611814371597785">
<NAME>Length of stay (inpatients only) only low overall RoB</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7592145453566523" CI_START="-1.0512145453566522" EFFECT_SIZE="-0.1459999999999999" ESTIMABLE="YES" MEAN_1="2.492" MEAN_2="2.638" MODIFIED="2010-03-27 07:08:47 +1000" MODIFIED_BY="[Empty name]" ORDER="288" SD_1="2.583" SD_2="1.958" SE="0.46185264244489643" STUDY_ID="STD-Patel-2002a" TOTAL_1="50" TOTAL_2="48" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06495190180065566" CI_END="-0.17876422742983314" CI_START="-0.4584228238249596" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.31859352562739635" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2011-04-25 21:36:24 +1000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.7988338383934197" P_Q="1.0" P_Z="7.981767203025287E-6" Q="0.0" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="397" TOTAL_2="399" UNITS="" WEIGHT="100.0" Z="4.465672387592785">
<NAME>Clinical score - all (outpatients) only low RoB</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.06495190180065566" CI_END="-0.17876422742983314" CI_START="-0.4584228238249596" DF="1" EFFECT_SIZE="-0.31859352562739635" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" MODIFIED="2010-09-27 09:43:02 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7988338383934197" P_Z="7.981767203025287E-6" STUDIES="2" TAU2="0.0" TOTAL_1="397" TOTAL_2="399" WEIGHT="100.0" Z="4.465672387592785">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-0.10283318796108776" CI_START="-0.49804242949102806" EFFECT_SIZE="-0.3004378087260579" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.75" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="397" SD_1="2.58" SD_2="2.4" SE="0.10082053666478066" STUDY_ID="STD-Plint-2009a" TOTAL_1="199" TOTAL_2="199" WEIGHT="50.07283308238738"/>
<CONT_DATA CI_END="-0.1389095393738656" CI_START="-0.5346948869501741" EFFECT_SIZE="-0.33680221316201986" ESTIMABLE="YES" MEAN_1="-2.45" MEAN_2="-1.65" MODIFIED="2010-03-27 05:39:07 +1000" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="2.32" SD_2="2.42" SE="0.10096750519351702" STUDY_ID="STD-Plint-2009b" TOTAL_1="198" TOTAL_2="200" WEIGHT="49.92716691761262"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-04-25 21:36:58 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Epinephrine versus salbutamol/albuterol</NAME>
<DICH_OUTCOME CHI2="8.679959379139861" CI_END="1.094853248316957" CI_START="0.4133112620699137" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6726924838611072" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="50" I2="30.87525254531123" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.03935591121512428" LOG_CI_START="-0.3837227607280159" LOG_EFFECT_SIZE="-0.17218342475644588" METHOD="MH" MODIFIED="2011-03-03 07:59:08 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19239314619108183" P_Q="1.0" P_Z="0.11064029624114906" Q="0.0" RANDOM="YES" SCALE="125.58" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11669756399354299" TOTALS="YES" TOTAL_1="222" TOTAL_2="222" WEIGHT="99.99999999999999" Z="1.5953217859337092">
<NAME>Admissions at enrollment or &lt; 24 hours (outpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.520159178977209" CI_START="0.013298562271804459" EFFECT_SIZE="0.3162393162393162" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8762270333868271" LOG_CI_START="-1.8761953087451602" LOG_EFFECT_SIZE="-0.49998413767916666" MODIFIED="2010-11-05 07:42:14 +1000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.6167865084786592" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" VAR="2.6139986139986138" WEIGHT="2.261747330516803"/>
<DICH_DATA CI_END="66.01504002537548" CI_START="0.11664955435973315" EFFECT_SIZE="2.775" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.819642890934455" LOG_CI_START="-0.9331169160170653" LOG_EFFECT_SIZE="0.443262987458695" MODIFIED="2010-11-05 07:42:14 +1000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="1.616984736984131" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" VAR="2.6146396396396394" WEIGHT="2.2612165143178897"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-07-16 06:22:13 +1000" MODIFIED_BY="[Empty name]" ORDER="1013" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="2.5823268309533103"/>
<DICH_DATA CI_END="1.3330730009046985" CI_START="0.3333984291504061" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.1248539326261581" LOG_CI_START="-0.4770364507375207" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-07-16 06:22:14 +1000" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.3535533905932738" STUDY_ID="STD-Khashabi-2005b" TOTAL_1="24" TOTAL_2="24" VAR="0.125" WEIGHT="25.55319420261594"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-16 06:22:15 +1000" MODIFIED_BY="[Empty name]" ORDER="403" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="11" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-16 06:22:15 +1000" MODIFIED_BY="[Empty name]" ORDER="5110" O_E="0.0" SE="0.0" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="23" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7804735811144385" CI_START="0.21724011819628775" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.10764179314019841" LOG_CI_START="-0.6630599695878359" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2010-07-16 06:22:37 +1000" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.0" SE="0.32625538620965683" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" VAR="0.10644257703081234" WEIGHT="27.678322522670108"/>
<DICH_DATA CI_END="2.223442434008262" CI_START="0.7082616159040452" EFFECT_SIZE="1.2549019607843137" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.34702588983793614" LOG_CI_START="-0.14980629406603457" LOG_EFFECT_SIZE="0.0986097978859508" MODIFIED="2010-07-16 06:22:37 +1000" MODIFIED_BY="[Empty name]" ORDER="402" O_E="0.0" SE="0.2918416841841668" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" VAR="0.08517156862745096" WEIGHT="30.594795305440826"/>
<DICH_DATA CI_END="1.9661479679423957" CI_START="0.10344252692375007" EFFECT_SIZE="0.45098039215686275" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2936161987670859" LOG_CI_START="-0.9853008789277727" LOG_EFFECT_SIZE="-0.3458423400803435" MODIFIED="2010-07-16 06:22:16 +1000" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.7512422221795955" STUDY_ID="STD-Ralston-2005b" TOTAL_1="17" TOTAL_2="23" VAR="0.5643648763853367" WEIGHT="9.068397293485111"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.941242822841094" CI_END="1.5381642922628531" CI_START="0.7109749874751283" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.045751566303523" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.18700272520046235" LOG_CI_START="-0.1481456777408496" LOG_EFFECT_SIZE="0.0194285237298064" METHOD="MH" MODIFIED="2011-03-03 07:59:22 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6246140447075443" P_Q="1.0" P_Z="0.8202387719115797" Q="0.0" RANDOM="YES" SCALE="125.58" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="103" WEIGHT="100.0" Z="0.22723788297371283">
<NAME>Admissions overall up to 7 days (outpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.187823483266284" CI_START="0.5298204473060077" EFFECT_SIZE="1.6578947368421053" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.714985190706647" LOG_CI_START="-0.2758712850331039" LOG_EFFECT_SIZE="0.21955695283677157" MODIFIED="2010-11-05 07:42:54 +1000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.5820339986681885" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" VAR="0.3387635756056808" WEIGHT="11.440705445859574"/>
<DICH_DATA CI_END="2.303890385114592" CI_START="0.256833389363674" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.362461812306586" LOG_CI_START="-0.5903485169202596" LOG_EFFECT_SIZE="-0.11394335230683675" MODIFIED="2010-11-05 07:42:53 +1000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.5596855038750452" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" VAR="0.31324786324786325" WEIGHT="12.372612039891422"/>
<DICH_DATA CI_END="1.5959542758929044" CI_START="0.6592500233191007" EFFECT_SIZE="1.025735294117647" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.20302044465138924" LOG_CI_START="-0.1809498461725917" LOG_EFFECT_SIZE="0.011035299239398806" MODIFIED="2010-07-07 10:24:10 +1000" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.22554604951359983" STUDY_ID="STD-Mull-2004" TOTAL_1="32" TOTAL_2="31" VAR="0.050871020451191226" WEIGHT="76.186682514249"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.918733383617295" CI_END="-0.09334300084982783" CI_START="-0.46162222118706076" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2774826110184443" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2011-03-03 07:59:35 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8209049592948816" P_Q="1.0" P_Z="0.0031419490108770386" Q="0.0" RANDOM="YES" SCALE="4.92" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="2.9534977479005176">
<NAME>Length of stay (inpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8138166602375714" CI_START="-4.013816660237572" EFFECT_SIZE="-1.1000000000000005" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="5.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="412" SD_1="4.4" SD_2="3.742" SE="1.4866684710644613" STUDY_ID="STD-Bertrand-2001" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.39936499405146725"/>
<CONT_DATA CI_END="0.07351056394949429" CI_START="-0.9535105639494942" EFFECT_SIZE="-0.43999999999999995" ESTIMABLE="YES" MEAN_1="3.47" MEAN_2="3.91" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="410" SD_1="1.31" SD_2="1.31" SE="0.262" STUDY_ID="STD-Bilan-2007" TOTAL_1="50" TOTAL_2="50" WEIGHT="12.8586588441786"/>
<CONT_DATA CI_END="-0.05581821173628021" CI_START="-0.4601817882637198" EFFECT_SIZE="-0.258" ESTIMABLE="YES" MEAN_1="4.203" MEAN_2="4.461" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="411" SD_1="0.281" SD_2="0.284" SE="0.1031558691172409" STUDY_ID="STD-John-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="82.94885047016884"/>
<CONT_DATA CI_END="0.8794718488618345" CI_START="-1.0114718488618342" EFFECT_SIZE="-0.06599999999999984" ESTIMABLE="YES" MEAN_1="2.492" MEAN_2="2.558" MODIFIED="2010-03-27 07:09:59 +1000" MODIFIED_BY="[Empty name]" ORDER="290" SD_1="2.583" SD_2="2.25" SE="0.48239246043274037" STUDY_ID="STD-Patel-2002b" TOTAL_1="50" TOTAL_2="51" WEIGHT="3.7931256916011025"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1961308296160107" CI_START="-0.2721308296160103" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4620000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2011-03-03 07:59:49 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2174131809533063" Q="0.0" RANDOM="YES" SCALE="4.92" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.2334359549116496">
<NAME>Length of stay (outpatients only)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1961308296160107" CI_START="-0.2721308296160103" EFFECT_SIZE="0.4620000000000002" ESTIMABLE="YES" MEAN_1="1.729" MEAN_2="1.267" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="413" SD_1="1.267" SD_2="1.158" SE="0.37456342841334883" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.702297390563507" CI_END="-0.010981035435971231" CI_START="-0.28020642950066355" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1455937324683174" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2011-03-03 08:00:06 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6133153737422599" P_Q="0.4950968248584682" P_Z="0.03401885618580094" Q="2.3921549919940492" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="448" TOTAL_2="443" UNITS="" WEIGHT="400.0" Z="2.119848114655136">
<NAME>Clinical score - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.53795864066956" CI_END="0.07660703611407027" CI_START="-0.319136723450701" DF="7" EFFECT_SIZE="-0.12126484366831536" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" MODIFIED="2010-11-10 02:41:22 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5946094796358585" P_Z="0.22969124364884475" STUDIES="8" TAU2="0.0" TOTAL_1="199" TOTAL_2="198" WEIGHT="99.99999999999997" Z="1.2011546382546456">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.007313347664503922" CI_START="-0.9167357878019327" EFFECT_SIZE="-0.45471122006871434" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-1.3" MODIFIED="2010-11-10 02:41:22 +1000" MODIFIED_BY="[Empty name]" ORDER="177" SD_1="1.153" SD_2="1.015" SE="0.2357311518872842" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" WEIGHT="18.341633889745104"/>
<CONT_DATA CI_END="0.6308265370789439" CI_START="-0.277032399041258" EFFECT_SIZE="0.17689706901884295" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-1.7" MODIFIED="2010-11-10 02:41:21 +1000" MODIFIED_BY="[Empty name]" ORDER="178" SD_1="1.277" SD_2="0.917" SE="0.23160092309891336" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" WEIGHT="19.001653968081765"/>
<CONT_DATA CI_END="0.9168812919566629" CI_START="-0.5185532482258952" EFFECT_SIZE="0.19916402186538382" ESTIMABLE="YES" MEAN_1="-1.93" MEAN_2="-2.27" MODIFIED="2010-07-07 10:26:43 +1000" MODIFIED_BY="[Empty name]" ORDER="1014" SD_1="1.589" SD_2="1.73" SE="0.366189009467797" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" WEIGHT="7.600836069427716"/>
<CONT_DATA CI_END="0.5991232853881124" CI_START="-0.9219138174376819" EFFECT_SIZE="-0.16139526602478474" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="0.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="416" SD_1="0.77" SD_2="0.68" SE="0.3880267991717044" STUDY_ID="STD-Beck-2007" TOTAL_1="12" TOTAL_2="15" WEIGHT="6.769374397932526"/>
<CONT_DATA CI_END="0.44643021592848076" CI_START="-0.6862629285977451" EFFECT_SIZE="-0.11991635633463214" ESTIMABLE="YES" MEAN_1="-7.5" MEAN_2="-7.0" MODIFIED="2010-03-27 06:32:12 +1000" MODIFIED_BY="[Empty name]" ORDER="275" SD_1="4.0" SD_2="4.2" SE="0.2889576424517911" STUDY_ID="STD-Khashabi-2005b" TOTAL_1="24" TOTAL_2="24" WEIGHT="12.206849959766322"/>
<CONT_DATA CI_END="0.48095668697731647" CI_START="-0.7300529060956487" EFFECT_SIZE="-0.12454810955916612" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="6.7" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="418" SD_1="2.6" SD_2="2.1" SE="0.30893669542533797" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="10.679058943372393"/>
<CONT_DATA CI_END="0.15246831420020723" CI_START="-0.8201130096053217" EFFECT_SIZE="-0.33382234770255725" ESTIMABLE="YES" MEAN_1="-4.02" MEAN_2="-3.44" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="414" SD_1="1.4" SD_2="2.0" SE="0.24811203967958756" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="16.55679605185097"/>
<CONT_DATA CI_END="0.7503972404110806" CI_START="-0.5803473196670372" EFFECT_SIZE="0.0850249603720217" ESTIMABLE="YES" MEAN_1="-1.09" MEAN_2="-1.23" MODIFIED="2010-04-08 00:52:39 +1000" MODIFIED_BY="[Empty name]" ORDER="5108" SD_1="1.26" SD_2="1.85" SE="0.33948189114056715" STUDY_ID="STD-Okutan-1998b" TOTAL_1="16" TOTAL_2="19" WEIGHT="8.843796719823192"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.506464660412595" CI_END="0.10998827706849189" CI_START="-0.3076977054737473" DF="6" EFFECT_SIZE="-0.09885471420262772" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" MODIFIED="2010-11-10 02:41:20 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4806759396355461" P_Z="0.3535432530442386" STUDIES="7" TAU2="0.0" TOTAL_1="181" TOTAL_2="175" WEIGHT="100.0" Z="0.9277384812383884">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.05332038965523139" CI_START="-0.8683099223753306" EFFECT_SIZE="-0.4074947663600496" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.0" MODIFIED="2010-11-10 02:41:20 +1000" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="1.2" SD_2="1.229" SE="0.23511409375383024" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" WEIGHT="20.539331349745506"/>
<CONT_DATA CI_END="0.6347477215291669" CI_START="-0.2731938445126034" EFFECT_SIZE="0.18077693850828172" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-1.8" MODIFIED="2010-11-10 02:41:19 +1000" MODIFIED_BY="[Empty name]" ORDER="180" SD_1="1.277" SD_2="0.8544" SE="0.2316220025478778" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" WEIGHT="21.163329991767245"/>
<CONT_DATA CI_END="0.6693875042762075" CI_START="-0.7621895259468566" EFFECT_SIZE="-0.04640101083532457" ESTIMABLE="YES" MEAN_1="-3.53" MEAN_2="-3.42" MODIFIED="2010-07-07 10:27:04 +1000" MODIFIED_BY="[Empty name]" ORDER="1015" SD_1="2.74" SD_2="1.77" SE="0.36520493272201965" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.512759389851352"/>
<CONT_DATA CI_END="0.33911856682066194" CI_START="-0.8213903569773595" EFFECT_SIZE="-0.24113589507834882" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="420" SD_1="0.959" SD_2="1.439" SE="0.29605363490144915" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="12.953968381418601"/>
<CONT_DATA CI_END="0.8978129332953565" CI_START="-0.7392315468587211" EFFECT_SIZE="0.07929069321831773" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.3" MODIFIED="2010-04-08 02:13:31 +1000" MODIFIED_BY="[Empty name]" ORDER="5111" SD_1="0.995" SD_2="1.386" SE="0.4176210616794174" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="6.50996781983629"/>
<CONT_DATA CI_END="0.19887548820577805" CI_START="-1.024993096625757" EFFECT_SIZE="-0.4130588042099895" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="7.5" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="423" SD_1="2.5" SD_2="1.7" SE="0.3122171107441908" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="11.647433165254053"/>
<CONT_DATA CI_END="0.6156707280533126" CI_START="-0.3509150729788699" EFFECT_SIZE="0.13237782753722133" ESTIMABLE="YES" MEAN_1="-4.76" MEAN_2="-4.99" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="422" SD_1="1.4" SD_2="2.0" SE="0.24658254147945777" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="18.673209902126953"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7025848527563952" CI_END="0.4361069334272453" CI_START="-0.8563226611063226" DF="1" EFFECT_SIZE="-0.21010786383953867" ESTIMABLE="YES" I2="41.26577607095161" ID="CMP-002.05.03" MODIFIED="2010-09-27 09:44:36 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19195037015426686" P_Z="0.5239585240391225" STUDIES="2" TAU2="0.09305877513234945" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="0.6372553642161985">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="0.10480679901161127" CI_START="-1.0693503793250072" EFFECT_SIZE="-0.48227179015669797" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-3.3" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="426" SD_1="0.959" SD_2="1.439" SE="0.29953539646601174" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="59.474171114150444"/>
<CONT_DATA CI_END="1.0096489266546242" CI_START="-0.6310297201745783" EFFECT_SIZE="0.18930960324002297" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-3.9" MODIFIED="2010-04-08 02:13:40 +1000" MODIFIED_BY="[Empty name]" ORDER="5112" SD_1="0.995" SD_2="1.039" SE="0.41854816205059536" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="40.525828885849556"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4074629875424848" CI_END="-0.02052652297088642" CI_START="-0.9824568132178015" DF="1" EFFECT_SIZE="-0.501491668094344" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.04" MODIFIED="2010-09-27 09:44:46 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5232600239279519" P_Z="0.04099200265509432" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="2.0436108894326006">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="-0.02160369218961744" CI_START="-1.2069677363818105" EFFECT_SIZE="-0.614285714285714" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-4.7" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="427" SD_1="0.48" SD_2="0.48" SE="0.3023943433507435" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="65.85423388285216"/>
<CONT_DATA CI_END="0.5391311956184373" CI_START="-1.1070406504365489" EFFECT_SIZE="-0.28395472740905586" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-4.3" MODIFIED="2010-04-08 02:13:49 +1000" MODIFIED_BY="[Empty name]" ORDER="5113" SD_1="0.663" SD_2="0.693" SE="0.4199495141338768" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="34.145766117147836"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.443681123793677" CI_END="-0.2762790874555835" CI_START="-0.8762870848615915" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5762830861585875" ESTIMABLE="YES" I2="72.30622882271588" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2011-03-03 08:00:19 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.006005712510147143" P_Q="0.47025342223732935" P_Z="1.6659565996104107E-4" Q="0.5213805927783176" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.16397271165958674" TOTALS="SUB" TOTAL_1="199" TOTAL_2="189" UNITS="" WEIGHT="200.0" Z="3.764930129776683">
<NAME>Clinical score - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.443333618016588" CI_END="-0.13426489962367194" CI_START="-1.449475947835406" DF="3" EFFECT_SIZE="-0.791870423729539" ESTIMABLE="YES" I2="79.22917188412926" ID="CMP-002.06.01" MODIFIED="2010-09-27 09:44:54 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.002359804245133934" P_Z="0.01826830834623023" STUDIES="4" TAU2="0.3424215764747738" TOTAL_1="127" TOTAL_2="121" WEIGHT="99.99999999999999" Z="2.3601345396887328">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.07138706406512713" CI_START="-0.5943784859241958" EFFECT_SIZE="-0.26149571092953433" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.1" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="430" SD_1="1.141" SD_2="1.141" SE="0.16984127138069796" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="30.321287140471537"/>
<CONT_DATA CI_END="0.34859648638022434" CI_START="-1.1003970394443638" EFFECT_SIZE="-0.3759002765320697" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.3" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="432" SD_1="1.6" SD_2="1.497" SE="0.3696479979362029" STUDY_ID="STD-Bertrand-2001" TOTAL_1="16" TOTAL_2="14" WEIGHT="23.498693051339167"/>
<CONT_DATA CI_END="-1.1596102455594526" CI_START="-2.9793334868549852" EFFECT_SIZE="-2.069471866207219" ESTIMABLE="YES" MEAN_1="-5.33" MEAN_2="-3.93" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="429" SD_1="0.72" SD_2="0.59" SE="0.46422364279376493" STUDY_ID="STD-John-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="20.177101160516578"/>
<CONT_DATA CI_END="-0.2052428725591372" CI_START="-1.3845053942771286" EFFECT_SIZE="-0.7948741334181328" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-0.4" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="431" SD_1="1.47" SD_2="1.96" SE="0.30083780391371057" STUDY_ID="STD-Sanchez-1993" TOTAL_1="24" TOTAL_2="24" WEIGHT="26.002918647672704"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.18249047623834852" CI_START="-0.8567523178076246" DF="0" EFFECT_SIZE="-0.5196213970229866" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" MODIFIED="2010-09-27 09:44:58 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.002520235297010014" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="3.020901261121727">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="-0.18249047623834846" CI_START="-0.8567523178076247" EFFECT_SIZE="-0.5196213970229866" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="433" SD_1="1.914" SD_2="1.914" SE="0.17200873252972187" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.539086355601144" CI_END="0.2107286766458566" CI_START="-0.6221256637903874" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.20569849357226538" ESTIMABLE="YES" I2="30.670420920138532" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2011-04-25 21:36:41 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.17298358455881369" P_Q="0.6303572653923415" P_Z="0.3329722629726939" Q="0.2315766223561287" RANDOM="YES" SCALE="4.42" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.11990266026883611" TOTALS="SUB" TOTAL_1="318" TOTAL_2="304" UNITS="" WEIGHT="200.00000000000006" Z="0.968144414939617">
<NAME>Oxygen saturation - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.373308364992623" CI_END="0.42953669592910954" CI_START="-1.1787358599506117" DF="4" EFFECT_SIZE="-0.3745995820107511" ESTIMABLE="YES" I2="57.325633125021504" ID="CMP-002.07.01" MODIFIED="2011-04-25 21:36:38 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05241671756044397" P_Z="0.36122602623334066" STUDIES="6" TAU2="0.41225412116742677" TOTAL_1="171" TOTAL_2="164" WEIGHT="100.00000000000003" Z="0.9130314220442866">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-0.1466255013642026" CI_START="-1.4533744986357973" EFFECT_SIZE="-0.7999999999999999" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.2" MODIFIED="2010-10-16 07:03:29 +1000" MODIFIED_BY="[Empty name]" ORDER="181" SD_1="1.552" SD_2="1.311" SE="0.33336046161538274" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" WEIGHT="32.16201515276416"/>
<CONT_DATA CI_END="1.0713880458971463" CI_START="-0.27138804589714594" EFFECT_SIZE="0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="0.7" MODIFIED="2010-10-16 07:03:28 +1000" MODIFIED_BY="[Empty name]" ORDER="182" SD_1="1.513" SD_2="1.453" SE="0.3425512158350711" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" WEIGHT="31.784755723415344"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.4" MEAN_2="0.0" MODIFIED="2010-07-07 10:27:32 +1000" MODIFIED_BY="[Empty name]" ORDER="1016" SD_1="1.72" SD_2="0.0" SE="0.0" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
<CONT_DATA CI_END="1.5321980687401129" CI_START="-2.9321980687401132" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="6.2" MODIFIED="2010-03-27 06:33:34 +1000" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="3.9" SD_2="3.99" SE="1.1388974931924294" STUDY_ID="STD-Khashabi-2005b" TOTAL_1="24" TOTAL_2="24" WEIGHT="9.8476875616926"/>
<CONT_DATA CI_END="0.13849602822429885" CI_START="-4.138496028224299" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="96.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="454" SD_1="4.0" SD_2="3.0" SE="1.0910894511799618" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="10.50274153996092"/>
<CONT_DATA CI_END="1.811949621024597" CI_START="-1.371949621024597" EFFECT_SIZE="0.22000000000000008" ESTIMABLE="YES" MEAN_1="-0.84" MEAN_2="-1.06" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="456" SD_1="4.1" SD_2="2.3" SE="0.8122341193928523" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="15.702800022166993"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.009686135394208" CI_END="0.3429780306055312" CI_START="-0.6305882576706479" DF="3" EFFECT_SIZE="-0.14380511353255832" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.02" MODIFIED="2011-04-25 21:36:41 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5703987822679715" P_Z="0.5625816869183755" STUDIES="5" TAU2="0.0" TOTAL_1="147" TOTAL_2="140" WEIGHT="100.00000000000001" Z="0.5790110991118306">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.25185283622403687" CI_START="-1.651852836224037" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.3" MODIFIED="2010-10-16 07:03:58 +1000" MODIFIED_BY="[Empty name]" ORDER="183" SD_1="2.427" SD_2="1.706" SE="0.4856481260534023" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" WEIGHT="26.153598140382613"/>
<CONT_DATA CI_END="0.6320531922077899" CI_START="-0.6320531922077899" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.1" MODIFIED="2010-10-16 07:03:57 +1000" MODIFIED_BY="[Empty name]" ORDER="184" SD_1="1.513" SD_2="1.277" SE="0.3224820441565992" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" WEIGHT="59.314900305128305"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="1.07" MEAN_2="0.0" MODIFIED="2010-07-07 10:28:43 +1000" MODIFIED_BY="[Empty name]" ORDER="1017" SD_1="1.25" SD_2="0.0" SE="0.0" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.138496028224299" CI_START="-2.138496028224299" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="95.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="458" SD_1="3.0" SD_2="4.0" SE="1.0910894511799618" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="5.181484066365282"/>
<CONT_DATA CI_END="2.011949621024597" CI_START="-1.1719496210245968" EFFECT_SIZE="0.42000000000000004" ESTIMABLE="YES" MEAN_1="-0.64" MEAN_2="-1.06" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="460" SD_1="4.1" SD_2="2.3" SE="0.8122341193928523" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="9.350017488123811"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.467985052134469" CI_END="2.0737629471094143" CI_START="0.6220427547820182" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3479028509457163" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2011-03-03 08:01:03 +1000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6896788516466484" P_Q="0.8487519848124646" P_Z="2.7306095126633756E-4" Q="0.03637073617404812" RANDOM="YES" SCALE="4.42" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="183" TOTAL_2="175" UNITS="" WEIGHT="200.0" Z="3.6396008769115054">
<NAME>Oxygen saturation - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4316143159604209" CI_END="2.1154085511355003" CI_START="0.514802159959036" DF="2" EFFECT_SIZE="1.3151053555472683" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" MODIFIED="2010-09-27 09:45:27 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48879748733328077" P_Z="0.0012786531592141443" STUDIES="3" TAU2="0.0" TOTAL_1="111" TOTAL_2="107" WEIGHT="100.00000000000001" Z="3.2207282776796267">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="3.323434362890068" CI_START="-0.12343436289006804" EFFECT_SIZE="1.6" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="2.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="462" SD_1="5.2" SD_2="5.2" SE="0.8793194040728801" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="21.56351752966934"/>
<CONT_DATA CI_END="2.8413634199408513" CI_START="0.49863658005914835" EFFECT_SIZE="1.67" ESTIMABLE="YES" MEAN_1="5.87" MEAN_2="4.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="463" SD_1="1.71" SD_2="1.56" SE="0.597645379803107" STUDY_ID="STD-John-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="46.67945609818458"/>
<CONT_DATA CI_END="2.020151366995115" CI_START="-0.8201513669951151" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.6" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="461" SD_1="2.52" SD_2="2.5" SE="0.7245803383108506" STUDY_ID="STD-Sanchez-1993" TOTAL_1="24" TOTAL_2="24" WEIGHT="31.75702637214609"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.2234343628900683" CI_START="-0.22343436289006835" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.02" MODIFIED="2010-09-27 09:45:31 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08803325893635214" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="1.705864777977396">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="3.2234343628900683" CI_START="-0.22343436289006813" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="3.5" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="464" SD_1="5.2" SD_2="5.2" SE="0.8793194040728801" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.973266709278494" CI_END="-2.017532489790896" CI_START="-6.158401096379198" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.087966793085047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2010-09-27 09:46:05 +1000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5327935926564751" P_Q="0.4771256608701395" P_Z="1.0890287657007402E-4" Q="2.48986554730432" RANDOM="YES" SCALE="14.341924648594375" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="248" TOTAL_2="250" UNITS="" WEIGHT="400.0" Z="3.8698487905144003">
<NAME>Respiratory rate - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1721155472554905" CI_END="-0.079725425455901" CI_START="-7.42910644340968" DF="3" EFFECT_SIZE="-3.75441593443279" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.01" MODIFIED="2010-09-27 09:45:49 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5374616762833728" P_Z="0.0452323786816246" STUDIES="4" TAU2="0.0" TOTAL_1="91" TOTAL_2="92" WEIGHT="100.0" Z="2.0024870112178044">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="11.445452594063939" CI_START="-12.845452594063937" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.7" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="467" SD_1="16.0" SD_2="16.0" SE="6.196773353931867" STUDY_ID="STD-Beck-2007" TOTAL_1="12" TOTAL_2="15" WEIGHT="9.154067888451554"/>
<CONT_DATA CI_END="-0.7031980872400023" CI_START="-11.296801912759998" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-17.8" MEAN_2="-11.8" MODIFIED="2010-03-27 06:34:11 +1000" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="9.0" SD_2="9.71" SE="2.7024996145543976" STUDY_ID="STD-Khashabi-2005b" TOTAL_1="24" TOTAL_2="24" WEIGHT="48.129801653412656"/>
<CONT_DATA CI_END="3.81724500433263" CI_START="-13.81724500433263" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="55.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="466" SD_1="13.0" SD_2="16.0" SE="4.4986770542121866" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="17.369036106464314"/>
<CONT_DATA CI_END="7.5588876202258986" CI_START="-7.038887620225897" EFFECT_SIZE="0.2600000000000007" ESTIMABLE="YES" MEAN_1="-5.77" MEAN_2="-6.03" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="468" SD_1="13.5" SD_2="16.5" SE="3.723990684420016" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="25.34709435167148"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.3084484292752174" CI_END="0.8901316097390182" CI_START="-6.076461394228911" DF="3" EFFECT_SIZE="-2.593164892244946" ESTIMABLE="YES" I2="9.323053868570932" ID="CMP-002.09.02" MODIFIED="2010-09-27 09:45:57 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.346468579302897" P_Z="0.1445350685075166" STUDIES="4" TAU2="1.2057377236993614" TOTAL_1="89" TOTAL_2="88" WEIGHT="100.00000000000001" Z="1.4591091490141495">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.291435628671854" CI_START="-10.291435628671854" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-24.0" MEAN_2="-19.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="473" SD_1="8.2" SD_2="10.02" SE="2.6997616641989457" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="37.18342595382791"/>
<CONT_DATA CI_END="10.192473332755114" CI_START="-5.192473332755114" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="-18.4" MEAN_2="-20.9" MODIFIED="2010-04-08 02:20:06 +1000" MODIFIED_BY="[Empty name]" ORDER="5117" SD_1="9.16" SD_2="9.66" SE="3.9248034114057" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="19.0160272556467"/>
<CONT_DATA CI_END="1.9624386377870282" CI_START="-11.962438637787027" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="54.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="471" SD_1="11.0" SD_2="12.0" SE="3.5523298860110977" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="22.846848850748657"/>
<CONT_DATA CI_END="6.9788876202258985" CI_START="-7.618887620225897" EFFECT_SIZE="-0.3199999999999994" ESTIMABLE="YES" MEAN_1="-6.76" MEAN_2="-6.44" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="470" SD_1="13.5" SD_2="16.5" SE="3.723990684420016" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="20.953697939776742"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9656391517582463" CI_END="3.7643701336987982" CI_START="-10.637946679117736" DF="1" EFFECT_SIZE="-3.4367882727094683" ESTIMABLE="YES" I2="49.125962458292044" ID="CMP-002.09.03" MODIFIED="2010-09-27 09:46:05 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16091181195643733" P_Z="0.3495809444454713" STUDIES="2" TAU2="13.450688521080355" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="0.9354024528895062">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="-0.2896657153567421" CI_START="-13.110334284643256" EFFECT_SIZE="-6.699999999999999" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-20.6" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="475" SD_1="10.58" SD_2="11.58" SE="3.2706388154104644" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="55.90254422580363"/>
<CONT_DATA CI_END="8.819443777310779" CI_START="-7.41944377731078" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="-23.8" MEAN_2="-24.5" MODIFIED="2010-04-08 02:20:16 +1000" MODIFIED_BY="[Empty name]" ORDER="5118" SD_1="9.77" SD_2="10.09" SE="4.142649477927103" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="44.09745577419637"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.05541621868033143" CI_END="-2.7079452659286103" CI_START="-11.046874146041105" DF="1" EFFECT_SIZE="-6.877409705984857" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.04" MODIFIED="2010-04-08 02:37:14 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8138932459558265" P_Z="0.001225390358313698" STUDIES="2" TAU2="0.0" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="3.2329032959625583">
<NAME>&gt; 24 hours</NAME>
<CONT_DATA CI_END="-2.2403430573784373" CI_START="-12.159656942621568" EFFECT_SIZE="-7.200000000000003" ESTIMABLE="YES" MEAN_1="-39.1" MEAN_2="-31.9" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="476" SD_1="8.13" SD_2="9.01" SE="2.530483713855309" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="70.67360963498687"/>
<CONT_DATA CI_END="1.5992951527773522" CI_START="-13.799295152777354" EFFECT_SIZE="-6.100000000000001" ESTIMABLE="YES" MEAN_1="-31.5" MEAN_2="-25.4" MODIFIED="2010-04-08 02:20:22 +1000" MODIFIED_BY="[Empty name]" ORDER="5119" SD_1="8.17" SD_2="10.6" SE="3.928283995781765" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="29.326390365013122"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.599360942420827" CI_END="-0.9088681939042664" CI_START="-6.294689260956135" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6017787274302004" ESTIMABLE="YES" I2="77.94013988817647" I2_Q="74.34641429185355" ID="CMP-002.10" MODIFIED="2010-09-27 09:54:41 +1000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0035044718685809384" P_Q="0.04834107851329028" P_Z="0.008755409915565726" Q="3.8980905491213416" RANDOM="YES" SCALE="14.341924648594375" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.079312840158575" TOTALS="SUB" TOTAL_1="183" TOTAL_2="175" UNITS="" WEIGHT="200.0" Z="2.621459754477104">
<NAME>Respiratory rate - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.040792258517335" CI_END="-2.0748975915812706" CI_START="-8.32684687219198" DF="2" EFFECT_SIZE="-5.200872231886626" ESTIMABLE="YES" I2="71.5941057971058" ID="CMP-002.10.01" MODIFIED="2010-09-27 09:54:36 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.029587751312369903" P_Z="0.0011105524618304694" STUDIES="3" TAU2="5.1401902523613385" TOTAL_1="111" TOTAL_2="107" WEIGHT="100.0" Z="3.260910095449943">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="4.30287496273867" CI_START="-6.30287496273867" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-6.0" MEAN_2="-5.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="479" SD_1="16.0" SD_2="16.0" SE="2.7055981663780924" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="20.41460273880804"/>
<CONT_DATA CI_END="-5.727097413690942" CI_START="-9.472902586309061" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" MEAN_1="-16.67" MEAN_2="-9.07" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="480" SD_1="3.17" SD_2="1.91" SE="0.9555801030438701" STUDY_ID="STD-John-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="42.0223977129047"/>
<CONT_DATA CI_END="-2.2963266065519368" CI_START="-7.303673393448063" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="-11.0" MEAN_2="-6.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="478" SD_1="4.4" SD_2="4.45" SE="1.2774078570814154" STUDY_ID="STD-Sanchez-1993" TOTAL_1="24" TOTAL_2="24" WEIGHT="37.56299954828726"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.30287496273867" CI_START="-4.30287496273867" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.02" MODIFIED="2010-09-27 09:54:41 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7116775447935295" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="0.3696040352284359">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="6.30287496273867" CI_START="-4.30287496273867" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-9.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="481" SD_1="16.0" SD_2="16.0" SE="2.7055981663780924" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="33.4046530928909" CI_END="3.004684415292853" CI_START="-3.127279960082173" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06129777239465973" ESTIMABLE="YES" I2="58.089671037537435" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2010-10-16 07:04:26 +1000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0025178937666839873" P_Q="0.7739204076539284" P_Z="0.9687426549883467" Q="1.113068071586329" RANDOM="YES" SCALE="23.942219827564877" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="24.434018857632417" TOTALS="SUB" TOTAL_1="340" TOTAL_2="336" UNITS="" WEIGHT="400.0" Z="0.039185298175747764">
<NAME>Heart rate - all (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.8163594376243823" CI_END="4.269223495599352" CI_START="-3.672553879776361" DF="4" EFFECT_SIZE="0.29833480791149536" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.01" MODIFIED="2010-10-16 07:04:19 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5890121301606603" P_Z="0.8829322874638824" STUDIES="5" TAU2="0.0" TOTAL_1="125" TOTAL_2="123" WEIGHT="100.0" Z="0.14725305210750603">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="11.121499804035448" CI_START="-4.721499804035447" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="2.3" MODIFIED="2010-10-16 07:04:19 +1000" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="14.703" SD_2="19.577" SE="4.041655799044894" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" WEIGHT="25.12815454935776"/>
<CONT_DATA CI_END="5.36163779476782" CI_START="-10.761637794767822" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="3.0" MODIFIED="2010-10-16 07:04:18 +1000" MODIFIED_BY="[Empty name]" ORDER="186" SD_1="21.832" SD_2="13.003" SE="4.113156087742933" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" WEIGHT="24.262126504890446"/>
<CONT_DATA CI_END="8.995999337055338" CI_START="-7.935999337055336" EFFECT_SIZE="0.5300000000000002" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="5.87" MODIFIED="2010-07-07 10:29:20 +1000" MODIFIED_BY="[Empty name]" ORDER="1018" SD_1="13.63" SD_2="9.7" SE="4.319466788080831" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" WEIGHT="21.99981181166566"/>
<CONT_DATA CI_END="5.745452594063938" CI_START="-18.54545259406394" EFFECT_SIZE="-6.4" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="8.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="482" SD_1="16.0" SD_2="16.0" SE="6.196773353931867" STUDY_ID="STD-Beck-2007" TOTAL_1="12" TOTAL_2="15" WEIGHT="10.689269326934465"/>
<CONT_DATA CI_END="13.380175886141284" CI_START="-5.380175886141284" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="163.0" MEAN_2="159.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="484" SD_1="15.0" SD_2="16.0" SE="4.785891965429423" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="17.920637807151667"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="17.378838976237788" CI_END="7.454421160195613" CI_START="-4.757877350246387" DF="5" EFFECT_SIZE="1.3482719049746135" ESTIMABLE="YES" I2="71.2293784018798" ID="CMP-002.11.02" MODIFIED="2010-10-16 07:04:26 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0038346388350316563" P_Z="0.6651811379876607" STUDIES="6" TAU2="41.0228799402847" TOTAL_1="147" TOTAL_2="143" WEIGHT="100.00000000000001" Z="0.43277100913606975">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="11.755226778213943" CI_START="-4.955226778213943" EFFECT_SIZE="3.4" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="3.6" MODIFIED="2010-10-16 07:04:26 +1000" MODIFIED_BY="[Empty name]" ORDER="187" SD_1="16.687" SD_2="19.759" SE="4.262949137901974" STUDY_ID="STD-Anil-2010a" TOTAL_1="38" TOTAL_2="36" WEIGHT="16.39642286818744"/>
<CONT_DATA CI_END="7.329302234767704" CI_START="-4.529302234767703" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="5.5" MODIFIED="2010-10-16 07:04:25 +1000" MODIFIED_BY="[Empty name]" ORDER="188" SD_1="13.363" SD_2="12.831" SE="3.025209790351906" STUDY_ID="STD-Anil-2010b" TOTAL_1="39" TOTAL_2="36" WEIGHT="19.344309076578412"/>
<CONT_DATA CI_END="0.635786508700904" CI_START="-16.575786508700904" EFFECT_SIZE="-7.97" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="8.1" MODIFIED="2010-07-07 10:29:40 +1000" MODIFIED_BY="[Empty name]" ORDER="1019" SD_1="13.47" SD_2="10.38" SE="4.390788084159836" STUDY_ID="STD-Barlas-1998b" TOTAL_1="15" TOTAL_2="15" WEIGHT="16.095617903276"/>
<CONT_DATA CI_END="1.0522883456414087" CI_START="-15.45228834564141" EFFECT_SIZE="-7.2" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-6.8" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="485" SD_1="14.58" SD_2="13.97" SE="4.210428564368736" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="16.52062324507001"/>
<CONT_DATA CI_END="13.754530847093644" CI_START="-3.9545308470936433" EFFECT_SIZE="4.9" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-10.8" MODIFIED="2010-04-08 02:21:59 +1000" MODIFIED_BY="[Empty name]" ORDER="5120" SD_1="9.72" SD_2="11.91" SE="4.517700792941632" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="15.799395011473193"/>
<CONT_DATA CI_END="22.81724500433263" CI_START="5.18275499566737" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="165.0" MEAN_2="151.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="13.0" SD_2="16.0" SE="4.4986770542121866" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.84363189541496"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.963610875573238" CI_END="9.471507574413392" CI_START="-16.58350344600938" DF="1" EFFECT_SIZE="-3.555997935797994" ESTIMABLE="YES" I2="79.85337640141842" ID="CMP-002.11.03" MODIFIED="2010-09-27 09:55:17 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.025886256624921833" P_Z="0.592654507442602" STUDIES="2" TAU2="70.6263187582345" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="0.5349932784752861">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="-2.3891520304663567" CI_START="-17.610847969533648" EFFECT_SIZE="-10.000000000000002" ESTIMABLE="YES" MEAN_1="-17.6" MEAN_2="-7.6" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="489" SD_1="11.93" SD_2="14.3" SE="3.883157052663744" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="51.548856660135286"/>
<CONT_DATA CI_END="12.186757206274937" CI_START="-5.586757206274939" EFFECT_SIZE="3.299999999999999" ESTIMABLE="YES" MEAN_1="-12.9" MEAN_2="-16.2" MODIFIED="2010-04-08 02:22:06 +1000" MODIFIED_BY="[Empty name]" ORDER="5121" SD_1="10.63" SD_2="11.11" SE="4.534143115063616" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="48.451143339864714"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.117170847746287" CI_END="5.911674792664564" CI_START="-13.845004577816994" DF="1" EFFECT_SIZE="-3.9666648925762145" ESTIMABLE="YES" I2="67.91962812295003" ID="CMP-002.11.04" MODIFIED="2010-09-27 09:55:25 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.07747147115057229" P_Z="0.4312660510322386" STUDIES="2" TAU2="34.64240632411064" TOTAL_1="34" TOTAL_2="35" WEIGHT="100.0" Z="0.7870270284190298">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="-1.5887390117301035" CI_START="-15.811260988269895" EFFECT_SIZE="-8.7" ESTIMABLE="YES" MEAN_1="-26.8" MEAN_2="-18.1" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="491" SD_1="11.22" SD_2="13.3" SE="3.628261051918614" STUDY_ID="STD-Kuyucu-2004a" TOTAL_1="23" TOTAL_2="23" WEIGHT="53.13529596610113"/>
<CONT_DATA CI_END="10.068473150911217" CI_START="-7.26847315091122" EFFECT_SIZE="1.3999999999999986" ESTIMABLE="YES" MEAN_1="-19.1" MEAN_2="-20.5" MODIFIED="2010-04-08 02:22:15 +1000" MODIFIED_BY="[Empty name]" ORDER="5122" SD_1="9.8" SD_2="11.4" SE="4.422771652584959" STUDY_ID="STD-Kuyucu-2004b" TOTAL_1="11" TOTAL_2="12" WEIGHT="46.86470403389887"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.54271186742627" CI_END="2.0042373680594903" CI_START="-1.508017682303923" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2481098428777837" ESTIMABLE="YES" I2="45.874870068015376" I2_Q="76.33690299541071" ID="CMP-002.12" MODIFIED="2010-09-27 09:55:55 +1000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.13610628185386342" P_Q="0.03980954911950796" P_Z="0.781850489535235" Q="4.225989522022655" RANDOM="YES" SCALE="23.942219827564877" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="4.168483503347079" TOTALS="SUB" TOTAL_1="183" TOTAL_2="175" UNITS="" WEIGHT="200.0" Z="0.2769083391025556">
<NAME>Heart rate - all (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.316722345403616" CI_END="2.7557163182615136" CI_START="-0.9665773477614225" DF="2" EFFECT_SIZE="0.8945694852500455" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" MODIFIED="2010-09-27 09:55:44 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5176990944864326" P_Z="0.3461586361236939" STUDIES="3" TAU2="0.0" TOTAL_1="111" TOTAL_2="107" WEIGHT="99.99999999999999" Z="0.9420664407878134">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="3.30287496273867" CI_START="-7.30287496273867" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="495" SD_1="16.0" SD_2="16.0" SE="2.7055981663780924" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="12.317951828877458"/>
<CONT_DATA CI_END="3.45168572910665" CI_START="-0.7716857291066503" EFFECT_SIZE="1.3399999999999999" ESTIMABLE="YES" MEAN_1="10.27" MEAN_2="8.93" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="494" SD_1="3.01" SD_2="2.89" SE="1.0774104757859622" STUDY_ID="STD-John-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="77.67883532834401"/>
<CONT_DATA CI_END="6.884517826710498" CI_START="-4.884517826710498" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="493" SD_1="10.5" SD_2="10.3" SE="3.0023601827007145" STUDY_ID="STD-Sanchez-1993" TOTAL_1="24" TOTAL_2="24" WEIGHT="10.003212842778524"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3028749627386702" CI_START="-10.30287496273867" DF="0" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.02" MODIFIED="2010-09-27 09:55:55 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.06459942413448795" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="1.8480201761421795">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.3028749627386702" CI_START="-10.30287496273867" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="2.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="496" SD_1="16.0" SD_2="16.0" SE="2.7055981663780924" STUDY_ID="STD-Abu_x002d_Shukair-2001" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-09-27 09:56:20 +1000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="12.33" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="66" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Hospital readmissions (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-27 09:56:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="0.0" Z="0.0">
<NAME>2 to 10 days</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-27 07:46:51 +1000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.0" STUDY_ID="STD-Patel-2002b" TOTAL_1="50" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-09-27 09:56:20 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="0.0" STUDY_ID="STD-Bertrand-2001" TOTAL_1="16" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.597274125781796" CI_END="2.421766014791156" CI_START="0.2804487709577534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8241245672805999" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.3841321803454494" LOG_CI_START="-0.5521464589079332" LOG_EFFECT_SIZE="-0.08400713928124198" METHOD="MH" MODIFIED="2010-09-27 09:56:42 +1000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.43962012467497646" P_Q="0.4434810784771209" P_Z="0.7250530575509422" Q="0.587259189532636" RANDOM="YES" SCALE="8.326893624304766" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="40" WEIGHT="100.0" Z="0.35171360433208654">
<NAME>Return visits (ED or any healthcare provider) - (outpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.640292411447435" CI_START="0.30286028576523877" DF="0" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.5611362703461713" LOG_CI_START="-0.5187576722062951" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2010-09-27 09:56:36 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9386908084591001" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="75.17060063020743" Z="0.07691544770880866">
<NAME>2 to 10 days</NAME>
<DICH_DATA CI_END="3.640292411447435" CI_START="0.30286028576523877" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5611362703461713" LOG_CI_START="-0.5187576722062951" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Menon-1995" TOTAL_1="20" TOTAL_2="21" VAR="0.4023809523809524" WEIGHT="75.17060063020743"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4435154897057303" CI_START="0.045501182801755684" DF="0" EFFECT_SIZE="0.39583333333333326" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="0.53700204087981" LOG_CI_START="-1.3419773137253268" LOG_EFFECT_SIZE="-0.4024876364227583" MODIFIED="2010-09-27 09:56:42 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4010934627062718" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="19" WEIGHT="24.829399369792576" Z="0.8396699726134411">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="3.4435154897057307" CI_START="0.045501182801755705" EFFECT_SIZE="0.3958333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5370020408798101" LOG_CI_START="-1.3419773137253266" LOG_EFFECT_SIZE="-0.40248763642275825" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="1.1037217739928686" STUDY_ID="STD-Mull-2004" TOTAL_1="16" TOTAL_2="19" VAR="1.218201754385965" WEIGHT="24.829399369792576"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6120518559348127" CI_START="0.8429566275523815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1657142857142857" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.20737900793068434" LOG_CI_START="-0.07419477045147571" LOG_EFFECT_SIZE="0.06659211873960431" METHOD="MH" MODIFIED="2010-09-27 09:57:00 +1000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.3538944316385677" Q="0.0" RANDOM="YES" SCALE="8.326893624304766" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="0.9270618530870177">
<NAME>Return visits (ED or any healthcare provider) - (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6120518559348127" CI_START="0.8429566275523815" DF="0" EFFECT_SIZE="1.1657142857142857" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="0.20737900793068434" LOG_CI_START="-0.07419477045147571" LOG_EFFECT_SIZE="0.06659211873960431" MODIFIED="2010-09-27 09:57:00 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3538944316385677" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0" Z="0.9270618530870177">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="1.6120518559348127" CI_START="0.8429566275523815" EFFECT_SIZE="1.1657142857142857" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="28" LOG_CI_END="0.20737900793068434" LOG_CI_START="-0.07419477045147571" LOG_EFFECT_SIZE="0.06659211873960431" MODIFIED="2010-03-27 07:47:14 +1000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.16539783123436294" STUDY_ID="STD-Patel-2002b" TOTAL_1="50" TOTAL_2="51" VAR="0.027356442577030807" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8794718488618345" CI_START="-1.0114718488618342" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06599999999999984" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.16" MODIFIED="2011-03-03 08:01:47 +1000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.8911746090782919" Q="0.0" RANDOM="YES" SCALE="4.92" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="51" UNITS="" WEIGHT="100.0" Z="0.13681805876649303">
<NAME>Length of stay (inpatients only) only low RoB overall</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8794718488618345" CI_START="-1.0114718488618342" EFFECT_SIZE="-0.06599999999999984" ESTIMABLE="YES" MEAN_1="2.492" MEAN_2="2.558" MODIFIED="2010-03-27 07:47:35 +1000" MODIFIED_BY="[Empty name]" ORDER="294" SD_1="2.583" SD_2="2.25" SE="0.48239246043274037" STUDY_ID="STD-Patel-2002b" TOTAL_1="50" TOTAL_2="51" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.9451681549206965" CI_END="1.5568159542821305" CI_START="0.2804902107154239" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6608113460449423" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="35" I2="71.20300105933379" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.19223727360592388" LOG_CI_START="-0.5520822912935993" LOG_EFFECT_SIZE="-0.17992250884383773" METHOD="MH" MODIFIED="2011-03-03 08:02:02 +1000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.031036757553546623" P_Q="1.0" P_Z="0.34335636402156167" Q="0.0" RANDOM="YES" SCALE="125.58" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3833467772839366" TOTALS="YES" TOTAL_1="72" TOTAL_2="76" WEIGHT="100.0" Z="0.9475543945687226">
<NAME>Admissions at enrollment or &lt; 24 hours (outpatients only) only low RoB overall</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7804735811144385" CI_START="0.21724011819628775" EFFECT_SIZE="0.4117647058823529" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="-0.10764179314019841" LOG_CI_START="-0.6630599695878359" LOG_EFFECT_SIZE="-0.38535088136401713" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.32625538620965683" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" VAR="0.10644257703081234" WEIGHT="39.028758110425336"/>
<DICH_DATA CI_END="2.223442434008262" CI_START="0.7082616159040452" EFFECT_SIZE="1.2549019607843137" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.34702588983793614" LOG_CI_START="-0.14980629406603457" LOG_EFFECT_SIZE="0.0986097978859508" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.2918416841841668" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" VAR="0.08517156862745096" WEIGHT="40.80068667839785"/>
<DICH_DATA CI_END="1.9661479679423957" CI_START="0.10344252692375007" EFFECT_SIZE="0.45098039215686275" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.2936161987670859" LOG_CI_START="-0.9853008789277727" LOG_EFFECT_SIZE="-0.3458423400803435" MODIFIED="2010-03-27 06:48:14 +1000" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.7512422221795955" STUDY_ID="STD-Ralston-2005b" TOTAL_1="17" TOTAL_2="23" VAR="0.5643648763853367" WEIGHT="20.170555211176804"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.565840315302493" CI_END="0.08895873204868118" CI_START="-0.48272122890884317" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.196881248430081" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.18" MODIFIED="2011-04-25 21:36:58 +1000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.632886249840034" P_Q="0.6924896188588546" P_Z="0.1770202668702619" Q="0.1564036237048648" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="122" TOTAL_2="121" UNITS="" WEIGHT="200.0" Z="1.3499866446531354">
<NAME>Clinical score - all (outpatients) only low RoB</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol/Albuterol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3223955160416401" CI_END="0.10554468623343741" CI_START="-0.5730980746605092" DF="2" EFFECT_SIZE="-0.2337766942135359" ESTIMABLE="YES" I2="0.0" ID="CMP-002.18.01" MODIFIED="2011-04-25 21:36:55 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8511237591448676" P_Z="0.17691198522423873" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="100.0" Z="1.3503242869040692">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.5991232853881124" CI_START="-0.9219138174376819" EFFECT_SIZE="-0.16139526602478474" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="0.2" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="516" SD_1="0.77" SD_2="0.68" SE="0.3880267991717044" STUDY_ID="STD-Beck-2007" TOTAL_1="12" TOTAL_2="15" WEIGHT="19.906862911193816"/>
<CONT_DATA CI_END="0.48095668697731647" CI_START="-0.7300529060956487" EFFECT_SIZE="-0.12454810955916612" ESTIMABLE="YES" MEAN_1="6.4" MEAN_2="6.7" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="517" SD_1="2.6" SD_2="2.1" SE="0.30893669542533797" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="31.404166753016316"/>
<CONT_DATA CI_END="0.15246831420020723" CI_START="-0.8201130096053217" EFFECT_SIZE="-0.33382234770255725" ESTIMABLE="YES" MEAN_1="-4.02" MEAN_2="-3.44" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="515" SD_1="1.4" SD_2="2.0" SE="0.24811203967958756" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="48.688970335789875"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8795581830770278" CI_END="0.42372140120582735" CI_START="-0.6371597829661585" DF="1" EFFECT_SIZE="-0.1067191908801656" ESTIMABLE="YES" I2="46.79600722107478" ID="CMP-002.18.02" MODIFIED="2011-04-25 21:36:58 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17038458132429846" P_Z="0.6933414095176719" STUDIES="2" TAU2="0.06960932262391184" TOTAL_1="55" TOTAL_2="53" WEIGHT="100.0" Z="0.39432459299885336">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.19887548820577805" CI_START="-1.024993096625757" EFFECT_SIZE="-0.4130588042099895" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="7.5" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="519" SD_1="2.5" SD_2="1.7" SE="0.3122171107441908" STUDY_ID="STD-Menon-1995" TOTAL_1="21" TOTAL_2="21" WEIGHT="43.83589302601137"/>
<CONT_DATA CI_END="0.6156707280533126" CI_START="-0.3509150729788699" EFFECT_SIZE="0.13237782753722133" ESTIMABLE="YES" MEAN_1="-4.76" MEAN_2="-4.99" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="518" SD_1="1.4" SD_2="2.0" SE="0.24658254147945777" STUDY_ID="STD-Mull-2004" TOTAL_1="34" TOTAL_2="32" WEIGHT="56.16410697398863"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-03-03 08:04:00 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Epinephrine versus steroid</NAME>
<DICH_OUTCOME CHI2="1.0155665679556642" CI_END="1.8849373141688615" CI_START="0.6619551062157756" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1170245655359274" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="29" I2="1.5327964159946452" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2752969118026939" LOG_CI_START="-0.1791714634060595" LOG_EFFECT_SIZE="0.04806272419831718" METHOD="MH" MODIFIED="2010-09-27 09:57:39 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31357322771363727" P_Q="1.0" P_Z="0.678467246961543" Q="0.0" RANDOM="YES" SCALE="94.4560302450142" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.017000092071796723" TOTALS="YES" TOTAL_1="230" TOTAL_2="214" WEIGHT="100.0" Z="0.41455561515942013">
<NAME>Admissions (outpatients only)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<DICH_DATA CI_END="81.01190363542146" CI_START="0.2663500355480702" EFFECT_SIZE="4.645161290322581" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9085488374385386" LOG_CI_START="-0.5745472409165846" LOG_EFFECT_SIZE="0.667000798260977" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" VAR="2.1274641577060933" WEIGHT="3.3232554739694566"/>
<DICH_DATA CI_END="1.696293178728441" CI_START="0.6669183049539646" EFFECT_SIZE="1.0636206896551723" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="29" LOG_CI_END="0.22950091566842906" LOG_CI_START="-0.175927362306345" LOG_EFFECT_SIZE="0.026786776681042006" MODIFIED="2010-03-27 05:50:07 +1000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.2381505773847252" STUDY_ID="STD-Plint-2009c" TOTAL_1="200" TOTAL_2="199" VAR="0.056715697508677984" WEIGHT="96.67674452603055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5234367713631334" CI_START="0.7651848518208385" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0796808510638298" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.18282443399818857" LOG_CI_START="-0.11623363618229984" LOG_EFFECT_SIZE="0.03329539890794437" METHOD="MH" MODIFIED="2010-03-27 05:50:56 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6625304737084656" Q="0.0" RANDOM="YES" SCALE="94.4560302450142" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="199" WEIGHT="100.0" Z="0.43642214818734465">
<NAME>Admissions overall up to 7 days (outpatients only)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5234367713631334" CI_START="0.7651848518208385" EFFECT_SIZE="1.0796808510638298" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="47" LOG_CI_END="0.18282443399818857" LOG_CI_START="-0.11623363618229984" LOG_EFFECT_SIZE="0.03329539890794437" MODIFIED="2010-03-27 05:50:51 +1000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.17566819078534127" STUDY_ID="STD-Plint-2009c" TOTAL_1="200" TOTAL_2="199" VAR="0.030859313253795054" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3747309552440424" CI_END="0.49666095705582336" CI_START="0.14956578562559164" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3231133713407075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2010-09-27 09:58:10 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9454115769931983" P_Q="0.9415045832416545" P_Z="2.631720139864968E-4" Q="0.1205521391470924" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="289" TOTAL_2="243" UNITS="" WEIGHT="300.0" Z="3.649088912078966">
<NAME>Clinical score - all (outpatients)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.25417881609694987" CI_END="0.49996098172156755" CI_START="0.12260264534989943" DF="1" EFFECT_SIZE="0.3112818135357335" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2010-09-27 09:57:59 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6141479308758111" P_Z="0.0012226733350290226" STUDIES="2" TAU2="0.0" TOTAL_1="229" TOTAL_2="213" WEIGHT="100.0" Z="3.2335373822055917">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="1.093248955184671" CI_START="-0.16257776900150656" EFFECT_SIZE="0.4653355930915821" ESTIMABLE="YES" MEAN_1="-1.135" MEAN_2="-1.93" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="300" SD_1="1.72" SD_2="1.589" SE="0.3203698471226967" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="9.029183013178685"/>
<CONT_DATA CI_END="0.49381265149524023" CI_START="0.09817018460271823" EFFECT_SIZE="0.2959914180489792" ESTIMABLE="YES" MEAN_1="-1.75" MEAN_2="-2.45" MODIFIED="2010-03-27 05:51:15 +1000" MODIFIED_BY="[Empty name]" ORDER="260" SD_1="2.4" SD_2="2.32" SE="0.10093105536971578" STUDY_ID="STD-Plint-2009c" TOTAL_1="199" TOTAL_2="198" WEIGHT="90.97081698682132"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9789462638255264" CI_START="-0.2700888773775946" DF="0" EFFECT_SIZE="0.3544286932239659" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" MODIFIED="2010-09-27 09:58:03 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.2659977909143091" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.1123265485347946">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.9789462638255264" CI_START="-0.2700888773775946" EFFECT_SIZE="0.3544286932239659" ESTIMABLE="YES" MEAN_1="-2.65" MEAN_2="-3.53" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="301" SD_1="2.28" SD_2="2.74" SE="0.3186372686068088" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0485210804579308" CI_START="-0.20444021052604672" DF="0" EFFECT_SIZE="0.42204043496594207" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" MODIFIED="2010-09-27 09:58:10 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.18671268521602222" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="1.3203664925725838">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="1.0485210804579308" CI_START="-0.20444021052604655" EFFECT_SIZE="0.4220404349659421" ESTIMABLE="YES" MEAN_1="-2.915" MEAN_2="-3.95" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="302" SD_1="2.67" SD_2="1.75" SE="0.3196388558328561" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.6196640915259213" CI_END="-0.3957199877894963" CI_START="-1.1959138126807554" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7958169002351259" ESTIMABLE="YES" I2="17.119381131984902" I2_Q="29.613664344505978" ID="CMP-003.04" MODIFIED="2011-03-03 08:03:15 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.30557067913312463" P_Q="0.24153788309900326" P_Z="9.679574530331556E-5" Q="2.841460606486182" RANDOM="YES" SCALE="25.9" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.04375280938407245" TOTALS="SUB" TOTAL_1="289" TOTAL_2="243" UNITS="" WEIGHT="300.0" Z="3.8984866271896426">
<NAME>Oxygen saturation - all (outpatients)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7782034850397406" CI_END="-0.5213169637098615" CI_START="-1.4641081683489614" DF="1" EFFECT_SIZE="-0.9927125660294114" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" MODIFIED="2010-09-27 09:58:23 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.37769118424516035" P_Z="3.667435570985721E-5" STUDIES="2" TAU2="0.0" TOTAL_1="229" TOTAL_2="213" WEIGHT="100.0" Z="4.127490512945108">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.600970210347549" CI_START="-1.660970210347549" EFFECT_SIZE="-0.5299999999999999" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="1.4" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="312" SD_1="2.018" SD_2="1.72" SE="0.577036220700226" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="17.37275606617658"/>
<CONT_DATA CI_END="-0.5714102923221501" CI_START="-1.60858970767785" EFFECT_SIZE="-1.09" ESTIMABLE="YES" MEAN_1="-1.02" MEAN_2="0.07" MODIFIED="2010-03-27 05:57:36 +1000" MODIFIED_BY="[Empty name]" ORDER="263" SD_1="2.57" SD_2="2.7" SE="0.2645914474798616" STUDY_ID="STD-Plint-2009c" TOTAL_1="199" TOTAL_2="198" WEIGHT="82.62724393382342"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9371138239380896" CI_START="-1.06711382393809" DF="0" EFFECT_SIZE="-0.06500000000000017" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" MODIFIED="2010-09-27 09:58:27 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8988383537746906" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.12712893081791718">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.9371138239380896" CI_START="-1.06711382393809" EFFECT_SIZE="-0.06500000000000017" ESTIMABLE="YES" MEAN_1="1.005" MEAN_2="1.07" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="313" SD_1="2.172" SD_2="1.25" SE="0.5112919583434368" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.568918760228395" CI_START="-1.7389187602283949" DF="0" EFFECT_SIZE="-0.5849999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.03" MODIFIED="2010-09-27 09:58:36 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.3203985585648438" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.9936392148863143">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="0.568918760228395" CI_START="-1.7389187602283949" EFFECT_SIZE="-0.5849999999999999" ESTIMABLE="YES" MEAN_1="0.795" MEAN_2="1.38" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="314" SD_1="1.804" SD_2="1.89" SE="0.5887448796663401" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.19999051384539" CI_START="-1.4399905138453895" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.38000000000000034" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2010-09-27 09:58:52 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6823742697775516" Q="0.0" RANDOM="YES" SCALE="2.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="198" UNITS="" WEIGHT="100.0" Z="0.4092253824727856">
<NAME>Respiratory rate - all (outpatients)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.19999051384539" CI_START="-1.4399905138453895" DF="0" EFFECT_SIZE="0.38000000000000034" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" MODIFIED="2010-09-27 09:58:52 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6823742697775516" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="198" WEIGHT="100.0" Z="0.4092253824727856">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="2.19999051384539" CI_START="-1.4399905138453895" EFFECT_SIZE="0.38000000000000034" ESTIMABLE="YES" MEAN_1="-3.3" MEAN_2="-3.68" MODIFIED="2010-03-27 05:58:01 +1000" MODIFIED_BY="[Empty name]" ORDER="264" SD_1="9.6" SD_2="8.89" SE="0.9285836516391335" STUDY_ID="STD-Plint-2009c" TOTAL_1="199" TOTAL_2="198" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.923389200025861" CI_END="-2.0400817812335883" CI_START="-8.313845831616177" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.176963806424883" ESTIMABLE="YES" I2="56.66862120088823" I2_Q="59.55061336440228" ID="CMP-003.06" MODIFIED="2010-09-27 09:59:16 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.07438019361399795" P_Q="0.084396895361457" P_Z="0.0012179911130434675" Q="4.9444507478387525" RANDOM="YES" SCALE="12.534892259530926" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="14.133486681541347" TOTALS="SUB" TOTAL_1="289" TOTAL_2="243" UNITS="" WEIGHT="300.0" Z="3.2346331575033944">
<NAME>Heart rate - all (outpatients)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1631968314273662" CI_END="-3.785676123884411" CI_START="-11.343529784681206" DF="1" EFFECT_SIZE="-7.564602954282808" ESTIMABLE="YES" I2="14.030027164629251" ID="CMP-003.06.01" MODIFIED="2010-09-27 09:59:05 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28080358088174195" P_Z="8.72976700957157E-5" STUDIES="2" TAU2="1.5694619737576676" TOTAL_1="229" TOTAL_2="213" WEIGHT="100.0" Z="3.923428532268384">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="4.033147361293969" CI_START="-11.69314736129397" EFFECT_SIZE="-3.8300000000000005" ESTIMABLE="YES" MEAN_1="2.57" MEAN_2="6.4" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="10.55" SD_2="13.63" SE="4.0118835975137666" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="21.044335004591794"/>
<CONT_DATA CI_END="-5.087617455058784" CI_START="-12.032382544941214" EFFECT_SIZE="-8.559999999999999" ESTIMABLE="YES" MEAN_1="-3.76" MEAN_2="4.8" MODIFIED="2010-03-27 05:58:27 +1000" MODIFIED_BY="[Empty name]" ORDER="265" SD_1="17.7" SD_2="17.6" SE="1.7716563020192844" STUDY_ID="STD-Plint-2009c" TOTAL_1="199" TOTAL_2="198" WEIGHT="78.95566499540821"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.46791534320146" CI_START="-7.587915343201461" DF="0" EFFECT_SIZE="0.43999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" MODIFIED="2010-09-27 09:59:09 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9144532700631729" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.10742317480065912">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="8.46791534320146" CI_START="-7.587915343201461" EFFECT_SIZE="0.43999999999999995" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="0.13" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="323" SD_1="11.85" SD_2="13.47" SE="4.095950439153286" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.685367316381912" CI_START="-8.085367316381912" DF="0" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.03" MODIFIED="2010-09-27 09:59:16 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9603523568377734" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0" Z="0.04971141878116986">
<NAME>3 to 6 hours</NAME>
<CONT_DATA CI_END="7.685367316381912" CI_START="-8.085367316381912" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2010-03-26 02:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="324" SD_1="12.17" SD_2="12.99" SE="4.023220517611897" STUDY_ID="STD-Barlas-1998c" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3818180100281074" CI_START="0.9307673621562735" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1340860215053763" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.1404508487942879" LOG_CI_START="-0.031158853881166834" LOG_EFFECT_SIZE="0.05464599745656056" METHOD="MH" MODIFIED="2011-03-03 08:04:00 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.2119468761424056" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="199" WEIGHT="100.0" Z="1.2482299688692968">
<NAME>Return visits (ED or any healthcare provider) (outpatients)</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Epinephrine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours epinephrine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3818180100281074" CI_START="0.9307673621562735" DF="0" EFFECT_SIZE="1.1340860215053763" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="93" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.1404508487942879" LOG_CI_START="-0.031158853881166834" LOG_EFFECT_SIZE="0.05464599745656056" MODIFIED="2010-09-27 09:59:50 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2119468761424056" STUDIES="1" TAU2="0.0" TOTAL_1="200" TOTAL_2="199" WEIGHT="100.0" Z="1.2482299688692968">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="1.3818180100281074" CI_START="0.9307673621562735" EFFECT_SIZE="1.1340860215053763" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="93" LOG_CI_END="0.1404508487942879" LOG_CI_START="-0.031158853881166834" LOG_EFFECT_SIZE="0.05464599745656056" MODIFIED="2010-03-27 05:58:52 +1000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.10080438883329064" STUDY_ID="STD-Plint-2009c" TOTAL_1="200" TOTAL_2="199" VAR="0.010161524808053251" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-03-03 08:06:42 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Epinephrine and steroid versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0430525456370165" CI_START="0.3952543030252238" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6420833333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.018306187338696274" LOG_CI_START="-0.40312339332506975" LOG_EFFECT_SIZE="-0.1924086029931867" METHOD="MH" MODIFIED="2010-09-27 10:00:13 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.0735039295396196" Q="0.0" RANDOM="YES" SCALE="2.7946219124247804" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="200" TOTAL_2="201" WEIGHT="100.0" Z="1.7896889515365497">
<NAME>Admissions at enrollment or &lt; 24 hours (outpatients only)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0430525456370165" CI_START="0.3952543030252238" EFFECT_SIZE="0.6420833333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="36" LOG_CI_END="0.018306187338696274" LOG_CI_START="-0.40312339332506975" LOG_EFFECT_SIZE="-0.1924086029931867" MODIFIED="2010-09-01 06:32:40 +1000" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.2475498217919648" STUDY_ID="STD-Plint-2009d" TOTAL_1="200" TOTAL_2="201" VAR="0.06128091426923354" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9507902825648895" CI_START="0.44157789257244057" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6479567649568597" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.02191526557449767" LOG_CI_START="-0.3549926775210058" LOG_EFFECT_SIZE="-0.18845397154775173" METHOD="MH" MODIFIED="2011-03-03 08:06:14 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.026562961556256412" Q="0.0" RANDOM="YES" SCALE="2.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="201" WEIGHT="100.0" Z="2.2178807912465035">
<NAME>Admissions overall up to 7 days (outpatients only)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9507902825648895" CI_START="0.44157789257244057" EFFECT_SIZE="0.6479567649568597" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="53" LOG_CI_END="-0.02191526557449767" LOG_CI_START="-0.3549926775210058" LOG_EFFECT_SIZE="-0.18845397154775173" MODIFIED="2010-08-27 07:08:59 +1000" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.19565132053715886" STUDY_ID="STD-Plint-2009d" TOTAL_1="199" TOTAL_2="201" VAR="0.03827943922793409" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.14154829900494642" CI_START="-0.5368736517077191" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33921097535633277" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2010-09-27 10:00:32 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="7.695676972899285E-4" Q="0.0" RANDOM="YES" SCALE="0.6263802122026152" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.00000000000001" Z="3.3635145852078976">
<NAME>Clinical score (outpatients only)</NAME>
<GROUP_LABEL_1>Epi + Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.14154829900494642" CI_START="-0.5368736517077191" DF="0" EFFECT_SIZE="-0.33921097535633277" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" MODIFIED="2010-09-27 10:00:32 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="7.695676972899285E-4" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.00000000000001" Z="3.3635145852078976">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="-0.14154829900494642" CI_START="-0.5368736517077191" EFFECT_SIZE="-0.33921097535633277" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.65" MODIFIED="2010-03-27 06:08:09 +1000" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="2.58" SD_2="2.42" SE="0.10085015740621986" STUDY_ID="STD-Plint-2009d" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6117492882711234" CI_START="-0.5317492882711233" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2011-03-03 08:06:42 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.890935533549175" Q="0.0" RANDOM="YES" SCALE="0.71" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="0.13712051941274245">
<NAME>Oxygen saturation (outpatients only)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6117492882711234" CI_START="-0.5317492882711233" DF="0" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.01" MODIFIED="2010-09-27 10:00:49 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.890935533549175" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="0.13712051941274245">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.6117492882711234" CI_START="-0.5317492882711233" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="-0.73" MEAN_2="-0.77" MODIFIED="2010-03-27 06:08:32 +1000" MODIFIED_BY="[Empty name]" ORDER="270" SD_1="2.56" SD_2="3.23" SE="0.2917141808630203" STUDY_ID="STD-Plint-2009d" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7430405391736883" CI_START="-3.063040539173689" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2010-09-27 10:01:12 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.23220516924161827" Q="0.0" RANDOM="YES" SCALE="3.4664124269973295" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="1.194697735158945">
<NAME>Respiratory rate (outpatients only)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7430405391736883" CI_START="-3.063040539173689" DF="0" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" MODIFIED="2010-09-27 10:01:12 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.23220516924161827" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="1.194697735158945">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="0.7430405391736883" CI_START="-3.063040539173689" EFFECT_SIZE="-1.1600000000000001" ESTIMABLE="YES" MEAN_1="-4.04" MEAN_2="-2.88" MODIFIED="2010-03-27 06:08:54 +1000" MODIFIED_BY="[Empty name]" ORDER="271" SD_1="9.17" SD_2="10.2" SE="0.9709568921595648" STUDY_ID="STD-Plint-2009d" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.032331581646819" CI_START="4.847668418353184" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.440000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2010-09-27 10:01:24 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="4.1279200916184866E-6" Q="0.0" RANDOM="YES" SCALE="12.534892259530926" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="199" TOTAL_2="200" UNITS="" WEIGHT="100.0" Z="4.604835509625961">
<NAME>Heart rate (outpatients only)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.032331581646819" CI_START="4.847668418353184" DF="0" EFFECT_SIZE="8.440000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" MODIFIED="2010-09-27 10:01:24 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="4.1279200916184866E-6" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0" Z="4.604835509625961">
<NAME>60 minutes</NAME>
<CONT_DATA CI_END="12.032331581646819" CI_START="4.847668418353184" EFFECT_SIZE="8.440000000000001" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="-3.24" MODIFIED="2010-03-27 06:09:12 +1000" MODIFIED_BY="[Empty name]" ORDER="272" SD_1="17.8" SD_2="18.8" SE="1.8328559146916326" STUDY_ID="STD-Plint-2009d" TOTAL_1="199" TOTAL_2="200" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.384869652317274" CI_START="0.8989330993712723" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1157531845272877" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.14140889835110815" LOG_CI_START="-0.04627262823898362" LOG_EFFECT_SIZE="0.04756813505606229" METHOD="MH" MODIFIED="2010-09-27 10:01:40 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.32046100083054185" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="201" WEIGHT="100.0" Z="0.9935110100126525">
<NAME>Return visits (outpatients only)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.384869652317274" CI_START="0.8989330993712723" DF="0" EFFECT_SIZE="1.1157531845272877" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="86" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.14140889835110815" LOG_CI_START="-0.04627262823898362" LOG_EFFECT_SIZE="0.04756813505606229" MODIFIED="2010-09-27 10:01:40 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32046100083054185" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="201" WEIGHT="100.0" Z="0.9935110100126525">
<NAME>10 to 30 days</NAME>
<DICH_DATA CI_END="1.384869652317274" CI_START="0.8989330993712723" EFFECT_SIZE="1.1157531845272877" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="86" LOG_CI_END="0.14140889835110815" LOG_CI_START="-0.04627262823898362" LOG_EFFECT_SIZE="0.04756813505606229" MODIFIED="2010-03-27 06:09:35 +1000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.11024505775755987" STUDY_ID="STD-Plint-2009d" TOTAL_1="199" TOTAL_2="201" VAR="0.012153972759967711" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-03-03 08:07:49 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Epinephrine and steroid versus salbutamol</NAME>
<CONT_OUTCOME CHI2="6.120424926456719" CI_END="-0.008849719647397059" CI_START="-0.8376131054770202" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4232314125622086" ESTIMABLE="YES" I2="67.3225303139556" I2_Q="67.32253031395558" ID="CMP-005.01" MODIFIED="2010-09-27 10:02:18 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04687789560182154" P_Q="0.04687789560182165" P_Z="0.04530389544926996" Q="6.1204249264567165" RANDOM="YES" SCALE="2.27" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.27712472128363974" TOTALS="SUB" TOTAL_1="69" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="2.0018218466964806">
<NAME>Clinical score - all scores (inpatients)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5247557064246219" CI_START="-0.8738515644586348" DF="0" EFFECT_SIZE="-0.17454792901700644" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" MODIFIED="2010-09-27 10:02:08 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6246916930707185" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.489211891817689">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="0.5247557064246219" CI_START="-0.8738515644586348" EFFECT_SIZE="-0.17454792901700644" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-3.3" MODIFIED="2010-04-08 02:25:02 +1000" MODIFIED_BY="[Empty name]" ORDER="5123" SD_1="0.959" SD_2="1.386" SE="0.3567941252786511" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6979552400526904" CI_START="-0.6979552400526904" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" MODIFIED="2010-09-27 10:02:14 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="0.6979552400526904" CI_START="-0.6979552400526904" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-3.9" MODIFIED="2010-04-08 02:25:09 +1000" MODIFIED_BY="[Empty name]" ORDER="5124" SD_1="0.959" SD_2="1.039" SE="0.35610615580595983" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.269064401738789E-31" CI_END="-0.46005136023837623" CI_START="-1.9823735364432442" DF="0" EFFECT_SIZE="-1.2212124483408102" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-005.01.03" MODIFIED="2010-09-27 10:02:18 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0016632506848098573" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="3.144580632973526">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="-0.46005136023837645" CI_START="-1.9823735364432444" EFFECT_SIZE="-1.2212124483408104" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-4.3" MODIFIED="2010-04-08 02:25:15 +1000" MODIFIED_BY="[Empty name]" ORDER="5125" SD_1="0.48" SD_2="0.693" SE="0.3883546300372739" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.341216675553826" CI_END="-2.554957529708587" CI_START="-10.394530245887587" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.474743887798087" ESTIMABLE="YES" I2="68.46031128836448" I2_Q="68.46031128836445" ID="CMP-005.02" MODIFIED="2010-09-27 10:02:39 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04197810056259621" P_Q="0.04197810056259621" P_Z="0.0012058663010129785" Q="6.341216675553823" RANDOM="YES" SCALE="21.94" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="26.155246043394847" TOTALS="SUB" TOTAL_1="69" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="3.2374889011528487">
<NAME>Respiratory rate - all (inpatients)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3132804050091673" CI_START="-9.51328040500917" DF="0" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.01" MODIFIED="2010-09-27 10:02:34 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3434392522157419" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="99.99999999999999" Z="0.947391657369063">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="3.3132804050091673" CI_START="-9.51328040500917" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="-24.0" MEAN_2="-20.9" MODIFIED="2010-04-08 02:25:54 +1000" MODIFIED_BY="[Empty name]" ORDER="5126" SD_1="8.21" SD_2="9.66" SE="3.272141965666872" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.361464964340744" CI_START="-9.961464964340745" DF="0" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" MODIFIED="2010-09-27 10:02:39 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.44349213014104794" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.7663095726975112">
<NAME>12 to 24 hours</NAME>
<CONT_DATA CI_END="4.361464964340744" CI_START="-9.961464964340745" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="-27.3" MEAN_2="-24.5" MODIFIED="2010-04-08 02:25:59 +1000" MODIFIED_BY="[Empty name]" ORDER="5127" SD_1="10.58" SD_2="10.09" SE="3.6538757961010844" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.578585311241976E-31" CI_END="-6.843735691109256" CI_START="-20.556264308890746" DF="0" EFFECT_SIZE="-13.700000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-005.02.03" MODIFIED="2010-04-08 02:36:09 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="8.990101919700825E-5" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="3.9163464794348006">
<NAME>&gt; 24 hours</NAME>
<CONT_DATA CI_END="-6.8437356911092575" CI_START="-20.556264308890746" EFFECT_SIZE="-13.700000000000003" ESTIMABLE="YES" MEAN_1="-39.1" MEAN_2="-25.4" MODIFIED="2010-04-08 02:26:04 +1000" MODIFIED_BY="[Empty name]" ORDER="5128" SD_1="8.13" SD_2="10.6" SE="3.49815831462827" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7475158014314701" CI_END="1.0839158879905235" CI_START="-8.43850882808981" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6772964700496433" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2011-03-03 08:07:49 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6881436366076075" P_Q="0.6881436366076075" P_Z="0.13008481216393974" Q="0.74751580143147" RANDOM="YES" SCALE="16.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="69" TOTAL_2="36" UNITS="" WEIGHT="300.0" Z="1.5137675238540098">
<NAME>Heart rate - all (inpatients)</NAME>
<GROUP_LABEL_1>Epi+Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epi+steroid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.351789655037778E-33" CI_END="5.800589342687889" CI_START="-12.200589342687888" DF="0" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-005.03.01" MODIFIED="2010-09-27 10:03:03 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.4859089103828643" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.00000000000001" Z="0.6968304531773216">
<NAME>120 minutes</NAME>
<CONT_DATA CI_END="5.800589342687889" CI_START="-12.200589342687888" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="-14.0" MEAN_2="-10.8" MODIFIED="2010-04-08 02:26:34 +1000" MODIFIED_BY="[Empty name]" ORDER="5129" SD_1="14.6" SD_2="11.91" SE="4.592221802891986" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.555147700842876" CI_START="-9.355147700842881" DF="0" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" MODIFIED="2010-09-27 10:03:10 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.73014884156331" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="0.34492754648230456">
<NAME>24 to 72 hours</NAME>
<CONT_DATA CI_END="6.555147700842876" CI_START="-9.355147700842881" EFFECT_SIZE="-1.4000000000000021" ESTIMABLE="YES" MEAN_1="-17.6" MEAN_2="-16.2" MODIFIED="2010-04-08 02:26:39 +1000" MODIFIED_BY="[Empty name]" ORDER="5130" SD_1="11.93" SD_2="11.11" SE="4.058823408793257" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6138406062602977" CI_START="-14.213840606260298" DF="0" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.03" MODIFIED="2010-09-27 10:03:18 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.11869474591892425" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0" Z="1.560275688751496">
<NAME>3 to 10 days</NAME>
<CONT_DATA CI_END="1.6138406062602977" CI_START="-14.213840606260298" EFFECT_SIZE="-6.300000000000001" ESTIMABLE="YES" MEAN_1="-26.8" MEAN_2="-20.5" MODIFIED="2010-04-08 02:26:44 +1000" MODIFIED_BY="[Empty name]" ORDER="5131" SD_1="11.22" SD_2="11.4" SE="4.037747973270766" STUDY_ID="STD-Kuyucu-2004c" TOTAL_1="23" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2011-03-03 08:08:55 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Epinephrine versus salbutamol and ipratropium bromide</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.08575996417754372" CI_START="-1.1222879836137618" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6040239738956528" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2011-03-03 08:08:28 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.02235450002636053" Q="0.0" RANDOM="YES" SCALE="1.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="2.284289883988205">
<NAME>Clinical score (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol+IB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol+IB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.08575996417754372" CI_START="-1.1222879836137618" DF="0" EFFECT_SIZE="-0.6040239738956528" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" MODIFIED="2010-10-16 03:07:33 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.02235450002636053" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="2.284289883988205">
<NAME>6 to 12 hours</NAME>
<CONT_DATA CI_END="-0.08575996417754372" CI_START="-1.1222879836137618" EFFECT_SIZE="-0.6040239738956528" ESTIMABLE="YES" MEAN_1="-5.77" MEAN_2="-4.33" MODIFIED="2010-10-16 03:07:33 +1000" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="2.211" SD_2="2.487" SE="0.26442527199790883" STUDY_ID="STD-Kadir-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.563982058035935" CI_START="-0.8239820580359347" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3700000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2011-03-03 08:08:55 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.543606623444002" Q="0.0" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="99.99999999999999" Z="0.6073681504667925">
<NAME>Oxygen saturation (inpatients)</NAME>
<GROUP_LABEL_1>Epinephrine</GROUP_LABEL_1>
<GROUP_LABEL_2>Salbutamol+IB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours epinephrine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours salbutamol+IB</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.563982058035935" CI_START="-0.8239820580359347" DF="0" EFFECT_SIZE="0.3700000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.01" MODIFIED="2010-10-16 03:09:28 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.543606623444002" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999" Z="0.6073681504667925">
<NAME>6 to 12 hours</NAME>
<CONT_DATA CI_END="1.563982058035935" CI_START="-0.8239820580359347" EFFECT_SIZE="0.3700000000000001" ESTIMABLE="YES" MEAN_1="5.07" MEAN_2="4.7" MODIFIED="2010-10-16 03:09:28 +1000" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="2.159" SD_2="2.544" SE="0.609185713336527" STUDY_ID="STD-Kadir-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-05-03 05:57:34 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Bronc_Included_Studies_2011_jpg.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2011-05-03 05:57:34 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow of citations through the search and screening procedures, studies included in the review, and comparisons addressed</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-04-25 21:22:54 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-04-25 21:22:54 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-03-26 03:25:39 +1000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2010-03-26 03:25:39 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-07-18 16:30:32 +1000" MODIFIED_BY="Liz Dooley">Epinephrine for bronchiolitis</TITLE>
<DATE_SUBMITTED>
<DATE DAY="2" MONTH="1" YEAR="2007"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2010-03-26 03:25:39 +1000" MODIFIED_BY="[Empty name]">
<P>You used change from baseline in clinical score. In your Fig. 2, you have shown SDs for changes for the trial by Abul-Ainine 2001, but we could not find any SDs for change in clinical score in this article. We believe your result is wrong as you found epinephrine to be better than the control, but the trial authors' fig. 1 shows that the opposite is true. We estimated SDs from the trial report's fig. 1 after 60 min. and got SDs of 3.99 and 3.86, which are similar to your reported SDs for changes of 4.12 and 4.04. We calculated SMD based on values after treatment and got 0.32, in contrast to your finding of -0.44 (which seems to be wrong as it should have a positive sign according to fig. 1).</P>
<P>We have the same problem with the second trial, the one by Kristjansson 1993, where we could not find any SDs for change in clinical score in the article. We estimated SDs from the trial report's fig. 1 after 60 min. and got SDs of 0.76 and 1.38, whereas you got SDs of 0.77 and 1.15 for changes. We calculated SMD based on values after treatment and got -0.62 (-1.38 to 0.15), or nearly identical results to yours, -0.62 (-1.37 to 0.13). Does this mean that you did not use changes from baseline, which your review states, but values after treatment?</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2008-07-18 16:31:01 +1000" MODIFIED_BY="Liz Dooley">
<P>We are in the process of updating this review and will take into consideration your comments in our update.</P>
<P>We have confirmed that our original calculation for the SMD in the Abul-Ainine trial was incorrect - it should be in the other direction. I believe that your other concerns stem from the difficulty in extracting from graphs and methods of SD imputation. The concerns for the second trial appear trivial as the estimates are almost identical.</P>
<P>The updated review will incorporate these observations. However, I don't think that these discrepancies would have changed our overall conclusions.</P>
<P>Lisa Hartling</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-07-18 16:31:10 +1000" MODIFIED_BY="Liz Dooley">
<P>Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B<BR/>Feedback added 4 January 2007</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2011-04-25 21:40:54 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-04-25 21:39:55 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-04-25 21:39:55 +1000" MODIFIED_BY="[Empty name]">Search strategy: Cochrane Central Register of Controlled Trials - Ovid version</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-19 07:06:38 +1000" MODIFIED_BY="[Empty name]">
<P>1. exp BRONCHIOLITIS/</P>
<P>2. (bronchiolitis or wheez*).mp. [mp=title, original title, abstract, mesh headings, heading words, keyword]</P>
<P>3. exp Respiratory Syncytial Viruses/ or exp exp Respiratory Syncytial Virus Infections/</P>
<P>4. Respiratory Syncytial Virus$.mp.</P>
<P>5. or/1-4</P>
<P>6. exp Bronchodilator Agents/</P>
<P>7. exp Adrenergic Agents/</P>
<P>8. exp Glucocorticoids/ or exp Adrenal Cortex Hormones/</P>
<P>9. (Glucocorticoid* or Corticosteroid*).mp.</P>
<P>10. exp Anti-Inflammatory Agents/</P>
<P>11. exp Drug Therapy, combination/</P>
<P>12. exp Epinephrine/</P>
<P>13. adrenal cortex hormone*.ti,ab.</P>
<P>14. (epinephrine or adrenalin*).mp.</P>
<P>15. albuterol.mp.</P>
<P>16. beclomet?asone.mp.</P>
<P>17. betamet?asone.mp.</P>
<P>18. budesonide.mp.</P>
<P>19. dexamet?asone.mp.</P>
<P>20. salbutamol.mp.</P>
<P>21. ipratropium.mp.</P>
<P>22. prednisolone.mp.</P>
<P>23. prednisone.mp.</P>
<P>24. methylprednisone.mp.</P>
<P>25. terbutaline.mp.</P>
<P>26. fluticasone.mp.</P>
<P>27. exp Orciprenaline/ or (orciprenaline or fenoterol).mp.</P>
<P>28. aminophylline.mp.</P>
<P>29. androstadienes.mp.</P>
<P>30. hydrocortisone.mp.</P>
<P>31. or/6-30</P>
<P>32. 5 and 31</P>
<P>33. exp Infant/</P>
<P>34. (Infant* or infancy or Newborn* or Baby* or Babies or Neonat* or Preterm* or Prematur* or Postmatur*).mp.</P>
<P>35. or/33-34</P>
<P>36. 32 and 35</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-04-25 21:40:07 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-04-25 21:40:07 +1000" MODIFIED_BY="[Empty name]">Search strategy: EMBASE - Ovid version</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-19 07:07:27 +1000" MODIFIED_BY="[Empty name]">
<P>1. exp BRONCHIOLITIS/</P>
<P>2. (bronchiolitis or wheez*).mp.</P>
<P>3. exp Respiratory Syncytial Pneumovirus/</P>
<P>4. Respiratory Syncytial Virus$.mp.</P>
<P>5. or/1-4</P>
<P>6. exp Bronchodilating Agents/</P>
<P>7. exp Adrenergic Receptor Stimulating Agents/</P>
<P>8. exp Glucocorticoid/ or exp corticosteroid/</P>
<P>9. (glucocorticoid* or corticosteroid*).mp.</P>
<P>10. exp Anti-Inflammatory Agent/</P>
<P>11. exp Drug combination/</P>
<P>12. exp Adrenalin/</P>
<P>13. adrenal cortex hormone*.ti,ab.</P>
<P>14. (epinephrine or adrenalin*).mp.</P>
<P>15. albuterol.mp.</P>
<P>16. betamet?asone.mp.</P>
<P>17. beclomet?asone.mp.</P>
<P>18. budesonide.mp.</P>
<P>19. exp Dexamethasone/ or dexametha?one.mp.</P>
<P>20. salbutamol.mp.</P>
<P>21. ipratropium.mp.</P>
<P>22. exp Prednisolone/ or prednisolone.mp.</P>
<P>23. exp Prednisone/ or prednisone.mp.</P>
<P>24. methylprednisone.mp.</P>
<P>25. terbutaline.mp.</P>
<P>26. fluticasone.mp.</P>
<P>27. Orciprenaline/ or Fenoterol/ or (orciprenaline or fenoterol).mp.</P>
<P>28. aminophylline.mp.</P>
<P>29. androstadienes.mp.</P>
<P>30. exp hydrocortisone/</P>
<P>31. hydrocortisone.mp.</P>
<P>32. or/6-31</P>
<P>33. 5 and 32</P>
<P>34. exp clinical trial/</P>
<P>35. randomi?ed.ti,ab.</P>
<P>36. placebo.ti,ab.</P>
<P>37. dt.fs.</P>
<P>38. randomly.ti,ab.</P>
<P>39. trial.ti,ab.</P>
<P>40. groups.ti,ab.</P>
<P>41. or/34-40</P>
<P>42. animal/</P>
<P>43. human/</P>
<P>44. 42 not (42 and 43)</P>
<P>45. 41 not 44</P>
<P>46. 33 and 45                     </P>
<P>47. limit 46 to (child or preschool child &lt;1 to 6 years&gt;)</P>
<P>48. exp Infant/</P>
<P>49. (Infant* or infancy or Newborn* or Baby* or Babies or Neonat* or Preterm* or Prematur* or Postmatur*).mp.</P>
<P>50. 48 or 49</P>
<P>51. 46 and 50</P>
<P>52. 47 or 51</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-04-25 21:40:19 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-04-25 21:40:19 +1000" MODIFIED_BY="[Empty name]">Search strategy: IRAN MedEx</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-19 07:07:59 +1000" MODIFIED_BY="[Empty name]">
<P>(Bronchiolitis or bronquiolitis or broncho-alveolites virales or bronchiolite*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-04-25 21:40:31 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-04-25 21:40:29 +1000" MODIFIED_BY="[Empty name]">Search strategy: LILACS BIREME/OPAS/OMS - Latin American and Caribbean Center on Health Sciences Information</TITLE>
<APPENDIX_BODY MODIFIED="2011-04-25 21:40:31 +1000" MODIFIED_BY="[Empty name]">
<P>wheeze OR Sibilancias OR bronquiolitis OR bronchiolitis OR bronquiolite [Words] and infant OR pediatric OR newborn OR nacidos OR Lactentes OR lactantes OR pediátrica [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2011-04-25 21:40:39 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-04-25 21:40:39 +1000" MODIFIED_BY="[Empty name]">Search strategy: MEDLINE - Ovid version</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-01 08:07:30 +1000" MODIFIED_BY="[Empty name]">
<P>1. exp BRONCHIOLITIS/</P>
<P>2. (bronchiolitis or wheez*).mp.</P>
<P>3. exp Respiratory Syncytial Viruses/ or exp Respiratory Syncytial Virus Infections/</P>
<P>4. Respiratory Syncytial Virus$.mp.</P>
<P>5. or/1-4</P>
<P>6. exp Bronchodilator Agents/</P>
<P>7. exp Adrenergic Agents/</P>
<P>8. exp Glucocorticoids/ or exp Adrenal Cortex Hormones/</P>
<P>9. (Glucocorticoid* or Corticosteroid*).mp.</P>
<P>10. exp Anti-Inflammatory Agents/</P>
<P>11. exp Drug Therapy, combination/</P>
<P>12. exp Epinephrine/</P>
<P>13. (epinephrine or adrenalin*).mp.</P>
<P>14. albuterol.mp.</P>
<P>15. betamet?asone.mp.</P>
<P>16. beclomet?asone.mp.</P>
<P>17. budesonide.mp.</P>
<P>18. dexamet?asone.mp.</P>
<P>19. salbutamol.mp.</P>
<P>20. ipratropium.mp.</P>
<P>21. prednisolone.mp.</P>
<P>22. prednisone.mp.</P>
<P>23. methylprednisone.mp.</P>
<P>24. terbutaline.mp.</P>
<P>25. fluticasone.mp.</P>
<P>26. exp Orciprenaline/ or (orciprenaline or fenoterol).mp.</P>
<P>27. aminophylline.mp.</P>
<P>28. androstadienes.mp.</P>
<P>29. hydrocortisone.mp.</P>
<P>30. or/6-29</P>
<P>31. 5 and 30</P>
<P>32. randomized controlled trial.pt.</P>
<P>33. clinical trial.pt.</P>
<P>34. randomi?ed.ti,ab.</P>
<P>35. placebo.ti,ab.</P>
<P>36. dt.fs.</P>
<P>37. randomly.ti,ab.</P>
<P>38. trial.ti,ab.</P>
<P>39. groups.ti,ab.</P>
<P>40. or/32-39</P>
<P>41. animals/</P>
<P>42. humans/</P>
<P>43. 41 not (41 and 42)</P>
<P>44. 40 not 43</P>
<P>45. 44 and 31</P>
<P>46. exp Infant/</P>
<P>47. (Infant* or infancy or Newborn* or Baby* or Babies or Neonat* or Preterm* or Prematur* or Postmatur*).mp.</P>
<P>48. or/46-47</P>
<P>49. 45 and 48</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2011-04-25 21:40:54 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-04-25 21:40:54 +1000" MODIFIED_BY="[Empty name]">Search strategy: PubMed - U.S. National Library of Medicine</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-19 07:10:25 +1000" MODIFIED_BY="[Empty name]">
<P>Searched for a few of pre 1965 older articles identified through reference lists</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2010-03-19 07:11:05 +1000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2010-03-19 07:10:47 +1000" MODIFIED_BY="[Empty name]">Scopus - Elsevier B.V.</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-19 07:11:05 +1000" MODIFIED_BY="[Empty name]">
<P>(((TITLE(bronchiolitis OR wheez*) AND TITLE-ABS-KEY(steroid* OR glucocorticoid* OR corticosteroid*))) AND KEY("epinephrine" OR "adrenaline" OR "albuterol" OR "corticosteroids" OR "hydrocortisone" OR "steroids" OR ("inhaled steroids") OR "salbutamol" OR "betamethasone" OR "beclomethasone" OR "dexamethasone" OR "steroid" OR ("inhaled budesonide") OR "glucocorticoids" OR "bronchodilator" OR ("steroid use") OR "prednisolone" OR "methylprednisone" OR ("oral prednisolone") OR "prednisone" OR "ipratropium" OR "terbutaline" OR "orciprenaline" OR "fenoterol" OR "aminophylline" OR "androstadienes" OR "hydrocortisone")) AND (TITLE-ABS-KEY("Clinical Trial" OR "Clinical Trials" OR "Randomized Controlled Trial*" OR "Random Allocation" OR "double-blind method" OR "single-blind method" OR placebos OR research design OR comparative study OR evaluation studies OR follow-up studies OR prospective)) AND (infan* OR newborn* OR neonat* OR baby OR babies)</P>
<P>(((TITLE(bronchiolitis) AND TITLE-ABS-KEY(steroid* OR glucocorticoid*OR corticosteroid*))) AND KEY("epinephrine" OR "albuterol" OR "corticosteroids" OR "hydrocortisone" OR "steroids" OR ("inhaled steroids") OR "salbutamol" OR "dexamethasone" OR "steroid" OR ("inhaled budesonide") OR "glucocorticoids"OR "bronchodilator"OR ("steroid use") OR "prednisolone" OR ("oral prednisolone") OR "prednisone")) AND (TITLE-ABS-KEY("Clinical Trial" OR "Clinical Trials" OR "Randomized Controlled Trial*" OR "Random Allocation" OR "double-blind method" OR "single-blind method" OR placebosOR research design OR comparativestudy OR evaluationstudies OR follow-up studies OR prospective))</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>